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Atrophic non-union is a major complication following fracture of a bone. It
represents a biological failure of the fracture healing process and occurs in 5-10% of
cases. A number of factors predispose to atrophic non-union including high energy
injuries, open fractures, diabetes, and smoking. Atrophic non-unions cause immense
patient morbidity and consume large amount of health care resources. Bone grafts
taken from the iliac crest contain biologic components required for fracture healing
and are considered as the gold standard treatment of aseptic atrophic non-union.
However, harvesting bone grafts from the iliac crest is associated with significant
patient morbidity which can reduce quality of life. Mesenchymal stem cells (MSCs)
have the ability to proliferate and undergo multilineage differentiation. The
emergence of MSC therapy provides an alternative strategy for treating impaired
fracture healing. MSCs contribute to normal fracture healing both directly as bone
progenitor cells and indirectly as mediator secreting cells. Although a number of
studies have shown that MSCs can promote bone regeneration in small animal fresh
critical size defects, this is not analogous to most clinical aseptic atrophic non-unions
which do not have a significant bone gap. There remains therefore a clinical need for
an appropriate strategy for using stem cells in atrophic non-unions. Thus, the aim of
this study aim was to develop a clinically relevant strategy to promote fracture
healing in an atrophic non-union model using the percutaneous injection of MSCs as
a minimally invasive technique. An atrophic non-union model was established and
validated. A small (1 mm) non-critical size defect was created at the mid shaft tibia
and the fracture site was stabilised using an external fixator. Atrophic non-union was
induced by stripping the periosteum for one bone diameter either side of the
osteotomy site and curettage of the intramedullary canal over the same distance. The
procedure reliably created an atrophic non-union. Fracture healing was evaluated
using (1) serial radiography, (2) micro-computed tomography, (3) histomorphology
and (5) biomechanical testing. Fracture scoring systems including the radiographic
union scale in tibia (RUST) and the Lane & Sandhu score were validated in a pre-
clinical model. A simple sample preparation technique for evaluating bone
iii
mechanical properties was developed and used to assess the stiffness and strength of
the fracture repair. Percutaneous injection of MSCs locally into the fracture site in
the early ‘post-injury’ period at three weeks after induction of atrophic non-union
was found to improve the fracture healing process significantly (83% of cases), while
MSCs implantation in the late ‘post-injury’ period at eight weeks after induction of
atrophic non-union showed no significant improvement of fracture healing (20% of
cases). Percutaneous local implantation of MSCs rescued the fracture healing process
in cases destined to progress to atrophic non-union. In clinical practice, there may be
an advantage using MSCs from a universal donor as the processes of MSC isolation
and preparation are expensive and time consuming. To investigate the feasibility of
using non-autologous cells, the atrophic non-union was used to determine the bone
regenerative potential of using xenogeneic donor hMSCs in an atrophic non-union.
The results demonstrated that the therapeutic effect of using hMSCs in a xenogeneic
manner to promote fracture healing in the rat atrophic non-union model was
comparable with rMSCs (88% of cases in both hMSCs and rMSCs) and there were
neither significant clinical adverse effects nor adverse immune responses with the
xenogeneic transplantation. However, MSCs did not persist at the fracture following
injection. Perivascular stem cells (PSCs) taken from adipose tissue, which is an
expendable source, have advantages over conventional MSCs as they are a defined
and homogenous population and can be used without culture expansion. The
administration of PSC using percutaneous injection improved the fracture healing
process in atrophic non-union (60% of cases). This suggested that PSCs may present
an appropriate choice for use in cell therapies to promote fracture healing in atrophic
non-union. The results from this thesis can be applied to the development of a
clinically relevant strategy using MSCs as a minimally invasive technique to promote
fracture healing in atrophic non-union, in particular (1) the effectiveness of a cell
therapy is likely to be highly dependent of the timing of injection relative to the stage
of fracture healing, (2) hMSCs were as effective as rMSCs in promoting fracture
healing, suggesting that it may be feasible to use an allogeneic strategy in humans,
(3) the injected MSCs were not detectable even in case of successful repair,
suggesting that they may act through a paracrine effect and (4) PSCs isolated from
adipose tissue contributed to fracture healing in the atrophic non-union model,
iv
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“Prevention is better than cure”
Desiderius Erasmus, 1523
An epidemiological study at the Royal Infirmary of Edinburgh, Scotland in the year
2000 reported the incidence of fracture to be 11.3 per 1,000 people (5,953 fractures
in a population of 534,715 (Court-Brown and Caesar, 2006). In general, bone has a
physiologically reparative response to injury consisting of three basic steps:
inflammation, proliferation and remodelling, allowing the spontaneous healing of
fractures (Simmons, 1985). Failure of these physiological processes may results in
fracture non-union, a complication that occurs in 5-10% of cases (Littenberg et al.,
1998, Tzioupis and Giannoudis, 2007). Recently, the overall incidence of non-union
in Scotland over the period 2005-2010 was reported as 18.94 per 100,000 (979 non-
unions per year in a population of 5,169,140) (Mills and Simpson, 2013). Non-unions
cause considerable morbidity and consume large amounts of health care resources.
Bone grafts taken from the iliac crest contain biologic components required for
fracture healing and transplantation to the non-union site is currently considered the
gold standard treatment. In this procedure the non-union site is decorticated to
encourage local bleeding and the bone graft, harvested from an alternative site
(commonly the iliac crest), is applied (Sen and Miclau, 2007). Harvesting bone graft
from the iliac crest can result in infection, painful scaring and numbness around the
harvest site affecting quality of life (Schwartz et al., 2009).
Good surgical technique and appropriate implant selection can prevent non-union.
Surgeons should use techniques that are mindful of the contribution of surrounding
soft tissues to the fracture healing process. Procedures that minimise tissue trauma
can preserve vital biological components around the fracture site (Perren, 2002) and
prevent atrophic non-union. High energy or open fractures inherently result in severe
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soft tissue damage thus impairing the biological capacity for fracture healing (Megas,
2005) and increasing the risk of atrophic non-union. It has therefore been suggested
that augmentation of biologic components at the fracture site may enhance the
fracture healing process in patients at high risk of atrophic non-union. The biological
components that support bone healing consist of cellular components, including
mesenchymal stem cells (MSCs) or bone progenitors, and soluble mediators, such as
growth factors or cytokines: both parts are required in the process of fracture healing
(Giannoudis et al., 2007).
The transplantation of MSCs holds great promise as a strategy to improve bone
healing in atrophic non-union. Most studies have used bone defect models to
evaluate the effects of MSCs in bone repair (Bruder et al., 1998, Peterson et al.,
2005, Nair et al., 2009). Pre-clinical models should closely represent clinical
scenarios to best evaluate new therapeutic interventions in atrophic non-union.
However, a discrete bone defect or bone loss is not a common cause of atrophic non-
union in the clinical setting. Thus, a non-critical size defect atrophic non-union
model is a more appropriate setting in which to study a role for MSCs in fracture
repair. A minimally invasive strategy for delivery of MSCs is desirable in modern
clinical practice. Therefore, the aim of this study is to develop a clinically relevant
strategy to improve fracture healing in atrophic non-union using an injectable MSC-
based approach. This minimally invasive intervention can be applied for prevention
in patients at high risk of atrophic non-union.
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Hypothesis and objective of the thesis
The hypothesis of this study was:
“Percutaneous injection of MSCs promotes the process of fracture repair in a
small animal model of atrophic non-union”
To evaluate this hypothesis, the following objectives were set:
1. To establish and validate a clinically relevant atrophic non-union model, and
to evaluate the characteristics of local progenitors at the site of atrophic non-
union and systemic progenitors from a remote site (contralateral femoral
bone).
2. To determine an optimal time for rat Mesenchymal Stem Cells (rMSCs)
injection in atrophic non-union model.
3. To investigate the therapeutic effects of human Mesenchymal Stem Cells
(hMSCs) injection on fracture healing in an atrophic non-union model,
determine cell fate and immune reactions after hMSC injection.
4. To evaluate the feasibility of using purified human perivascular stem cells
(PSCs) from adipose tissue as an alternative to bone marrow derived MSCs
for fracture repair in a small animal model of atrophic non-union.
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Chapter 1: Literature review
The aim of this thesis is to develop a clinically relevant strategy for using
Mesenchymal stem cells (MSCs) to improve fracture healing in atrophic non-union.
In the first part of this chapter, the background knowledge relevant to the study is
reviewed, including basic bone biology, the fracture healing process and the
pathological mechanisms involved in the development of atrophic non-union. In
addition recent treatments for atrophic non-union are reviewed. The rationales as
well as the prerequisites for stem cell treatment are defined. Pre-clinical non-union
fracture models relevant to the project are summarised. The second part of this
chapter considers a role for MSCs in bone regeneration. The biology of MSCs and
their potential in bone regeneration are reviewed. Issues and challenges relating to
the use of MSCs in clinical settings including appropriate modes of cell delivery,
immune responses after treatment and suitable cell types for implantation are
discussed. This literature review provides a basis for understanding clinical strategies
utilising MSCs in bone repair. It also refines and defines the key questions that are
addressed in this study.
1.1 Bone biology
Bone is a unique tissue, as it has the potential to regenerate after injury without scar
formation. A central function of bone is to provide structural support to the body,
protecting vital internal organs such as the brain, heart and lungs. In addition, it
facilitates movement of the body and extremities through tendinous attachments to
muscle.  It also plays a crucial role in calcium homeostasis, as it contains 99% of
total body calcium. Knowledge of bone biology and structures is fundamental to the
understanding of the fracture healing process and the developing therapeutic
interventions to facilitate fracture repair.
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1.1.1 Gross morphology structure
There are two types of bone tissue at the macroscopic level. Cortical (compact) bone
and trabecular (cancellous) bone (Figure 1.1). Distribution of these two major bone
types varies throughout different regions of bones. Trabecular bone is mainly found
in short bone and at the metaphyses of long bones, whereas cortical bone is dominant
in diaphyseal areas (Figure 1.2).
Figure 1.1 Bone compartments in rat femur
Figure 1.2 Coronal sections of metaphysis of rat tibia: *Epiphysis, **growth plate and ***Metaphysis
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1.1.2 The components of bone
Bone is a connective tissue, which consists of cells and mineralized extracellular
matrix. The mineral content is predominantly calcium phosphate, in the form of
hydroxyapatite [Ca10(PO4)6(OH)2]. Besides the calcified components of bone matrix,
the extracellular matrix contains several proteins which can be classified as either
collagenous or non-collagenous protein. Type I collagen is the major collagenous
protein, but there also significant amounts of type V collagen present, which are
structural backbone of bone (Niyibizi and Eyre, 1989). Non-collagenous proteins are
present in the bone matrix as ‘ground substances’. These include
glycosaminoglycans, glycoproteins (osteocalcin, osteonectin and osteopontin) and
sialoprotein. Glycoprotein and sialoprotein play a role as calcium binding proteins in
the mineralization process (Zurick et al., 2013). These proteins are secreted by
osteoblasts, which are one of the cellular components of bone tissue.
1.1.2.1 Cellular components
There are three main types of cells in bone: osteoblasts, osteocytes and osteoclasts.
Osteoblasts and osteocytes are differentiated from basic cell types known as bone
progenitor cells (MSCs or osteoprogenitor cells), whereas osteoclasts originate from
haematoprogenitor cells.
Osteoblasts are bone-forming cells that secrete several proteins present in the bone
matrix. This includes osteoid which is first laid down in unmineralised bone. Inactive
osteoblasts are flat, covering the bone surface. When active, these cells are
characteristically cuboidal or polygonal in shape (Figure 1.3). During the
differentiation process from osteoprogenitors, important cell-cell and cell-matrix
interactions occur. It has been reported that extracellular matrix-intergrin (ECM-
integrin) interactions are important in osteoblast gene expression (Gronthos et al.,
1997). β1 intergrins on the osteoblast membrane adhere to the RGD-containing
8
protein (the peptide sequence Arg-Gly-Asp) at the bone matrix and this interaction
stimulates intracellular kinase pathway via a spectrum of transcription factors
including Runx2 (Xiao et al., 2002). Mutations in this gene have been associated
with cleidocranial dysplasia, which presents with delayed or absent intramembranous
ossification (Mundlos, 1999).
Figure 1.3 Osteoblasts: Above image (arrow) shows (a) inactive osteoblasts (x400) and below section
shows (b) active osteoblasts (x400)
As osteoid deposition appears, the osteoblast is surrounded by an osteoid matrix and
then becomes an osteocyte. Osteocytes are typically smaller than the osteoblast cells
from which they derive (Figure 1.4) and are responsible for maintaining the bone
matrix. Osteocytes reside in spaces called lacunae, interacting with adjacent cells via
canaliculi. These cells respond to mechanical stimuli (mechanical strain and fluid
flow) though GAP junctions (Cherian et al., 2003). Recently, it has been shown that




molecule secreted by osteocytes (Robling et al., 2008). The inhibition of sclerostin
secretion can increase the osteogenic effect of the Wnt pathway (van Bezooijen et al.,
2007). Studies using genetically modified animals deficient in sclerostin have
demonstrated an association with increased bone formation and bone mass (Li et al.,
2008).
Figure 1.4 Osteocytes at in ground bone cortex (x400)
Osteoclasts are large, multinucleated cells that can be found at areas where bone is
being removed or remodelled (Figure 1.5). Osteoclasts contain numerous lysosomes
for bone matrix resorption. Howship’s lacunae, which are present at sites of bone
resorption contain osteoclasts. These cells play an important role in calcium
metabolism in a process mediated by parathyroid hormone (PTH) and calcitirol
(Faucheux et al., 2002). Unlike osteoblasts and osteocytes, the progenitor from which
osteoclasts derive is of haematopoietic stem cell origin. Monocytes fuse and become
multinucleated cells. Osteoclasts play a key role in bone resorption and remodelling.
Microfracture can stimulate and recruit osteoclasts into functional sites (Klein-
Nulend et al., 1995). The process of osteoclast formation or osteoclastogenesis is
dependent on monocyte stimulation factor (M-CSF) and receptor activator of nuclear
factor kappa B ligand (RANKL), which are produced by osteoblasts (Takahashi et
al., 2011). Osteoclast formation is inhibited by osteoprotegrin (OPG), which is also
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secreted by osteoblasts. These substances are involved in the physiology of
osteoclast formation.
Figure 1.5 Osteoclasts in a Howship’s lacuna, arrow (x400)
1.1.2.2 Periosteum and blood vessel of bone
The periosteum is a sheath of dense fibrous connective tissue covering the bone
surface that contains osteoprogenitor cells and the blood vessels that nourish the
underlying bone. Histologically, there are two layers of the periosteum (Figure 1.6):
an outer fibrous layer and an inner layer known as the cambium layer, where the
ostoprogenitor cells can be found. However, a report on the ultrastructure of the
periosteum using electron microscope suggested that there were three different zones
at the periosteum:  Zone I consisted of predominately osteoprogenitor cells that
located adjacent to the bone surface, Zone II was a relatively translucent zone where
fibroblasts and collagen fibrils were found equally with numerous capillaries, and
Zone III consisted of predominately collagen fibrils and fibroblasts (Squier et al.,
1990). The inner layer or zone of periosteum plays an important role for bone
regeneration as it contains progenitor cells that are able to proliferate and become
osteoblasts under appropriate stimuli, such as, fracture or injury.
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The main blood vessel supplying the shaft of long bones is the nutrient artery. It
gives branches within the Harversian and Volkmann’s canals. Periosteal arteries
provide the blood supply for the periosteum (Figure 1.7). These structures are
important in the fracture healing process. In high energy fractures, the periosteum
and surrounding soft tissues can be significantly disrupted (Govender et al., 2002). A
number of both clinical and experimental studies have demonstrated that periosteal
disruption at the fracture site is associated with impaired fracture healing (Landry et
al., 2000, Kokubu et al., 2003, McKibbin, 1978)




Figure 1.7 High magnification showing image of (a) a periosteal vessel, at arrow (x400) and (b)
Immunostaining of periosteum containing alpha-SMA positive cells within periosteal vessels, at arrow
(x200)
1.1.3 Bone development
There are two processes by which bone may form; (1) Intramembranous bone
formation and (2) Endochondral bone formation
1.1.3.1 Intramembranous bone formation
This type of bone formation is the developmental pathway of flat bones including the
cranial bones, and pelvic bones. The progenitors of bone cells, namely MSCs,
differentiate directly into bone cells during their development without a cartilage
template. This process starts with the condensation of mesenchymal progenitors.
After aggregating, these cells start differentiating into pre-osteoblasts and produce
initial osteoid which contains a number of cell-binding proteins such as sialoprotein
and osteopontin. Type 1 collagen and small proteoglycans are laid down and they
form cross-links as the bone matures. Osteocalcin is the most abundant of non-
collagenous matrix proteins. It is a Calcium-binding protein that appears at the
A B
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mineralization stage of bone formation. Collagen fibres are less organized in the
early stages of bone mineralisation in immature woven bone. Woven bone is
subsequently replaced by lamellar bone in which the collagen fibers are more
oriented in layers.
1.1.3.2 Endochondral bone formation
This is the process by which long bones and the vertebrae develop. It involves the
initial formation of cartilage tissue as the template. This structure is surrounded by
periosteum and perichondrium, which serve as a reservoir of progenitor cells. The
progenitor cells differentiate into chondrocytes, which become enlarged and produce
a calcified cartilage matrix. These cells provide and secrete vascular endothelial
growth factor (VEGF), which stimulates blood vessel formation. Vascular buds are
formed which invade the central zone of the cartilage matrix. A cavity forms in the
centre of the calcified cartilage matrix; this subsequently forms the primary
spongiosa, which is the immature trabeculae and bone marrow cavity. This is
surrounded with lamellar bone. As the bone develops, the secondary spongiosa,
which is the secondary centre of ossification is found in the epiphyseal regions.
1.1.4 The physiology of bone remodelling
As a viable tissue, bone has a regular turnover and remodels during the period of its
lifetime. This physiological process requires a diverse group of cells which take part
in the process and are known as the bone remodelling unit. The rate of bone turnover
is dependent on the bone type. In cancellous bone, the turnover is higher than in
compact bone (Burr, 2002, Parfitt, 2002). Dysregulation of this process can result in
osteoporotic fractures particularly of sites such as the vertebrae, the proximal femur
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and the distal end of the radius, which have greater proportion of cancellous bone
than in the diaphysis (Sandhu and Hampson, 2011).
There are four phases in the bone remodelling cycle: activation, resorption, reversal
and formation (Clarke, 2008) . Osteoclasts are activated and recruited into the bone
in response to local cytokines (M-CSF and RANKL) (Boyle et al., 2003).
Subsequently, fully differentiated osteoclasts secrete proteolytic enzymes including
capthesin K and matrix metalloproteinases (MMPs) (Delaisse et al., 2003). This is a
part of the resorption phase and results in the formation of Howship’s lacunae. Due
to the resorption of bone matrix, several growth factors including transforming
growth factor (TGF)-β, bone morphogenetic proteins (BMPs), platelet-derived
growth factor (PDGF), insulin-like growth factor (IGF)-I and II and fibroblasts
growth factor (FGF) are released (Mohan and Baylink, 1991). These growth factors
promote and stimulate the differentiation of MSCs and other tissue resident bone
progenitors. The differentiated osteoblasts then start to synthesise a new bone matrix
in the formation phase, which is subsequently mineralised.
1.2 The fracture healing process
Fracture healing is a complex process which involves many biological events. There
are two categories of bone healing which depend on the size of the fracture gap and
the stability at the fracture site during the healing process (McKibbin, 1978, Ito and
Perren, 2007) (Figure 1.8).
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Figure 1.8 Types of bone healing: There are two mechanisms by which bones will heal:  (a) primary
bone healing occurs under conditions of absolute stability, such as when a compression plate is used
and (b) secondary bone healing occurs under conditions of relative stability, such as using cast.
Modified from AO foundation website (https://www2.aofoundation.org/wps/portal/surgery)
1.2.1 Primary bone healing
Primary healing, sometimes known as direct healing, requires absolute stability of
fracture fixation (Jagodzinski and Krettek, 2007). Fractures treated with compression
plating heal by the primary healing process. Here, bone regenerates without external
callus, and cartilage and fibrous tissue formation at the fracture gap does not occur.
Progenitor cells differentiate directly into bone cells and form the bone matrix
essential for healing at the fracture site (McKibbin, 1978). Intra-articular fractures,
such as those of the tibial plateau or femoral neck fractures require absolute stability
and these fractures should heal by primary healing. Primary healing can be sub-
classified into contact healing and gap healing according to the size of the gap
between the healing bone ends.
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1.2.1.1 Contact healing
When the fracture sites are in direct apposition with no separating gap, healing can
occur without intramembranous bone formation. Osteoclasts make cutting cones or
bone resorption cavities crossing the fracture site. New osteons, which are the basic
fundamental functional unit of compact bone, form and establish a harversian system
with the original orientation.
1.2.1.2 Gap healing
Gap healing requires intramembranous bone formation as new osteons cannot cross
the fracture line directly. The process begins with differentiating bone progenitor
cells forming woven bone at the gap. The woven bone is then remodelled and re-
orientated into lamellar bone that has parallel fibres similar to the orientation of an
uninjured bone.
1.2.2 Secondary bone healing
Another type of fracture healing is secondary or indirect healing. This is the most
common way by which fracture healing occurs. Most of fractures are managed
without rigid fixation (relative stability) such as cast immobilisation, external
fixation or intramedullary fixation, in a process that involves the formation of callus.
Secondary fracture healing can be divided into three phases: the inflammatory,
reparative and remodelling phases (McKibbin, 1978). These phases may overlap and
affect one another during the fracture healing process (Figure 1.9).
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Figure 1.9 The phases of secondary bone fracture repair: There are three major phases of secondary
bone healing: the inflammatory, reparative and remodelling phases.
1.2.2.1 The inflammatory phase
In addition to the bone itself, surrounding soft tissues are also injured with trauma.
After injury, a haematoma forms at the fracture gap and in the surrounding area.
Inflammatory cells such as macrophages that release interleukin-1 and 6 (IL-1 and
IL-6), and tumour necrosis factor-alpha (TNF-α) are recruited, while degranulating
platelets also release platelet-derived growth factor (PDGF) and transforming growth
factor-beta (TGF-β) (Bolander, 1992). These pro-inflammatory cytokines and growth
factors can induce a cascading inflammatory response, which stimulates the healing
process (Warren, 1990). MSCs and progenitors originating from bone marrow,
periosteum and the soft tissues around the fracture sites are triggered to proliferate
and differentiate for fracture healing (Yoo and Johnstone, 1998).
1.2.2.2 The reparative phase
This phase follows the inflammatory phase, although it may begin before the
inflammatory phase has fully subsided. Bone formation or ossification occurs in this
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phase through intramembranous ossification or endochondral ossification. With
intramembranous ossification, the precursor cells differentiate into bone progenitors
and osteoblasts directly and form woven bone (Yoo and Johnstone, 1998), whereas
with endochondral ossification, cartilage is formed in an intermediate step before the
woven bone appears (McKibbin, 1978). The formation of tissues at the fracture sites
depends on numerous factors including strain and oxygen tension (Zuscik et al.,
2008). The enchondral ossification process is driven by relative hypoxic conditions
and some degree of motion. The progenitors differentiate into chondrocytes, which
proliferate rapidly and become hypertrophic. They create extracellular matrix and
provide a template for bone formation. This process is called chondrogenesis. When
the chondrocytes die, new vascular structures invade, which transport bone
progenitors that can form osteoid and eventually woven bone. Internal callus
formation (or endosteal healing) occurs through intramembranous ossification, which
requires high oxygen tension and low strain conditions (Claes and Heigele, 1999,
Carter et al., 1998, Lacroix and Prendergast, 2002).
1.2.2.3 The remodelling phase
The bone remodelling process may take up to two years. The callus which contains
the woven bone is gradually replaced by lamellar bone. The lamellar bone has an
isotrophic property, which is characterised by parallel organisation of collagen fibres
contributing to the greater mechanical strength of lamellar bone over woven bone. It
is thought that mechanical factors are important in the process of bone remodelling.
According to Wolff‘s Law as cited by Goldstein (1987), the remodelling of bone
trabeculae depends on external loading. Recently, a biological mechanism
responding to a mechanical stimulus has been reported, which can be explained
through a function of sclerostin or the SOST gene expressed on osteocytes
(Bonewald and Johnson, 2008). Fluid shift in the canaliculi network from mechanical
loading can reduce SOST protein production, which antagonizes the WNT pathway.
19
Mechanical factors play a major role in this final stage of fracture healing, as bone
remodels into its original form and structure (Robling et al., 2008, Tu et al., 2012).
1.3 Fracture Non-union
Impairment of the normal fracture healing can result in fracture non-union (Figure
1.10). Non-union occurs in about 5-10% of fractures (Littenberg et al., 1998,
Tzioupis and Giannoudis, 2007). The treatment of fractures that develop non-union
requires numerous operations with associated morbidity and financial costs
(Schwartz et al., 2009, Heckman and Sarasohn-Kahn, 1997)
Figure 1.10 Atrophic non-union of the tibia: Atrophic non-unions are characterised by an absence of
callus and atrophic bone ends. (Images: courtesy of Professor Hamish Simpson)
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1.3.1 Definition of fracture non-union
Fracture non-union is a pathological condition in which the fractured bone ends
cannot unite without additional intervention, either surgical or non-surgical. There
are no true consensus criteria for the diagnosis of non-union (Bhandari et al., 2002).
Recently, a systematic review revealed that 62% (n=123) of clinical studies, based
the diagnosis of union/non-union of long bones on both clinical and radiographic
features. Clinical criteria for union included the ability to weight bear and the
capacity to perform activities of daily living. Radiographic criteria included an
evaluation of bridging callus at the fracture site and obliteration of the fracture line
(Corrales et al., 2008).
Several definitions of fracture non-union have been proposed (Marsh, 1998, Green et
al., 1988, Bassett et al., 1981). According to the United States Food and Drug
Administration (FDA), a fracture non-union is defined as a fracture that is at least
nine months old that has not shown any signs of progression of healing for three
consecutive months.
1.3.2 Classification of fracture non-union
The classic classification of fracture non-union was proposed by Weber and Cech
(1976). Two broad groups (Hypertrophic and Atrophic) of non-union are described,
according to the radiographic appearance, which correlates with aetiology. With
respect to treatment, however, non-unions should be investigated for evidence of
infection. In the presence of infection, non-unions are described as septic non-unions
(Simpson et al., 2002).
Hypertrophic non-union has good biological activity with an abundance of callus
formation. The fracture cannot heal properly due to mechanical insufficiency.
Hypertrophic non-unions can be further divided by the amount of callus on
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radiographs as either; elephant’s foot, horse’s foot or oligotrophic. Conversely,
atrophic non-union is a pathological condition that occurs from biological
impairment resulting in an absence of the callus at the ends of the bone at the fracture
site. These bone ends may be rounded and sclerotic.
Atrophic non-union can be divided into types of atrophic non-union based on
mechanical and histological features; 1) stiff atrophic non-union 2) mobile atrophic
non-union. Although, there are no signs of radiographic bone healing in stiff atrophic
non-unions, fibrous tissue can be found across the non-union site, which provides
some mechanical stiffness. In contrast, the non-union gap in mobile atrophic non-
unions has a cystic cavity and is devoid of mechanical stability. This type of atrophic
non-union should be termed as typical pseudarthrosis (Mills and Simpson, 2012).
1.3.3 The pathophysiology of atrophic non-union fracture
Atrophic non-union is associated with biological failure. The severity of fracture has
a considerable impact on the risk of atrophic non-union (Karladani et al., 2001).
Open fractures are associated with significant soft tissue injury (Figure 1.11). The
periosteum, which is a rich source of the mesenchymal progenitor cells, may be
destroyed with high energy injuries and open fractures (Ozaki et al., 2000, Ball et al.,
2011). A prospective observational study performed in 41 trauma centres reported
that the risk of delayed or non-union in open fractures with a wound either less than
5 cm or, greater than 5 cm was increased by 3.6 and 5.7 times respectively, when
compared to fractures with no skin injuries (Audige et al., 2005). Other factors
predisposing to atrophic non-union have been described. It has been reported from
clinical studies that smoking (Schmitz et al., 1999) and vitamin D deficiency
(Brinker et al., 2007) predispose to fracture non-unions. In addition, reports from
animal studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) can also
inhibit the fracture healing process (Allen et al., 1980, Gerstenfeld et al., 2003). The
retrospective study, comparing 32 patients with non-union and 67 matched patient
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with united fracture (Giannoudis et al., 2000), identified an increase in the risk of
non-union of femoral diaphysis in patients who had NSAIDs with odds ratio of
10.73. It has been reported in patients who received indomethacin for heterotopic
ossification prophylaxis of the acetabulum; the risk of non-union of concurrent
fractures was a significant difference between patient with (26%) and without
indomethacin treatment (7%) (Burd et al., 2003).
It has been thought that atrophic non-unions occur in the setting of impaired
biological activity, especially blood supply.  Recent evidence does not, however,
support this hypothesis. Reed et al. (2002) demonstrated no difference in the number
of blood vessels in human atrophic non-union tissue when compare to hypertrophic
non-union tissue. Animal studies have shown the pattern of change in vascularity at
different time points in normal fracture healing and in atrophic non-union. The
vascularity of atrophic non-unions was less in the first three weeks following injury
but reached the same level as that in normal healing bone at later time-points (Reed
et al., 2003). Bajada et al (2009) successfully isolated MSCs from atrophic non-union
tissues; however, the growth kinetic and the osteogenic ability of these cells were
diminished. These findings suggest that risk of atrophic non-union might be related
to the number and functionality of progenitor cells at the site of atrophic non-union.
An understanding of the biological components contributing to atrophic non-union
might help to develop appropriate treatment strategies to restore the fracture healing
process.
Figure 1.11 Open tibial fracture:  Open or compound fracture is a risk of fracture non-union.
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1.3.4 Treatment of atrophic non-union
Patient history, examination and investigation are all important in the management of
atrophic non-union. Fracture severity and associated soft tissue injury should be
reviewed. High injury trauma and open fractures are frequently associated with
destruction of soft tissues, which may contribute to abnormal fracture healing. Poor
general health status and co-morbidities such as diabetes or malnutrition may further
impair the healing process, so these factors should be explored. The initial treatment
of fractures influences the management of established non-unions. Fixation
techniques that are used in fracture fixation have differing effects on the residual soft
tissues as well as the remaining blood supply to the fracture site (Wagner, 2003).
Infection of primary fixation increases the risk of septic non-union. Routine full
blood count (FBC), erythrocyte sedimentation rate (ESR) and C- reactive protein
(CRP) are useful for septic investigation. The CRP is the most sensitive biochemical
test for infection, but is non-specific (Wright and Khan, 2010). In most cases,
radiography is important in confirming the diagnosis, and in addition demonstrates if
there is any deformity. CT and MRI may be useful for investigation in some
circumstances where the diagnosis is unclear.
For any non-union, the cause should be identified and any deficient elements should
be corrected. For example, hypertrophic non-union results from excessive movement
especially in the later stages, and the treatment consists of increasing the stability of
the fracture. In atrophic non-union, which can occur as a result of deficient biological
support, cells and growth factors may be required. Non-unions with an associated
bone defect may need the defect to be filled by distraction osteogenesis, a tissue
engineered construct with an osteoconductive/inductive/genic scaffold or by bone
graft. The diamond concept describes four main elements required for tissue
engineering of bone: Osteogenic cells, Osteoconductive scaffolds, Mechanical
environment and Growth factors (Figure 1.12) (Giannoudis et al., 2007).
Conventional bone graft from the iliac crest (also known as iliac crest bone graft
(ICBG)) still remains the standard treatment for non-union as it contains osteogenic
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(osteogenic cells, bone progenitor cells), osteoinductive (growth factors) and
osteoconductive (bone matrix) properties. Figure 1.13 shows an atrophic non-union
that developed following fracture of the ulnar shaft that was subsequently treated
with ICBG. Chip bone grafts that are harvested from the iliac crest are applied into
the non-union site. However, the harvest of ICBG is associated with donor site
morbidities, including post-operative pain, immobility and prolonged hospital stay
(Schwartz et al., 2009).
Therefore, alternative methods to improve bone healing such as cellular therapy,
synthetic bone substitutes and other growth factors or adjuvant therapies e.g.
ultrasound, and electromagnetic radiation have been investigated in fracture non-
union. These interventions may promote and prevent atrophic non-unions in fractures
at greatest risk. However, further investigation of their effectiveness and mechanisms
by which they influence bone healing is still required.
Figure 1.12 Diamond concept of elements required for fracture healing: Modified from Giannoudis et
al. (2007)
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Figure 1.13 Atrophic non-union of the ulnar (a) and the bone graft from iliac crest (b) (yellow arrow)
applied at the non-union site (green arrow)
1.3.5 Augmentation in fracture non-unions
There are a number of reports in the literature of biophysical stimulation devices
such as ultrasound and electromagnetic units as well as orthobiologics such as BMP
proteins used in the management of fracture non-unions. Recently, cell therapies
such as stem cells have attracted great interest in the treatment of non-union of
fractures. These modalities should, however, be used at only appropriate time points
and only in selected patients.
Low intensity pulsatile ultrasound (LIPUS) is a biophysical technique that utilizes
mechanical energy (high acoustic pressure wave) transmitted from the skin into
bone. It has been suggested that LIPUS influences cellular activity via
micromechanical stimulation of matrix or protein synthesis from osteoblasts and
progenitor cells (Li et al., 2003, Yang et al., 1996). Although the mechanisms by
which biophysical treatments exert their effect remain unclear, several clinical trials
have shown that these treatments can improve fracture healing process (Gebauer et
al., 2005, Bashardoust Tajali et al., 2011). A meta-analysis of LIPUS treatment in
A BA
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early stage of fracture healing (fresh fractures) has reported that time to healing in
the LIPUS treatment arm was less than in the placebo group (Bashardoust Tajali et
al., 2011). According to a study from Japan, in which 72 cases of long bone fracture
were analysed, the overall union rate from LIPUS treatment was 75%, whereas the
cases which were treated within six months had 89.7% of union rate. The study
group recommended that LIPUS treatment should be started within six months of the
most recent treatment (Jingushi et al., 2007). These studies confirm that it is
important to consider the most appropriate timing of interventions when considering
the treatment of non-union.
Extracorporeal shock wave therapy (ESWT) has been introduced in the treatment of
non-unions. This technique was originally described in urology, where it was utilized
to breakdown ureteric stones. There are several proposed mechanisms by which
ESWT may promote bone regeneration. The finding from a study using a rabbit
model showed that ESWT induced micro-fractures which resulted in subperiosteal
haemorrhages, foci of fractures and displaced bony trabeculae. A radiolucent area
was observed in the bone marrow, but no gross fracture. In addition, intense bone
formation at cortical bone was demonstrated (Delius et al., 1995). It was considered
that micro-fractures created by ESWT may trigger neovascularization, proliferation
and activation of bone progenitors and stimulation of bone matrix synthesis. It has
been reported from clinical studies demonstrating the success of using ESWT in
management of cases with abnormal fracture healing without adverse effects (Elster
et al., 2010, Wang et al., 2001). Bara and Synder (2007) reported that there was an
unsatisfactory outcome in patients with atrophic non-unions who had a large fracture
gap. The authors considered that it was important to use ESWT for specific
indications in well-selected patients.
The effects of electromagnetic field on non-union have been widely investigated.
This technique was originally developed by Bassett et al in 1981. In a case series of
127 ununited fractures of the tibial diaphysis, they reported that 87% of cases were
successfully treated by electromagnetic stimulation (Bassett et al., 1981).
Electromagnetic coils were connected to a portable generator, which delivered the
current to the area around the fracture site (Aaron et al., 2004). It has been reported
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that electromagnetic field upregulates gene expression in osteoblasts to produce
growth and stimulate factors that contribute to fracture healing, as well as stimulating
the synthesis of extracellular matrix (Fitzsimmons et al., 1995, Chalidis et al., 2011).
Randomised, double-blind studies showed that the combination of either surgical
(Simonis et al., 2003) or non-surgical treatment (Sharrard, 1990) with
electromagnetic approach resulted in a better outcome. These studies conclude that
electromagnetic therapy may be best used as an adjunct to other treatment options.
A number cytokines, growth factors and hormones play important roles in the
fracture healing process. Bone Morphogenetic protein-7 (BMP-7) has already been
adopted in the management of fracture non-unions. BMP-7 plays a key role in
osteoblast differentiation via induction of Smad1 (Yavropoulou and Yovos, 2007). A
prospective randomised clinical study was conducted in 122 patients diagnosed with
tibial pseudoarthrosis of at least nine months duration. An intramedullary nail was
used for all cases with the authors comparing the influence of adjunctive autologous
bone graft and BMP-7. The success rate of both treatments was comparable.
However, in smokers, BMP-7 showed better healing outcomes than autologous bone
graft (Friedlaender et al., 2001). Regarding cost-effectiveness, the use of BMP-7 has
been recommended selected cases such as for severe open fractures or in high risk
patients (Garrison et al., 2007, Garrison et al., 2010)
Bone marrow aspirate contains cellular components, which may be beneficial in the
treatment of fracture non-union. Bone Marrow Aspirate contains a heterogeneous
population of mononuclear cells, including MSCs. MSCs are capable of osteogenic
differentiation and are involved in the normal fracture repair process. The first use of
bone marrow aspirate was reported in a case of an infected non-union of the
tibia(Connolly and Shindell, 1986). These authors subsequently reported a case
series of 100 tibial non-unions with an 80% success rate with bone marrow aspirate
injection (Connolly, 1998). In a study reported by Goel et al (2005), the treatment
was performed under local anaesthesia; 3 to 5 millilitres of bone marrow aspirate was
harvested each time from the iliac crest. Up to a maximum of 15 millilitres was
injected into the non-union site under fluoroscopy guidance. The procedure was
repeated at four to six weeks in the absence of clinical and radiological union. The
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union rate was 75 % (n=15), with average time following first injection of 14 weeks
(Goel et al., 2005). This study suggested that cellular injection might be used as a
minimally invasive technique. However, the technique was limited by the volume of
bone marrow aspirate that could be injected at the fracture site. Hence, concentrated
bone marrow aspirate has been introduced to increase the yield of MSC with less
overall volume. Hernigou et al. (2005) studied 60 atrophic non-union patients treated
with concentrated autologous bone marrow aspiration. The concentrated autologous
bone marrow aspirate was introduced using a percutaneous technique. This study
reported a success rate approximately 90% (n=53) with average time to union of 12
weeks. The number of colony forming unit fibroblasts from concentrated autologous
bone marrow aspirate in those cases, which failed to unite, was significantly lower
than the number of cells in successful cases. It was concluded that the success rate of
treatment was dependent on the number of MSCs. This supports the expansion of
MSCs isolated from bone marrow in cultures to increase the yield of cells available
to inject into the non-union. Until now, only case reports have reported the use of
MSCs in non-union (Bajada et al., 2007, Funk et al., 2007). Further investigations are
still required before the widespread clinical use of MSCs in the management of non-
union.
There are several emerging technologies that aim to improve and promote fracture
healing. They are of intent interests to orthopaedic surgeons and scientists. However,
the mechanisms by which these treatments bring about effects require further
investigation. Patient selection and the time point for delivering any intervention are
critical. It would be preferable to have an effective treatment to prevent non-union
rather than purely for treating well established non-union.
1.4 Animal models of non-union
Since the 1990s, major progress has been made in the field of regenerative medicine.
Developments in adult and embryonic stem cell research as well as the
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improvements of material sciences hold great promise for the regeneration of bone.
Pre-clinical research using appropriate animal models are needed before this work
can be translated into benefits for patients. Animal models should be selected for
appropriateness in order to gain the most accurate answer to the research question
(Einhorn, 1999). In this thesis, the primary question was to investigate the
therapeutic effects of adult stem cells in the prevention of atrophic non-union. Thus,
it was important to have a disease model of atrophic non-union that accurately
reflected the abnormal physiological process of fracture healing. Important
considerations included choosing an appropriate animal species, types of fixation and
mode of generation of the atrophic non-union.
1.4.1 Small animal models of fracture healing
Small animals are widely used in studies of fracture healing. Experimental models in
small animals present advantages over using larger animals. For example the cost of
maintenance is lower, the experimental time points are shorter, and a larger number
of animals can be used. Rats are the most commonly used animals in fracture healing
studies (O'Loughlin et al., 2008). In considering an appropriate animal model the
following factors should be taken into account: 1) appropriateness as an analog, 2)
transferability of information, 3) genetic uniformity of organisms, where applicable,
4) background knowledge of biological properties, 5) cost and availability, 6)
generalisability of the results, 7) ease of, and adaptability to experimental
manipulation, 8) ecological consequences, and 9) ethical implications (Davidson et
al., 1987).  The process of fracture healing has been investigated in small animals
such as mice and rats in order to understand the process of fracture healing in human
(Urist and Mc, 1950, Nunamaker, 1998). Although large animals may be more
appropriate for bone healing studies, the bone remodelling process in rats and mice
involves the generation of a resorption cavity that is similar to the large animals.
Moreover, the costs for maintenance of animals and biological agents given to the
animal are less in small animals than in large animals. There are also more molecular
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tools available for the investigation and assessment of fracture healing in the rodent
model. The rat model is more commonly used than the mouse model in fracture
healing studies, because the stabilization procedure is more reproducible. Rat bones
also are larger than mouse bones so the biomechanical aspects of fixation are more
easily controlled.
The animal model of fracture healing should reflect the clinical scenario. Therefore,
the fracture models have been classified into nine categories depended on the clinical
scenario; 1) normal fracture repair, 2) established delayed non-union, 4) established
hypertrophic nonunion, 5) atrophic non-union, 6) segmental or critical size defect, 7)
high-energy, comminuted and open injury models, 8) bone repair with infection 9)
fracture repair in compromised host models (Mills and Simpson, 2012).
Understanding these models is important and the best model should be selected
based on the central question being asked in the study.
1.4.2 Selecting the mode of fixation
Because of the small size of the rodent model, development of a fixation device is
challenging. Fixation devices contribute to the mechanical environment at the
fracture site with implications for the healing process. Many fracture fixations have
been reported in small animals. They can be simply divided into three categories
(Figure 1.14); intramedullary fixation device, plate fixation device and external
fixation device. Intramedullary fixation devices, for instance intramedullary pins
(Bhandari and Shaughnessy, 2001), locking nails (Holstein et al., 2007) or
interlocking nails (Garcia et al., 2011) and intramedullary compression screws
(Holstein et al., 2009) can be applied using less invasive surgical techniques for
surgical exposure. These fixations, however, introduce damage to the medullary
canal making histological assessment of the fracture gap difficult. Plate fixation is
the most reliable technique for anatomical reduction and stable fixation (Histing et
al., 2010). The drawback of plate fixation is that it requires an invasive surgical
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approach that disrupts soft tissues around the fracture site. External fixators have a
high axial and rotational stability (Claes et al., 2009). The fracture site is totally
unaffected by the presence of the fixators allowing histological assessment of the
fracture site.
Figure 1.14 Fixation devices in small animal models: (a) plate fixation from Histing et al. (2010), (b)
intramedullary fixation from Histing et al. (2010) and (c) external fixator from Reed et al. (2002)
1.4.3 Methods for creating atrophic non-union in animal
models
Models used in bone healing research can be applied to evaluate normal fracture
healing, healing of segmental bone defects, critical size defects and fracture non-
union without a critical size defects. The critical-size defect model describes a model
in which the fracture gap is sufficiently large to prevent bone healing or bone
bridging. Conversely, in an atrophic non-union model or non-union model without a
critical size defect, mechanical manipulation at the fracture that destroys soft tissues
or biological components around the fracture site is required. Pre-clinical studies
evaluating stem cell augmentation in bone repair have largely utilised critical-defect
models (Wolff et al., 1994, Tsuruga et al., 1997). However, in clinical practice,
atrophic non-union usually occurs in association with high energy mechanisms of
injury that causes severe soft tissue injury or loss, regardless of bone defect size.
Non-union models without critical size defects may be more appropriate in the study
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of stem cell therapy for established atrophic non-union or fractures at risk of atrophic
non-union. Procedures used to produce soft tissue injury or periosteal disruption
from high injury trauma have included cauterization (Kokubu et al., 2003, Kaspar et
al., 2008) or stripping of the periosteum with intramedullary curettage (Brownlow
and Simpson, 2000, Reed et al., 2003). The method using periosteum stripping and
intramedullary curettage is relatively simple and does not require specialised
equipment. Reed et al. (2003) reported that atrophic non-union can be induced at the
tibial mid shaft by stripping the periosteum and endosteum as well as creating a
small (1.0 mm) non-critical size gap. Here, the tibia was stabilised with an external
fixator. They also found that in the early stages of atrophic non-union the gap
between the bone ends was deficient of biological components such as vessels,
growth factors or cells that might cause an atrophic non-union. This technique is
thought to be appropriate and closely reflect atrophic non-union seen in clinical
scenario.
1.5 Mesenchymal stem cells and their role for bone
regeneration
There are two types of natural stem cells based on their origin; embryonic stem (ES)
cells and adult stem cells. ES cells are derived from the inner cell mass of the
blastocyst. They are pluripotential stem cells with the capacity to differentiate into
cells of all primary germ layers: ectoderm, mesoderm and endoderm (Thomson et al.,
1998). However, they are limited by a number of factors including a technical
limitation such as isolation and culture techniques, concern regarding tumour
formation and major ethical controversy (Baschetti, 2005, Vats et al., 2005).
Recently, it has been reported that somatic cells can be genetically induced to
pluripotent stem cells by introducing four factors including Oct3/4, Sox2, c-Myc, and
Klf4 (Takahashi and Yamanaka, 2006, Takahashi et al., 2007). These cells are
known as induce pluripotent stem (iPS) cells. Although these cell have high
proliferative potential and pluripotency, the induction of this cells is an artificial
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process which may also increase risk of forming teratoma (Gutierrez-Aranda et al.,
2010). For these reasons, it is unlikely that ES and iPS cells will be used for
orthopaedic clinical applications in the near future. Adult stem cells are found in
adult tissue. These cells can be used autologously, negating much of the ethical
controversy. They have been isolated from several tissue types (Zuk et al., 2002,
Noth et al., 2002, Tuli et al., 2003, Miura et al., 2003, Young et al., 2001, De Bari et
al., 2001, De Bari et al., 2006). Mesenchymal Stromal /Stem Cells (MSCs) derived
from the bone marrow are the most commonly described source of MSCs and have
been widely used to promote tissue regeneration in orthopaedic conditions.
1.5.1 Characteristics of bone marrow derived mesenchymal
stromal/ Stem cells
In orthopedic surgery, iliac bone graft is commonly used to treat fracture non-unions
and also used in other procedures such as spinal fusion. Bone marrow from iliac bone
contains MSCs that constitute approximately 1 in 10,000 of all nucleated cells
(Chamberlain et al., 2007). Friedenstein et al. (1970) reported that this rare
population of cells could be isolated on the basis of their ability to adhere to culture
plastic. These cells were capable of proliferation and differentiation into multiple
mesodermal lineages (Pittenger et al., 1999, Caplan, 1991). There is controversy
concerning which antigens identify MSCs and immunological techniques are
therefore not widely used to isolate MSCs. Currently, most of MSCs used in studies
are isolated by plastic adherence in a process similar to that described by
Friedenstein et al. (1970). A direct bone marrow plating method is commonly used
for cells from small animals (Lennon and Caplan, 2006, Nadri et al., 2007).  With
human bone marrow, density gradient centrifugation is the most commonly used
method for isolating MSCs.
MSCs are identified by their ability to proliferate and undergo mutilineage
differentiation. The colony-forming unit–fibroblast (CFU-F) is defined as a highly
adherent colony of fibroblastic-like cells formed from a single mother cell. Thus, the
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CFU-F assay has been used to assess bone marrow progenitors. The number of
colonies formed from the total number of seeded marrow cells indicates colony-
forming efficiency (CFE). This assay indicates the percentage of cells in the marrow
that are capable of clonogenic expansion. It has been demonstrated that CFU-F
populations are not homogeneous but rather contain a hierarchy of progenitors
including multipotential MSCs and committed progenitors (Friedenstein et al., 1992,
Latsinik et al., 1986).
MSCs express a number of surface markers. These markers include a mixture of cell
surface receptors, adhesion molecules, extracellular matrix proteins, cytokines and
other molecules whose function is to communicate with other cells. These markers
are used to characterise MSCs. However, controversy remains regarding the set of
surface markers that are expressed by bone marrow-derived stem cells. MSCs do not
express: CD45 which is expressed in Hematopoietic stem cell (HSC) (McKinney-
Freeman et al., 2009), CD14 which  is expressed in innate immune cells (Cros et al.,
2010) and CD34 which is expressed in HSCs, satellite cells and endothelial
progenitors (Nielsen and McNagny, 2008, Parant et al., 2009).
Mesenchymal stem cells have been reported to express: STRO-1, CD105, CD90,
CD73, CD166, CD44, CD29 and CD54. These markers are expressed on all isolated
MSCs from bone marrow (Pittenger et al., 1999, Jiang et al., 2002). STRO-1 is an
early marker for stromal precursors and the subpopulation of cells from bone marrow
which are STRO-1 positive are able to generate CFU-F as well as differentiate into
multiple mesenchymal lineages (Simmons and Torok-Storb, 1991).
Up until now, no unique marker for MSCs has been described. Thus, a combination
of markers is used to identify and sort MSCs. The combination of CD10+, CD13+,
CD56+, and MHC Class-I + markers has been reported to identify a population of
lineage-committed progenitor cells and lineage-uncommitted pluripotent cells(Young
et al., 1999). The combination of VCAM+, STRO-1+, CD73+, CD105+ markers has
been reported to isolate MSCs from human trabecular bone (Tuli et al., 2003). D7-
FIB+, CD13+; CD45-, GPA-, LNGFR+ has been reported to select adherent cell
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monolayers that undergo chondrogenesis, osteogenesis, and adipogenesis (Jones et
al., 2002).
MSCs constitute a heterogeneous population of cells, in terms of their morphology,
physiology and expression of surface antigens. The Mesenchymal and Tissue Stem
Cell Committee of the International Society for Cellular Therapy has proposed
criteria necessary to define human MSCs. First, MSCs must be plastic-adherent when
maintained in standard culture conditions. Second, MSCs must express CD105,
CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or
CD19 and HLA-DR surface molecules. Third, MSCs must differentiate to
osteoblasts, adipocytes and chondroblasts in vitro (Dominici et al., 2006)
1.5.2 The differentiation potential of MSCs
MSCs have an ability to differentiate in vitro in specific culture media (Figure1.15).
For osteogenic differentiation, dexamethasone, ascorbate and β-glycerophosphate are
required (Stenderup et al., 2001). 1, 25-vitamin D3 has been reported to increase
mineralization in human bone marrow-derived stem cells culture (Jorgensen et al.,
2004). Their morphology and cytoskeletal components are changed when they
differentiate into osteoblasts.  Furthermore, they express several different markers
with osteogenesis such as Runx-2/Cbfa-1, Osterix, alkaline phosphatase, Bone
sialoprotein, Osteopontin, Osteocalcin, Osteonectin and Osteocrin (Heng et al.,
2004).
For chrondrogenesis, transforming growth factor beta, ascorbate, and dexamethasone
are required. MSCs are capable of chrondrogenesis and the expression of
biochemical markers including transcription factors (sox-9, scleraxis) and
extracellular matrix (ECM) genes (collagen types II and IX, aggrecan, biglycan,
decorin, and cartilage oligomeric matrix protein) are associated with chrondrogenesis
which can be found during their development (Yoo and Johnstone, 1998, Herlofsen
et al., 2011, Pittenger et al., 1999).
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To induce adipogenesis, adipogenic media consisting of dexamethasone, insulin,
isobutylmethylxanthine, and indomethacin is required (Pittenger, 2008). In these
conditions, cells will differentiate increasing PPAR-γ (Peroxisome proliferator-
activated receptor gamma) and other adipose specific factors such as lipoprotein
lipase. PPAR-γ has been found to be important in the development of adipocytes
(Rosen and Spiegelman, 2000). It can also be used as a marker for adipogenic
differentiation.
Figure 1.15 Mesenchymal stem cells: MSCs are capable of proliferation and differentiation into bone,
fat and cartilage cells. Adapted from Pittenger (1999)
1.5.3 Mesenchymal stem cells as bone progenitor cells and
trophic factor secreting cells for bone regeneration
Osteogeneic differentiation of MSCs in bone repair or regeneration is desirable
because MSCs are believed to represent in vivo bone precursors. In in vitro culture, it
has long been accepted that MSCs can differentiate into osteoblasts (Pittenger et al.,
1999, Muraglia et al., 2000). MSCs contribute not only in a physiological process but
also in a reparative process. As bone is a dynamic tissue, which degrades and
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regenerates throughout life, it has an inherent capacity for remodelling. In this
process, osteoclasts make a tunnel into the bone (i.e. a cutting cone) and then MSCs,
osteoprogenitor cells and osteoblasts fill up the cone with new bone with living cells
(Buckwalter et al., 1996). Bone is unique in that it can regenerate itself without scar
formation after injury. MSCs play an important role in bone regeneration after injury
or trauma. They originate from the periosteum, endosteum, bone marrow, and
possibly the vasculature of the muscle tissue and are recruited to differentiate into
osteoblasts. Although bone can be generated through intramembranous or
endochondral formation, both processes result in mature osteoblasts which make a
mineralised tissue or bone nodule recognisable as bone. This process has three
developmental stages: proliferation, extracellular matrix development/maturation and
mineralization (Aubin, 1998).
Each stage involves several mediators. Bone morphogenetic proteins (BMPs) have
been widely reported to be integral to the bone formation process. BMP-mediated
osteoblast differentiation is dependent on the Smad signaling pathway. BMP
inducible transcription factors, Runx2 (Cbfa1) and Osx, play an essential role in
osteoblast differentiation and osteogenesis (Harada and Rodan, 2003). Runx2 is
expressed in mesenchymal cell condensations of the embryonic endochondral
skeleton and induces an osteoblast-specific pattern of gene expression (Ducy et al.,
1997).  Osx is a novel zinc finger-containing transcription factor that is specifically
expressed in developing bones. Ectopic expression of Osx in non-osteoblastic
lineages induced expression of osteocalcin and collagen I which are osteoblast
producing proteins (Nakashima et al., 2002). Abnormality of these genes may lead to
congenital bone disease. Runx2 gene defects cause Cleidocranial dysostosis
syndrome which is characterized by abnormal intramembranous ossification. This
phenotype has been demonstrated in a mouse model in which animals die at birth and
lack bone and tooth development (Aberg et al., 2004).
There are also several markers expressed during the developmental stage where
MSCs differentiate into osteoblasts. Osteocalcin which is a bone-specific
glycoprotein may promote bone matrix calcification. Osteopontin which is a
phosphoprotein that plays role in cell attachment and proliferation as well as
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mineralization of bone matrix. Osteonectin is one of the important non-collagenous
proteins associated with bone mineralization stages (Aubin, 1998). Expression of all
these factors could be used to indicate late osteogenesis in in vitro culture of MSCs
(Donzelli et al., 2007).
However, the role of MSCs in bone repair is not only to act as progenitors but also to
secrete trophic factors. Several studies have demonstrated that MSCs produce many
cytokines and mediators including interleukin-1, -6, -7, -8, -11, -14 and-15,
leukaemia inhibitory factor (LIF), stromal cell-derived factor (SDF-1), stem cell
factor (SCF-1), Flt-3 ligand, macrophage-, granulocyte- and granulocytemacrophage-
colony stimulating factors (M-, G-, and GM-CSF) and vascular endothelial growth
factor (VEGF) (Haynesworth et al., 1996, Majumdar et al., 1998, Hung et al., 2007)
Trophic mediators from MSCs are thought to contribute to regulation of the fracture
healing process. Pro-inflammatory cytokines which play a role in the inflammatory
phase of fracture healing include IL-1,-6 and TNF-α (Kon et al., 2001). These pro-
inflammatory cytokines recruit inflammatory cells and remote MSCs to the site of
injury as well as stimulating the synthesis of extracellular matrix (Einhorn et al.,
1995). Bone morphogenetic proteins (BMPs) are important in the process by which
MSCs differentiate into more committed osteoprogenitor cells and osteoblasts (Chen
et al., 2012). The FGFs and VEGFs are angiogenic factors involved in
neovascularization during the proliferative phase (Ferrara and Davis-Smyth, 1997).
Moreover, a number of other cytokines including platelet-derived growth factor
(PDGF), transforming growth factor-beta (TGF-b), growth differentiation factors
(GDFs) stimulate and enhance MSCs during fracture repair (Lieberman et al., 2002).
In addition to their contribution to bone healing, the paracrine effects of MSCs have
been shown to be chrondroprotective in OA models (Murphy et al., 2003).
Furthermore, evidence from cardiovascular regeneration studies confirms that the
therapeutic improvement seen following the application of MSCs in a heart injury
models occurs not only through engraftment, but also through enhancement of
angiogenesis and prevention of cardiomyocyte apoptosis (Xiang et al., 2009, Tang et
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al., 2005). It has been therefore suggested that secretion of growth factors and
cytokines is a major way by which MSCs may promote tissue regeneration.
1.5.4 Donor factors influencing MSC characteristics
There are several conditions such as aging, excessive alcohol ingestion, smoking,
and osteogenesis imperfecta that affect the behaviour and quantity of MSCs within
tissues. MSCs from patients with these conditions may be impaired and have
perturbed function in bone regeneration and fracture healing. In high energy trauma
or open fractures, the periosteum at the fracture site, which serves as a major source
of bone progenitors is damaged. This can negatively affect the fracture healing
capacity and increase an individual’s risk of non-union. Thus, in these impaired
hosts, an exogenous source of MSCs should be considered as a therapeutic option to
augment fracture healing.
It has been reported that ageing influences the behavior MSCs. (Stolzing et al., 2008,
Nishida et al., 1999, Muschler et al., 2001, Majors et al., 1997). There is a decrease
in the yield of MSCs isolated from the bone marrow of older patients. The CFU-F
assay is a classic method to determine the number of MSCs with in any given tissue.
The number of colony forming of bone marrow cells was found to fall with
increasing age of donors. Aging affects the differentiation potential of MSCs. MSCs
from older donors cultured under osteogenic and chondrogenic in vitro condition had
significant less ALP activity and GAG content compared to younger or donors
(Sethe et al., 2006). The finding from studies into osteoporosis have shown that the
aging process accelerates adipogenic differentiation capacity of MSCs and favours
adipogenic over osteogenic differentiation (Rodriguez et al., 2008). The fall in
osteogenic potential is a result of imbalance of two main transcription factors,
namely RUNX-2 and PPAR-γ (Kim et al., 2012). A report from animal study
evaluating the effects of transplantation of BMMSC in mice, animals underwent
whole body X-irradiation (500 cGy) to eradicate host bone marrow stem cells.
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Animals who subsequently received MSCs isolated from young mice had significant
improvement in bone mineral density over the period of six months after
transplantation compare to those who received cells isolated from aged mice (Shen et
al., 2011). The use of autologous MSCs in elderly patients may be limited by reduced
potency of the cell’s ability to promote bone repair and regeneration, so alternative
cell sources or interventions should be considered to promote the fracture healing in
this particular group.
A reduction in bone progenitors is associated with heavy alcohol consumption. It has
been reported from in vitro and in vivo studies (Giuliani et al., 1999) that the ability
of MSCs to form the colonies was reduced when cells were exposed to ethanol and
acetaldehyde and this effect was dosed dependent. The same study also reported that
CFU-F formation in bone marrow cultures from alcoholic patients was significantly
less than healthy controls. Alcohol also affects the gene expression of type I collagen
and significantly reduced its synthesis during the in vitro osteogeneic induction of
human bone marrow derived MSCs. It alters osteogenic differentiation (Gong and
Wezeman, 2004) and may distrup in the reparative process. It has been reported that
alcohol suppresses osteogenic differentiation and matrix synthesis by MSCs, while
adipogenesis is promoted (Chakkalakal, 2005). In this animal study, rats that were
given alcohol daily for 3 months (7.6 g of 95 % ethanol/ kg body weight per day) had
lower bone mineral density than controls (Broulik et al., 2010, Hogan et al., 1999).
Bone morphology and mechanical properties also deteriorated in animals treated
with alcohol (Broulik et al., 2010). The number of MSCs from patients, who have
chronic heavy alcohol consumption and their ability to differentiate is impaired,
suggesting that excessive alcohol intake may impair the fracture healing process and
inhibit bone regeneration.
Nicotine is an organic substance found in all types of cigarettes and is responsible for
smoking addiction (Sofuoglu and LeSage, 2012). A number of studies have shown
that nicotine has negative effects on bone quality including bone mass, bone turnover
and bone strength in small animals (Akhter et al., 2003, Iwaniec et al., 2001, Broulik
et al., 2007). Smoking is a risk factor for delayed healing of fractures and non-union.
In prospective cohort studies, smoking has been shown to increase the mean time to
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union and to be associated with other fracture complications such as osteomyelitis
(Adams et al., 2001, Castillo et al., 2005). It has been reported that smoking is
significantly associated with failure of operative treatment of established non-unions
of the scaphoid bone. In this study, the operative fixation consisted of internal
fixation with autologous bone grafting. There was a significant difference in the rate
of union between non-smokers (the success rate was 82.4%) and smokers (the
success rate was 40.0%). Smoking not only reduces the blood supply to the fracture
site but also impairs progenitor cells (Gullihorn et al., 2005). MSCs in autologous
bone grafts of smokers may be impaired because of the effects of smoking. The yield
of MSCs in bone marrow from smokers has been found to be significantly lower than
from non-smokers (Beyth et al., 2008). In addition there is a reduced yield of VEGF-
A and IL-6 from MSCs isolated and cultured from fracture heamatoma (Sloan et al.,
2009). Thus, the contribution of autologous MSCs to fracture healing in smokers
may be reduced. Therefore an alternative exogenous source of MSCs should be
considered if MSCs are used to treat non-unions in smokers.
High blood glucose alters the function of vascular progenitors (Khan and
Chakrabarti, 2006). Similarly, high glucose affects the growth and differentiation
potential of bone marrow MSCs (Keats and Khan, 2012, Li et al., 2007). Results
from in vitro studies (Keats and Khan, 2012) demonstrate that high blood glucose
decreases the expression of Runx-2 and SP7 (osteogenic transcription factors) by
MSCs in osteogenic media but increases the expression of Sox9 and Nkx3.2
(chondrogenic transcription factors) in chondrogenic conditions. The ability for
MSCs to resist glucose toxicity is dependent on MSC stemness (Li et al., 2007).
Results from pre-clinical studies indicate that MSCs from type 2 diabetic db/db mice
do not improve neovascularization in an ischemic limb model, while adipogenesis is
promoted. This study also showed that Nox4-acitvity generated oxidative stress and
decreased the multipotency of MSCs (Yan et al., 2012). Overall, these studies
suggest that the blood glucose levels should be well controlled, especially during the
fracture healing period. However, the evidence that high blood glucose levels impair
MSCs in fracture healing remains limited.
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Some congenital bone diseases increase the risk of fracture. Osteogenesis imperfecta
(OI) is a genetic disorder in which the collagen type 1 gene is mutated. OI patients
present with multiple fractures and the severity of disease depends on the type of OI
(van Dijk et al., 2011). There is abnormal collagen type 1 structure, which is the
main collagenous component of bone matrix. Autologous cell based therapy may be
problematic because of the effects of disease causing the alteration of MSCs or bone
progenitors (Gioia et al., 2012), unless the cells are genetically manipulated to
correct the mutation (Chamberlain et al., 2008). The cells for transplantations for OI
treatment can be donated from healthy bone marrow and preliminary results from
clinical studies show promising results with MSC treatment (Horwitz et al., 2002).
This suggests that allogeneic transplantation of MSC for bone regeneration is
possible.
Local progenitors that contribute to bone healing are found at the peristeoum and
also within the fracture haematoma (Oe et al., 2007, Malizos and Papatheodorou,
2005).  In more severe injuries and especially with open fractures, the risk of fracture
non-union is increased, which may be as a consequence of damage to the source of
progenitor cells. It has been demonstrated in animal models that removal of the
periosteum and fracture haematoma at the initial phase of fracture healing impairs
the process of fracture repair and there was a decrease in periosteal cell proliferation
compared to the control group (Ozaki et al., 2000, Grundnes and Reikeras, 1993).
Local anaesthetics such as levobupivacaine, lidocaine or bupivacaine that are used to
control pain locally, for example as a part of a haematoma block of distal end radius
fracture, may influence healing by having a negative effect on bone marrow MSC
proliferation and osteogenesis (Tayton et al., 2012). The local biological components
contributing to fracture healing are impaired in high energy fractures, so
augmentation of biological factors such as by providing additional bone marrow cells
during healing may improve fracture healing and prevent progression to non-union.
Bone fracture has a systemic effect on bone marrow MSCs. It has been reported that
the yield of MSC from bone marrow from patients with multiple fractures was
significantly increased whereas the yield and proliferation ability of MSC from bone
marrow decreased in an established atrophic non-union (Seebach et al., 2007). It has
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been reported that cells isolated from human non-union tissues demonstrate
increased levels of cell senescence and reduced capacity to form osteoblasts which is
associated with significantly elevated secretion of Dickkopf-1 (Dkk-1) (Bajada et al.,
2009). In addition, there is significant down-regulation of factors including canonical
Wnt-, IGF-, TGF-beta-, and FGF-signaling pathways in non-union osteoblasts. These
factors are involved in the proliferation and differentiation of bone progenitors
(Hofmann et al., 2008). These results suggest that progenitors at the site of atrophic
non-union have impaired function. Thus, exogenous MSCs or growth factors may be
required to support fracture healing.
1.6 Clinical issues relating to MSC transplantation for
bone regeneration in atrophic non-union
1.6.1 The options for application of MSCs for bone
regeneration
MSCs can be delivered systemically via intravenous injection. It has been reported
that MSCs can migrate to an injured site (Li and Jiang, 2011, Van Linthout et al.,
2011). Recently, the mechanism by which homing occurs has been investigated. The
matrix metalloproteinase (MMP)-dependent pathway may be associated with cell
trafficking. Hypoxia-inducible factor-1 (HIF-1) promotes stromal –derive factor-1
(SDF-1) which is a ligand of CXC chemokine receptor-4 (CXCR-4) on the
progenitor cells (Ceradini et al., 2004). The injury site is hypoxic and thus this
pathway may contribute to recruitment of MSCs to sites of injury. Furthermore, it
has been reported that a systemic intravenous injection of CXCR4-expressing MSCs
can reduce bone resorption, increase bone matrix formation and improve bone
stiffness and strength in osteoporotic mice induced by dexamethasone (Lien et al.,
2009). Horwitz et al. (2002) demonstrated the beneficial effects of intravenous
administration of MSCs in patients with osteogenesis imperfecta. Although, it was a
small cohort study, the results showed significant more acceleration of growth
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velocity in the MSC treatment group than in the control. The growth velocity was
improved from 60% to 94% (median, 70%) of the predicted median values for age-
and sex-matched unaffected children. In a fracture healing study, it was reported that
intravenous MSC transplantation had a positive effect on fracture healing in mouse
models and transplanted MSCs could migrate and engraft at the callus endosteal
niche (Granero-Molto et al., 2009). However, the exact mechanism by which this
occurs remains controversial and the migration efficacy is extremely low for
systemic transplantation of MSCs.  MSCs may distribute not only to the fracture site
but also to other tissues (Gao et al., 2001, Devine et al., 2003). Previous reports
demonstrated that most of the MSCs delivered by intravenous infusion were trapped
in the lungs (Gao et al., 2001, Schrepfer et al., 2007). Therefore, an alternative
method of delivery such as local injection may be more practical for orthopaedic
applications, particularly in the case of fracture non-union, which usually results
from local biological failure.
To overcome issues of migration and homing, local implantation at the fracture site
can be used. As mentioned in section 1.4, it has been demonstrated that percutaneous
injection of either bone marrow aspirate or bone marrow concentration technique are
reliable methods of delivery. Connolly (1998) reported that bone marrow aspirate
injection in fracture non-unions could improve the healing rate. Hernigou et al.
(2005) demonstrated that percutaneous injection of bone marrow concentrate could
treat fracture non-union. This mode of delivery is simple, and minimally invasive.
Thus, the delivery of expanded MSCs, isolated from bone marrow, might be also
applied by this technique. This technique overcomes problems with MSC migration
and other adverse systematic effects.
In non-union cases associated with extensive bone loss or bone defects, iliac bone
grafting remains the gold standard treatment.  It provides bone and progenitor cells,
growth factors as well as the construct for bone regeneration. However, the amount
of autologous bone graft is limited and harvesting bone graft from iliac crest can
result in a painful scar and numbness around the harvested site, both of which affect
quality of life (Littenberg et al., 1998). To address this, bioengineered materials have
been developed and have already applied in clinical practice. Many artificial
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materials are available for clinical use. So far, calcium phosphate based ceramics
such as hydroxyapatite (HA), β-tricalcium phosphate (β-TCP), bioactive glass and
ceramic based graft artificial materials have been most used in the fields of
orthopaedic trauma and arthroplasty. Calcium phosphate ceramics are synthetic
scaffolds that have been used as bone substitute in orthopaedics since 1980s (Hak,
2007, Bohner, 2000). Autologous MSC transplantation with ceramic cylinders has
been successfully used to treat segmental femoral defects in rats (Ohgushi et al.,
1989) and also in murine craniotomy defects (Krebsbach et al., 1998). In large
animal studies using dogs and sheeps, autologous bone marrow derived MSC were
delivered together with bioceramic scaffolds. They were reported to have good
outcomes for healing segmental defects (Arinzeh et al., 2003, Bruder et al., 1998).
Injectable biomaterial is desirable particular for a minimally invasive surgery and can
be used as a carrier for stem cell based-therapy for bone repair. Injectable silicate-
substituted calcium phosphate bone substitute material has been reported to be an
appropriate bone graft material with a particle size of 250–500 μm (Coathup et al.,
2013a).
1.6.2 Immunological effect of MSCs
Sufficient numbers of MSCs and their functional potential of differentiation are
important contributory factors to treatment outcomes (Zhang et al., 2008, Hernigou
et al., 2005). However, as mentioned in section 1.3.5, in the clinical setting, the
autologous source may be often limited as 1) the yield and differentiation capacity of
these cells in bone marrow is decreased in older patients, smokers and those with
medical co-morbidities, 2) isolation and expansion of autologous MSCs is time
consuming and such delays may detrimental, particularly where the timing of
implantation is crucial. Due to the limitation of autologous BMSCs in clinical
application, allogeneic sources of BMSCs may be a viable alternative option in
atrophic non-union repair. Allogeneic BMSCs can be isolated from young healthy
donors. In principle, it should be possible to use MSCs from a universal donor
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because of their immune-privileged properties. Thus, harvested MSCs would have
the potential to be expanded and cryopreserved for future use, so these cells can be
used immediately as required.
Previous studies have demonstrated that BMSCs are immune-privileged. These cells
can avoid or actively suppress immunological responses (Aggarwal and Pittenger,
2005, Jones and McTaggart, 2008). MSCs do not induce significant alloreactivity
(Barry et al., 2005). These cells are immune-privileged because they lack a major
histocompatibility complex (MHC). It has been reported that MSCs express low-
intermediate levels of MHC class I and they do not express MHC class II on their
surface membrane (Le Blanc et al., 2003). They also lack co-simulation molecules
such as CD80, CD86 or CD40 (Tse et al., 2003). Although it has been reported that
MCH class II can be induce for expression on the surface of MSCs by interferon
gamma (IFN-γ), induced MSCs failed to stimulate proliferation in allogeneic
lymphocytes (Le Blanc et al., 2003) because of the absence of co-stimulation
molecules.
Several studies have shown that the immunomodulatory properties of MSCs can be
beneficial. MSCs have been used in the treatment of graft-versus-host disease
(GvHD) in combination with allogeneic HSC transplantation. Here they reduce the
host immune response and improve engraftment of HSCs (Cohen and Sudres, 2009,
Sato et al., 2010).  Systemic delivery of allogeneic MSCs in bone disease has also
been reported (Le Blanc et al., 2005). A female fetus with multiple intrauterine
fractures, diagnosed as having severe osteogenesis imperfecta was transplanted with
allogeneic HLA-mismatched male fetal MSCs at the 32nd week of gestation in the
absence of immunosuppressive therapy. There was no evidence of immune rejection
of the transplanted cells and donor MSCs could be detected using centromeric XY-
specific probe at the age of nine months. This study demonstrated the possibility of
allogeneic transplantation in bone systemic bone disease, however, well-controlled
clinical trials are yet to be performed.
Xenotransplantation can be used to model extreme immune response conditions
(Samstein and Platt, 2001). Due to the unique immunologic tolerance of MSC, it may
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be feasible to use MSCs from a universal donor cells. Xenogeneic models have been
evaluated in in vivo cross-species administration of MSC in a variety of experimental
models (Li et al., 2012). The benefit of MSCs being immune privileged has been
shown in xenotransplantation for bone defect. Regeneration of the bone tissue after
unilateral xenogeneic transplantation of human MSCs was studied in rats with injury
to both femurs. The animals did not have local pathological reactions or
complications after implantation. Implantation of MSCs was reported to significantly
stimulate the reparative osteogenesis. The bone tissue formed after transplantation of
MSCs was integrated into bone and underwent complete remodeling (Fatkhudinov et
al., 2005). The authors suggested that xenotransplantation of prenatal MSCs without
immunosuppression was not followed by the development of early or delayed
complications or local reactions of graft rejection. The potential of human MSCs and
human osteoblasts for bone regeneration was also compared in rat calvarial defects
(Zong et al., 2010). Either human MSCs or human osteoblast in poly-lactic-co-
glycolic acid (PLGA) were transplanted into 5 mm in diameter full thickness defect
of nonimmunosupressed rat calvarium. Histological analysis showed that the human
MSC construct had effective bone regeneration and it was superior to the osteoblast
construct. These results suggest that immunogenic characteristics of the cell
construct affect functions of the implanted cells.
However, the results of xenotransplantation are inconsistent. Niemeyer et al (2010c),
investigated the bone regeneration potential of hMSC after xenogeneic
transplantation compared with autogenous rabbit MSC in a critical-size bone defect.
Xenogeneic transplantation showed inferior clinical outcomes for bone regeneration.
The same group reported results from a large animal study (Niemeyer et al., 2010b).
They investigated the effect of xenogeneic transplantation using a 3.0-cm-long sheep
tibia bone defect. Autologous bone marrow MSCs resulted in improved bone
regeneration potential as demonstrated using radiology and histology when compared
to xenogeneic hMSC. However, there were no significant local or systemic adverse
effects in both xenotransplantation and autotransplantation.
Using MSCs from a universal donor still remains controversial with recent studies
producing conflicting results of the bone regeneration potential of xenogeneic MSCs.
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There would be several advantages if allogeneic bone marrow derived MSCs could
be used in atrophic non-union without using immunosuppressive therapy. Before
adopting MSCs for augmentation therapy in non-union, it is important to understand
mechanisms how MSCs enhance the fracture healing process and to evaluate any
adverse effects that may result from an immune response.
1.6.3 Considerations of MSC source and preparation
In most of the studies that have been conducted to evaluate the therapeutic potential
of cell based therapy for bone regeneration utilise bone marrow stromal cells,
concentrated bone marrow cells, cultured MSCs or sorted MSCs. Bone marrow
derived MSCs represent a heterogeneous population (Huang et al., 2011). It has been
demonstrated that MSCs from primary culture of bone marrow contained at least
three types of cells based on morphology; spindle shape cells, star shaped cells and
large flat cells (Xiao et al., 2010). Bone marrow stromal cells are able to form
colonies under low density culture (Pochampally, 2008). This capacity indicates the
yield of MSC enrichment and differentiation potential, which can be determined
using the colony forming assay (CFU-F). Colonies varies in morphologies including
the number of cells, size and shape. It has been reported that circularity of colony can
be used as a parameter to select the highly potency MSC clone (Gothard et al., 2013).
MSCs from their native tissues can be isolated and expanded in specific culture
conditions. However, culture conditions can alter their phenotype and the expanded
cells may be heterogeneous. Recently, as mentioned in section 1.5.1, the several
markers of MSCs have been identified. These makers can be used for purification of
the MSCs immediately after extraction from tissues. Because of the absence of a
unique in vivo maker for MSC as well as possibility of changing phenotype after
expansion in culture condition, the identification of markers of MSCs in their in vivo
niche is important. With this information, MSCs can be isolated, sorted and utilised
for clinical application without expansion in culture.
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Recently, perivascular stem cells (PSCs) or pericytes have been comprehensively
characterised in terms of their MSC potential’s. Crisan et al. (2008) have been
demonstrated a perivascular origin of MSCs in multiple human organs including fat
tissues and bone marrow. These cells are known as multipotent pericytes or pericyte
precursor cells which express CD146, NG2 and PDGF-Rβ. These cells can be found
in perivascular areas with the blood vessel walls representing niche of these cells. It
was demonstrated that these cells express all known MSC markers and had the
ability to proliferate and differentiate into multiple mesodermal lineages including
bone. As these cells share MSCs characteristics, they could potentially contribute to
the fracture healing process and may have positive effects when used to treat atrophic
non-unions. It has been reported that the bone regeneration potential of PSCs after
intramuscular implantation in SCID mice (James et al., 2012b). PSCs were isolated
from lipoaspiration and purified using CD146+, CD34- and CD45- as the
immunophenotype markers. These cells were implanted with tricalcium phosphate
into the muscular pocket of biceps femoris muscles of mice. Ectopic bone formation
significantly increased in the presence of hPSCs in comparison with patient-matched
hSVF cells (human stromal vascular fraction). It should be possible and more
advantageous to use PSCs for bone regeneration as these cells represent a well-
defined population (CD146+, CD34-, CD45-) with potent bone regeneration
potential. Pericytes can be isolated in sufficient number to be in the non-union
fracture without the requirement for culture expansion.
Strategies for preparing MSCs are summarised in Figure 1.16. It is not clear which
technique is most appropriate for bone regeneration. However, in vitro studies
suggest that early passage MSCs have better osteogenic potential (Sugiura et al.,
2004) and so the use of non-cultured cells may represent the optimal strategy.
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Figure 1.16 Preparation methods of MSCs
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Part 2: General methods and experimental
validation of methods
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Chapter 2: General materials and methods
This chapter details the general materials and methods used in this thesis. The
methods of primary MSC isolation from both rat and human, culture techniques,
common cell assays and the method of MSC characterisation are described. Common
methods, techniques and materials required to establish an atrophic non-union model
are presented. A minimally invasive delivery technique using percutaneous injections
is described. Imaging techniques to facilitate evaluation of fracture healing are
provided including radiological assessments to determine of the progression of
fracture healing and detailed micro-CT evaluation. The Radiographic Union in Tibia
(RUST) scale and Lane & Sandhu fracture scoring systems were validated and used
in this study. The details of sample preparation and histological assessment are
given. Immunohistochemistry and Immunocytochemistry for cell tracking and
characterisation are detailed. Immunological responses following cell injection were
evaluated using the enzyme-linked immunosorbent assay (ELISA) from serum and
lymph node histomorphometric assessment. However, the experimental design and
methods specific to each chapter are listed separately in the relevant chapters.
2.1 Primary cell isolation and culture
In this study, the cell culture system was based on a mammalian cell culture. Primary
cells were derived from both rat and human tissues. A number of cell types were
isolated: (1) rat MSCs (rMSCs) derived from three sources, including bone marrow,
periosteum and fat tissue; (2) human MSCs (hMSCs) derived from bone marrow
(femoral head) and; (3) human perivascular stem cells (PSCs or “pericytes”) derived
from adipose tissue. All cell culture procedures were conducted in a class two, High-
Efficiency Particulate Air (HEPA) filtered laminar flow hood using sterile
equipment. Cell growth kinetics, morphology and characterisation studies were
performed in vitro. The functional or therapeutic potential for bone regeneration of
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these cells were determined in in vivo studies using rat model, simulating the clinical
scenario of atrophic non-union. This section details the general materials & reagents
used and describes the techniques & methods used in cell cultures.
2.1.1 Media, reagents and materials used for cell culture
The general chemicals and their manufacturer are listed below:
- Dulbecco’s Modified Eagle’s Medium (DMEM) - Low glucose (Gibco, UK)
- Dulbecco’s Modified Eagle’s Medium (DMEM) - High glucose (Gibco, UK)
- Fetal bovine serum (FBS) (Gibco, UK)
- Penicillin (10,000 units/ml) and streptomycin (10,000 µg/mL) (Gibco, UK)
- Phosphate-Buffered Saline (PBS) (Gibco, UK)
- 0.05% Trypsin-EDTA (Gibco, UK)
- Dimethyl sulfoxide (DMSO) (Sigma-Aldrich)
- 0.4% Trypan Blue Solution (Gibco, UK)
- Plasticware for cell culture (Corning, UK)
- Collagenase type II (Sigma-Aldrich, UK)
- Bovine serum albumin (BSA) (Sigma-Aldrich, UK)
2.1.2 Preparation of media and reagents for cell culture
These following solutions were prepared for use in the experiments.
- Basal medium for rMSC and hMSC cultures
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This medium was used for rMSC, rat fibroblast (isolated from tail tips) and hMSC
cultures. It consists of DMEM-Low glucose, 10% heat-inactivated FBS and 1%
penicillin/streptomycin.
- Basal medial for human pericyte cells
This medium was used for pericyte culture. It consists of DMEM-high glucose, 10%
heat-inactivated FBS and 1% penicillin/streptomycin.
- Freezing medium
Freezing medium consists of 90% FBS and 10% DMSO.
- Collagenase solution
Collagenase solution for the digestion of tissues was composed of 1 mg/mL
collagenase type II and 3.5% BSA in DMEM
- Red blood cell lysis buffer
Red cell lysis buffer consisted of 9 parts of 0.83% (w/v) ammonium chloride and 1
part of 2.059% (w/v) Tri base. The pH of this solution was adjusted using 1M
hydrochloric acid to 7.65.
2.1.3 Cell Isolation
2.1.3.1 Preparation of rat tissue and rMSC isolation
The rMSCs used in this study were isolated from adult (3-4-month-old) male Wistar
rats obtained from a recognised biological service. The animals were humanely
sacrificed using a carbon dioxide overdose (schedule 1, as per UK Home Office
Procedural Guidelines). Following confirmation of death, the skin around the groin
and both hind limbs was shaved and cleaned using 70% alcohol. Adipose tissue from
the inguinal areas was harvested for subsequent isolation of cells (Figure 2.1). For
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the isolation of rMSCs from bone marrow, femora were removed and cleared of
overlying skin and muscle (Figure 2.2). Periosteal tissues were carefully dissected
from the femur (Figure 2.3). All samples were then placed in sterile containers with
basal media and immediately transported from the animal facility to the laboratory
on ice (with 30 minutes). Each sample was then rinsed three times in sterile PBS.
Figure 2.1 Harvesting of Inguinal adipose tissue from Wistar Rats: Following schedule 1 killing, (a)
the skin overlying the lower limbs and inguinal region was shaved. (b) The skin overlying the groins
and femora was incised and removed, revealing underlying inguinal adipose tissue. (c, d) This tissue
was excised and placed in collection media for immediate processing.
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Figure 2.2 Harvesting of Bone marrow tissue from femoral bone: Following schedule 1 killing, (a)
excision of overlying skin and muscle incision was made (b) to reveal the underlying hip joint. (c) The
femoral head was disarticulated and (d) the muscles and periosteum were stripped from the femora.
(e) The femoral head was cut in order to expose the bone marrow, and (f) irrigation was performed of
the distal femora.
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Figure 2.3 Harvesting of periosteal tissue from Wistar Rats: (a) excision of overlying muscle and (b)
the periosteum tissue was identified.
The isolation of rMSCs was performed under sterile conditions. The tibia and femur
were separated before soft tissues were removed and the bone ends were cut using
scissors to expose the marrow. Bone marrow was obtained by flushing the femora
with DMEM using a 21-G needle and a 1-mL syringe using a published protocol
(Lennon and Caplan, 2006). Cells were liberated from adipose tissue and periosteum
by digestion in collagenase containing medium as described in a previously reported
technique (Zuk et al., 2002) for 45 minutes in a shaking water bath (180 rpm) at
37oC.  An equal volume of basal medium was added to halt the digestion and the
total suspension was passed through a sterilised nylon mesh to remove large clumps.
The suspension was then passed through a 100µm followed by a 70µm strainer and
centrifuged (1,200 rpm, RT, 5 mins). The supernatant was discarded and the pellet
was resuspended in 10 mL red cell lysis buffer and incubated at RT for 10 minutes.
An equal volume of basal medium was added and the suspension centrifuged (1,200
rpm, RT, 5 mins). The supernatant was again discarded and the pellet was
resuspended. The cell suspension was then passed through a 40µm strainer. Cell
solution was centrifuged at 1,200 rpm for 5 min and resuspended in 3 mL basal
medium and counted using a haemocytometer using tryphan blue to distinguish non-
viable cells. Isolated cells were then placed into 75 cm2 flasks containing basal
medium and incubated at 37 °C and 5% CO2. Cells from passage 2-4 from the
primary cultures were used in experiments to establish growth curves, population
58
doubling time (PDT) and colony forming ability or were preserved in freezing
medium (10% DMSO in FBS) in liquid nitrogen for further experiments.
2.1.3.2 Preparation of human tissue and hMSC isolation
hMSCs were isolated from the femoral heads of patients taken during a hip
replacement operation. These tissues were obtained under informed consent with the
approval of the local ethical committee (LREC 2002/1/22). The established protocol
for isolating hMSC in this study was previously reported. Isolated cells from this
technique expressed CD105 (one of MSC surface markers) in about 90% of the
isolated cells (Tremoleda et al., 2012). Samples were kept in basal medium at 4°C
until processing and cell extraction (maximum of 24 hours). Samples were prepared
under sterile conditions (Figure 2.4). Bone marrow and cancellous bone from the
femoral head were removed and transferred into 25 mL of basal medium in a 50 mL-
falcon tube. The tissue was digested using a collagenase solution for 45 minutes in a
shaking water bath (180 rpm) at 37oC.  An equal volume of basal medium was added
to halt the digestion and the total suspension was passed through a sterilised nylon
mesh to remove large clumps.  The suspension was then passed through a 100 µm
followed by a 70 µm strainer and centrifuged (1,200 rmp, RT, 5mins). The
supernatant was discarded and the pellet was re-suspended in 10 mL red cell lysis
buffer and incubated at RT for 10 minutes.  An equal volume of basal medium was
added and the suspension centrifuged (1,200 rpm, RT, 5mins).  The supernatant was
again discarded and the pellet was resuspended in 5 mL basal medium and counted
using a haemocytometer using tryphan blue to distinguish non-viable cells.
Nucleated cells were seeded in a 75 cm2 flask and maintained at 37 °C in 5% CO2
incubator for 48 hours. After incubation, the culture medium containing non-
adherent cells was removed and the remaining adherent cells were washed with
1xPBS three times before addition of fresh basal medium. Primary isolated adherent
cells were maintained with addition of fresh culture medium every three days until
the cells reached 80% confluence. Isolated cells were preserved in freezing medium
(10%DMSO in FBS) in liquid nitrogen after passages 2-3.
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Figure 2.4 Extraction of bone marrow from a human femoral head. (a) Femoral heads were obtained
from hip replacement procedures in which the proximal femur was divided through its surgical neck.
(b) Cancellous bone and (c, d) marrow visible on inspection of the cut surface of the femoral neck was
removed by curettage.
2.1.3.3 Isolation of human perivascular stem cells (PSCs) or Pericytes
PSCs at passage 3-4 were supplied by Dr. Christopher West. These cells were
extracted and isolated from whole fat or lipoaspirate which had been obtained from
patients during cosmetic surgery (Lothian Research Ethics Committee reference;
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10/S1103/45). After digestion with collagenase solution, cells from the stromal
vascular fraction (SVF) of adipose tissue were sorted using CD45, CD144, CD34 as
negative markers and CD 146 as the specific marker for PSCs from the subvascular
fraction (SVF) after collagenase digestion (Figure 2.5), according to a previous
report. (Crisan et al., 2008).
Figure 2.5 Gating strategy for the sorting of pericytes from adipose tissue. (a) Following double
scatter cell and (b) singlet selection, (c) non-viable cells staining for 7-AAD (7-amino-actinomycin D)
were excluded. (d) CD45+ haematopoetic cells and CD144+ endothelial cells were excluded, prior to
(e, d) selection of the CD146high and CD34- pericytes. (with permission from Dr. Chris West)
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2.1.3.4 Cell cultures and expansions
Prior to experimentation, the cells, which had been stored in cryo-vials in liquid
nitrogen were thawed rapidly in a water bath at 35.5 °C, prior to resuspension in 10
mL of basal media. This cell suspension was then centrifuged at 1,200 rpm for 5
minutes. The supernatant was removed and the cells were resuspended in 15 mL of
basal media and seeded onto new tissue culture flasks. Cell cultures were maintained
at 37 °C in 5% CO2 with basal media replaced every three days. When the cells had
reached confluence, they were detached using 0.25% trypsin with 0.1 mM EDTA for
5 min at 37°C. The cells were counted and split into fresh flasks (ratio 1:3) for
expansion.
2.1.3.5 Cell counting
Cell counting is an important technique used to study cell growth, proliferation and
colony forming in vitro and to prepare the cells for implantation experiments (in
vivo). The haemocytometer cell counting method was used to count cells in this
study. This technique is simple, convenient and readily available. It is considered to
be the gold standard method for counting cells. Cell viability was determined using
the dye-exclusion method. Dead cells and debris taken in trypan blue can be
distinguished and excluded from live cells. The haemocytometer consists of two
chambers divided into nine 1-mm squares (grid) (Figure 2.6). After applying a cover
slide, each grid occupies 0.1 µL of volume. Cells were counted from four outer
quarter grids of both chambers to determine average cell counts in 0.1 µL. The
average cell counts within grids together with the dilution factor used in the
preparation of cells are used to calculate the number of cell/mL as per the following
equation (2.1):
Total cells/ml = Average grid cell count x 104 x Dilution factor Equation 2.1
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The Dilution factor is the ratio of the total volume of cell suspension and trypan blue
to the volume of the original working cell suspension
Figure 2.6 Schematic of the markings on a haemocytometer: Each grid (highlighted here in red) holds
0.1 µl of volume following application of a cover slide
2.1.3.6 Growth curves
To investigate the growth pattern of rMSCs from the 3 sources (bone marrow,
periosteum and adipose tissue) and hMSC from bone marrow tissue, 3rd-4th
passaged cells from each source were seeded at 5× 104 cells/well in 6-well culture
plates. The culture medium was changed every three days until the end of
experiment. Cells were trypsinised and counted using a haemocytometer every
second day. Growth curves were plotted from these data (in replicate).
2.1.3.7 Determination of Population doubling time
To determine the population doubling time (PDT), rMSCs (from rat bone marrow,
periosteum and adipose tissue) and hMSC (from human bone marrow tissue) at
passage two from each source were seeded in 25 cm2 flasks at a density of 1.5× 105
cells. When the cells reached 80% confluence (average 1 week after seeding), the
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cells were counted and reseeded at 1.5× 105 cells. Cell counting was performed from
the third to the fifth passage. Population doubling number (PDN) and population
doubling time (PDT) were calculated according to the following equations (2.2 and
2.3):
PDN =log (N/N0) x3.31 Equation 2.2
PDN the population doubling number,
N= the number at the end of the period (which was 7 days),
N0= the initial number of cell which was 1.5× 105 cells
PDT=CT/PDN Equation 2.3
PDT= population doubling time
CT= the duration of culture which was 7 days
2.1.3.8 Colony forming assay
2nd -4th passaged MSCs were evaluated for their clonogenic ability by using colony
forming assays. Cells were seeded at low density (20 cells per cm2) and cultured in
10% FBS DMEM with 1% penicillin/streptomycin for 2 weeks without a change of
the medium. After two weeks, colonies were stained with Giemsa stain. Colonies
consisting of over 50 cells were counted manually under a light microscope. The
colony forming ability was compared by calculating the percentage of cells that
formed colonies [(Number of colonies/Number of cells seeded) x100]. To determine
the area covered by MSC colonies, six regions of each well were randomly captured
under 20x microscope and the images were analysed on image J (National Institutes
of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/) to establish the
percentage of the surface area of the well covered by colonies.
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2.1.3.9 Differentiation assays
To demonstrate the differentiation potential of MSCs, passage 3-4 MSCs were
cultured in vitro under (a) osteogenic, (b) chondrogenic and (c) adipogenic
conditions. (a) Osteogenic potential: to induce osteogenesis, cells were cultured in
basal medium until 60-70% confluent before being changed to osteogenic
differentiation medium (basal medium supplemented of 100 nM dexamethasone,
10mM β-glycerophosphate and 50 µg/ml L-ascorbic acid). Osteogenic medium was
refreshed every 3 days for 2 weeks. The cells were stained with Alkaline
Phosphatase (ALP) assay kit (Sigma-Aldrich®, UK) using the manufacturer’s
protocol. (b) Chondrogenic potential: to induce chondrogenesis using the micromass
culture technique, 4 × 105 cells were resuspended in polypropylene tubes, centrifuged
gently to form a micromass, then cultured in serum-free medium containing high-
glucose DMEM supplemented with 100 nM dexamethasone, 1x Insulin-transferrin-
selenium plus premix (ITS Premix, from BD®); final concentration: 6.25 μg/mL
bovine insulin, 6.25 μg/mL transferrin, 6.25 μg/mL selenous acid, 5.33 μg/mL
linoleic acid and 1.25 μg/mL bovine serum albumin), 50 μg/mL L-ascorbic acid, 100
μg/mL sodium pyruvate, 50 μg/mL proline, and 20 ng/mL transforming growth
factor-β3 (TGF-β3). The medium was changed every 3 days. After 3 weeks, cultured
pellets were frozen, sectioned (6 μm thick), and stained with Alcian blue. (c)
Adipogenic potential: to induce adipogenesis, cells were cultured in basal medium
until 60-70% confluence and then changed to adipogenic differentiation medium
(basal medium supplemented with 1 µM dexamethasone, 10 µg/mL insulin, 0.5 mM
isobutyl-methylxanthine (IBMX) and 0.5 mM indomethacin). Adipogenic medium
was changed every three days for two weeks. Oil Red O staining was used to assess
lipid accumulation in the cells.
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2.2 The Atrophic non-union procedure
2.2.1 Animals
The animals used in this thesis were Wistar rats, which are an outbred strain of
albino rats belonging to the species Rattus norvegicus. They were bred in house at
the biological research facility (BRF), the University of Edinburgh. Rats were housed
individually for at least seven days before starting experiments. Rats are commonly
used in fracture healing studies: approximately 38% of fracture healing experiments
published in the orthopaedic literature have been conducted using rats (O'Loughlin et
al., 2008). Rats are easy to operate on because their anatomy is larger than mice. In
addition, fixation is more predictable in terms of mechanical control. In this study,
the fracture site was created at the tibial mid shaft because it is an easily accessible
subcutaneous bone and easy to operate on. Importantly, the tibia is a common site of
fracture non-union (Antonova et al., 2013, Mills and Simpson, 2013), and therefore
animal studies evaluating healing in this bone have considerable clinical relevance.
2.2.2 Ethical considerations
All procedures were conducted following approval by the Local Research Ethics
Committee and the UK Home Office, and in accordance with the animal (Scientific
Procedure) Act 1986. It is known that a number of orthopaedic procedures such as
fracture models, osteotomies and fracture fixation studies have the potential to cause
discomfort and painful distress to animals. Therefore, great care was taken to
minimise and control discomfort through consultation with the local veterinarian and
Named Animal Care Welfare Officer (NACWO) before embarking on any animal
works. Each animal s’ health status was closely monitored by a qualified veterinary
surgeon. The surgical skills required to perform each procedure were first gained on
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cadaveric rats. More than 20 cadaveric procedures were performed to ensure
competency before embarking on procedures with live animals. The design of
external fixator was modified during the experiment to ensure that it did not interfere
with animal movement and it was stable enough for bone immobilisation. All
experiments were designed with consideration of published guidelines (Kilkenny et
al., 2010, Festing and Altman, 2002, Auer et al., 2007). The “3R” approach to animal
studies (Replacement, Reduction and Refinement) of Russell and Burch (1959) was
applied where possible. The number of animals used in each experiment is detailed
within the relevant chapter.
2.2.3 Assembly of the External Fixator
All the components of the external fixator were manufactured by the Physics
workshop at the University of Edinburgh, UK. The external fixator construct
consisted of aluminium rings, brass screws and nylon and brass nuts (Figure 2.7).
The construct was evaluated using an axial compression test in five cadaveric rats
prior to in vivo experiments (results detailed in Chapter 6). In the cadaveric setting,
the fixator was found to be strong and stiff enough to stabilise fracture fragments.
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Figure 2.7 The External fixator devise used in the generation and fixation of non-unions in Rats: (a)
layout prior to assembly (b) Coronal view and (c) lateral view of external fixator
2.2.4 Materials, surgical instruments and medicines
A list of materials, surgical instruments and medicines that were used as part of the
surgical procedure to create atrophic non-unions are detailed in Table 2.1. The
external fixator and surgical instruments were sterilised using a steam autoclave
before use.
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Table 2.1 List of equipment and medicine required in the animal studies
Materials Surgical instruments Medicines
Complete set of External
fixator
Needle holders 1 ml/kg of Synulox
Electric blanket Scissors 0.05mg/kg of buprenorphine
Surgical board Blunt forceps 10ml/kg of 0.9% saline
Sterile wound package Toothed forceps PBS
Marker pen Scalpel blades Xylocaine® spray (10mg
each dose)
Gloves Periosteal dissector Fucidin® ointment
Safety glasses Small soft tissue protector
Sutures (Vicryl rapide, 4/0) Scalpel blades
27G needle (Sterican,
Braun, Melsungen) X 6
needles









All procedures were performed under sterile conditions. The surgical steps are
outlined in Figure 2.8. Animals were placed on a heat pad and anaesthetised with
inhalation anaesthesia (Isoflurane; 5% for induction and 2% for maintenance). Pre-
medications (Synulox, buprenorphine and 0.9% saline) were introduced
subcutaneously. The right hind leg was placed centrally through the fixator. The
position of the fixation was in the middle of Tibia; the line of knee and ankle acted as
the reference position (Figure 2.8 A and B). Six 27G- needles were drilled through
the tibia using a Dremmel® Multitool and secured using compressive force between
ring and nut devices (Figure 2.8 C). An antero-medial skin incision was made,
exploiting the interval between tibialis anterior and tibialis posterior (Figure 2.8 D).
Following satisfactory exposure of the tibia, an osteotomy was created at its mid
shaft using a circular saw (RS Components, UK) ensuring that the surrounding soft
tissues were protected and regularly irrigated with 0.9% saline. The 1 mm gap was
created according to the thickness of the surgical saw blade (Figure 2.8 E). To
induce atrophic non-union, the periosteum was stripped one-diameter length of the
tibia bone both proximal and distal to the osteotomy site (Figure 2.8 F). The
endosteum and intramedullary canal were also curetted using a 23G needle (Figure
2.8 G). Finally, the wound was washed with saline and closed in layers using 3-0
vicryl (Figure 2.8 H). Post-operative analgesia with buprenorphine (0.3mg/kg) was
administered through jelly cubes for all animals in the initial 24 hours
postoperatively.
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Monitoring and clinical assessments of animals were carried out for 15 minutes post-
operation, at six hours after operation and daily until the completion of experiments.
Buprenorphine was given postoperatively for pain control at six hours after each
procedure. If there was evidence of discharge or swelling at the surgical site, local
wound care with 0.9%NSS and fucidin® ointment was used. On the rare occasion
that a wound became infected wound, Synulox® was prescribed under the direction
of the veterinarian physician for a short period of time (3-5 days). If a leg was
entrapped by the ring in the post-operative period, the external fixator was adjusted.
2.3 A minimally invasive technique for cell delivery
MSCs may be administered operatively within scaffolds, through local injection
without scaffolds, or intravenously, depending on the clinical situation. Percutaneous
injection is a minimally invasive method of delivering MSCs to the fracture site.
2.3.1 The optimisation of injection position in cadaveric study
The injection procedure was performed using cadavers to determine an optimal
distance and position of the needle for cell injection. Use of an appropriately size of
needle is essential in this procedure. A standard 26G needle BD with 0.45 mm
diameter was used for injection as MSCs average 11-19 µm in diameters (Majore et
al., 2009), allowing easy passage of the cells through the needle. The most
appropriate position for needle placement was optimised using 5 cadavers. An x-ray
was taken to assess the optimal depth of the needle from the medial side of the tibia.
The fracture gap was directly palpable. The optimum depth of needle was found to
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be 2.5 mm (Figure 2.9). A potential limitation of this technique was leakage of the
injected solution, which would result in a reduction of the final number of cells
reaching the desired location. Appropriate needle size and slow injection of the cell
suspension can minimise leakage. Importantly, cells should be injected only when
the surgical wound has completely healed as the cell suspension may leak through
unhealed surgical wounds.
Figure 2.9 Locally percutaneous injection technique
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2.3.2 Injection procedure
The animals were anaesthetised with inhalation anaesthesia (2.5% Isoflurane). The
fracture gap was identified between proximal and distal pins and confirmed using
palpation. The skin was cleansed with 70% alcohol. The cell suspension was then
injected slowly in order to avoid leakage. After injection, animals were routinely
monitored to ensure ongoing health of animal and welfare with particular attention
paid to animal weight, behaviour, and condition of the injected site.
2.4 Radiographic evaluation of fracture healing
Fracture alignment and fixation after operation was monitored radiographically.
Radiographs are a common and non-invasive method of evaluating the progression
of fracture healing and can be used to determine bone union. This section outlines the
radiographic settings used in this study, detailing the radiographic parameters applied
to compare the fracture healing process. In all animal experiments, X-rays were
taken immediately following operations (while still under anaesthesia) to confirm
fracture position, at the cell injection time, and every two weeks following injection
to evaluate the fracture healing process until completion of the study.
2.4.1 Radiographic settings
Fracture healing was monitored and evaluated using serial radiographs with digital
imaging every 2 weeks. A portable X-ray unit (Acu-Ray JR, Stern Manufacturing
Toronto, Canada) with an output of 60 kV, 2mAs and exposure time of 0.1 ms was
used. The focus-to-film distance was 90 cm (Figure 2.10). Images were captured on
digital X-ray plates (Fuji CR Cassette, Fuji Photo Film Co Ltd, Japan). An
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aluminium wedge was used to allow density standardisation of radiographic images
(Figure 2.11). Image J was used for analysis of the radiographic parameters of
fracture healing.
Figure 2.10 Positioning of the Radiographic equipment
Figure 2.11 An aluminium step wedge consisting of multiple steps (from 2 to 20 mm in thickness)
was used as the radiological reference for magnification and radiopacity
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2.4.2 Radiological technique
2.4.2.1 Position of rat legs for x-ray
Radiographs were taken immediately following the procedure to generate atrophic
non-union and cell injections under the same anaesthesia. For subsequent
radiographs, rats were induced with inhalation anaesthesia (2.5% Isoflurance) and
placed centrally alongside the aluminium wedge using laser crosshairs as guidance.
Radiographs were taken in antero-posterior and oblique views. The position of the
rat’s leg was controlled using the bar of the external fixator and the position of
sponge as the references (Figure 2.12).
Figure 2.12 X-ray position of rat legs
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2.4.2.2 The diagnosis of bone union
Following careful removal of the external fixator, bone samples were examined by
manual clinical assessment of non-union. Non-union was indicated by the presence
of motion at the facture site at the end of the study. Bone union was diagnosed in all
animals using serial digital radiographs every two weeks by two blinded orthopaedic
surgeons according to the criteria outlined in the AO-ASIF manual (Muller et al.
1991). The diagnosis of bone unions was also confirmed using the 3D images from
micro-CT evaluation.
2.4.2.3 Radiographic parameters
The progression to fracture healing was determined from serial radiographs. The
fracture healing process was evaluated using techniques including callus density,
callus index, callus area and fracture scoring systems. These parameters were
determined using image J (Image J 1.37v, Wayne Rasband, National Institutes of
Health, Bethesda, MD, USA). The size of the aluminium wedge was used to calibrate
the radiograph and to obtain the actual size of the fracture callus.
2.4.2.3.1 Callus radiopacity
The radiopacity of the callus at the fracture gap in the AP view was determined as an
equivalent thickness of the aluminium step wedge (Furtos et al., 2012, Cook and
Cunningham, 1995). The aluminium equivalent thickness (in mm) for the fracture
callus was calculated using a calibration curve generated from the correlation
between gray scale values and aluminium thickness from each image. Three equal
regions from each step were selected and the gray scale value was measured. A linear
regression model was used to generate an equation using gray scale values and the
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aluminium thickness from each step (Figure 2.13a). To determine the radiopacity of
callus, three equal regions at the fracture gap (one in the central area and two in the
periphery) and three equal regions at the soft tissue adjacent to the fracture gap were
selected for measurement (Figure 2.13b). The average gray value from both areas
was converted into equivalent aluminium thickness using the equation from the
linear regression model. Finally, the value of aluminium thickness at the soft tissue
was subtracted from the value at the callus area to obtain the radiopacity of callus.
Figure 2.13 The technique used to determine the radiopacity: (a) three regions from each step of the
Aluminium wedge steps were chosen to generate the calibrated graph and equation . And then, (b)





2.4.2.3.2 Callus index (proximal and distal)
These callus indexes were determined using the AP view on radiographs. The
original callus index is the maximal transverse width of callus divided by the width
of the bone at the fracture site (Eastaugh-Waring et al., 2009). However, it was found
that it was not possible to use the original callus index to compare non-unions gap
during bone healing. Thus, the modified proximal and distal callus indexes were used
in order to compare the callus index from the different treatment groups during
fracture healing. The initial differences in bone size were corrected by callus index.
The proximal callus index was the transverse width of callus at the proximal end of
the fracture divided by the width of bone at the proximal end and the distal callus
index was the transverse width of callus at the distal end of the fracture divided by
the width of bone at the distal end (Figure 2.14a). These modified callus indexes
were validated using original callus index and they showed the strong agreements
(Figure2.14 b, c).
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Figure 2.14 Proximal and distal callus index measurement (a) demonstrating how to measure the
proximal callus index (CD/AB, yellow) and the distal callus index (GH/EF, blue) (b) the correlation
between the proximal callus index and the original callus index (P-value < 0.001, Pearson's r) (c) the
correlation between the distal callus index and the original callus index (P-value = 0.001, Pearson's r)
2.4.2.3.3 The percentage increase in callus area
The method used to determine the callus area in this study has been described in a
previous report (Brownlow and Simpson, 2000). The marquee tool was used to
delineate the area of bone from AP initial (injection time) radiographs using the pins
of external fixator as the reference point. This area was measured and used as the
original bone area. The callus area from radiographs at each time point was then
delineated circumferentially and subtracted by the original bone area to obtain from
the area in area callus. The percentage increase in the callus area was reported in
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order to control for the initial size of bone when comparing between the different
treatment groups.
2.4.2.3.4 Fracture scoring systems
Fracture scoring systems are commonly used by both orthopaedic surgeons and
researchers to evaluate fracture healing in experimental and clinical fracture healing
studies. The Radiographic Union Score for Tibial fractures (RUST) was introduced
in clinical tibial study in 2010 (Whelan et al., 2010, Kooistra et al., 2010). It was
reported that its agreement was substantial among assessors. In this study, this
scoring system was used as a clinically relevant semi-quantitative fracture
assessment tool. The Lane & Sandhu scoring system has been used for fracture
evaluation in several pre-clinical animal studies (Bigham et al., 2008, Yang and Park,
2001, Kerimoglu et al., 2013, Kurklu et al., 2011). It was originally described in
1987 (Lane and Sandhu, 1987). As this scoring system describes bone healing at the
fracture site differently from RUST, it was also used in this study to determine the
progression of fracture healing.
The RUST scoring system shown in Table 2.2 assigns points to a given set of AP
and oblique radiographs based on assessments of healing at each of the four cortices
visible on these projections (i.e., medial and lateral cortices on an anteroposterior
radiographic image, anterior and posterior cortices on an oblique radiographic
image). Each cortex receives a score of 1 point if it appears to have a fracture line
with no callus; 2 points if there is callus present but a fracture line is still visible; and
3 points if there is bridging callus with no evidence of a fracture line. The summation
of the individual cortical scores is used to give a total for the set of films (range
between 4 and 12). The minimum score (4) indicating that the fracture has definitely
not healed and the maximum score (12) indicating that the fracture has definitely
healed. This score was not used for diagnostic purposes but for evaluating the
fracture progress.
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Table 2.2 RUST scoring system:  based on points to a given set of AP and oblique radiograhs based
on assessments of healing at each of the four cortices




The Lane & Sandhu scoring system is based on three factors present in the
radiographic image including 1) bone formation at the fracture gap, 2) presence of a
fracture line, and 3) bone remodelling. Table 2.3 outlines how scoring in each
category should be performed. The minimum score in this system is 0 and the
maximum is 12. The total scores were summarised from each category (range
between 0 and 4). This score was also used for evaluation of fracture healing over the
period of the experiment.
82
Table 2.3 Lane & Sandhu scoring system; based on three dimensions present in radiographs
Categories Points
Bone formation at fracture gap (the maximum score is 4)
No evidence of bone formation 0
Bone formation occupying 25% of the defect 1
Bone formation occupying 50% of the defect 2
Bone formation occupying 75% of the defect 3
Full gap bone formation 4
Presence of fracture line (the maximum score is 4)
Full fracture line 0
Partial fracture line 2
Absent fracture line 4
Remodelling (the maximum score is 4)
No remodelling 0
Remodelling of the intramedullary channel 2
Full remodelling of cortex 4
Sum of radiographic scores 12
Before using the RUST and Lane & Sandhu scoring systems for fracture evaluation
in fracture healing studies, both scoring systems were fully validated demonstrating
strong agreements both inter and intra observer (Chapter 4) with the same setting of
fixator, anatomic location and animal model.  Radiographic evaluation in this study
was performed by a blinded orthopaedic surgeon.
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2.5 Sample preparation for fracture healing
evaluation
At the end of each experiment, the animals were humanely sacrificed using carbon
dioxide overdose (schedule 1, in accordance with UK Home Office procedures). The
external fixator was removed carefully minimising callus disruption. Tibias were
stored in PBS before examination using Micro-CT and biomechanical testing. The
sample were then bisected and subjected to fixing with 4% Paraformaldehyde (PFA)
or freezing with OCT compound (Optimum Cutting Temperature compound) for
further histological evaluation. These steps were performed subsequently in order to
minimise the number of animals used for fracture healing evaluation (Figure 2.15).
Figure 2.15 The steps taken following retrieval of tibias from experimental animals including the
healing assessments and sample preparation techniques
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2.6 Micro-CT imaging
Micro-computed tomography (micro-CT) is x-ray imaging in 3D. It is a similar
technique to conventional CT commonly used in hospitals. In micro-CT imaging, a
high intensity of x-ray are required and projected to objects or samples. The
projection of x-ray beam attenuation (the reduction in the x-ray beam intensity as it
passes through objects) is acquired at multiple views using a 360°-rotation platform
to reconstruct a 3D-image which provides very fine scale internal structure of objects
without destruction of samples. This technique has been widely used in bone
research for evaluation of small bone samples from pre-clinical studies. This is a
non-invasive technique that can be used to assess the component of fracture healing
and also to evaluate fracture healing qualitatively and quantitatively. In this study,
bone samples using micro-CT were assessed according to published guidelines
(Bouxsein et al., 2010).
Tibial samples were scanned using micro-CT at the end of the experiments. Fracture
sites were evaluated using a Skyscan® 1172 X-ray micro-CT scanner (SkyScan,
Belgium) (Figure 2.16) with the beam set at 54 kVp, 185 µA and a 16-µm isometric
voxel size with 0.5-mm aluminium filter. Image reconstructions were created using
Skyscan® NRecon software and the analysis of fracture healing was performed using
Skyscan® CTan software.
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Figure 2.16 Micro-CT set up including (a) the micro-CT Scanner and (b) the hardware used to
process and reconstruct images
2.6.1 Calibration for micro-CT analysis using hydroxyapatite
(HA)
The Hounsfield unit (HU) is a universally available accepted reference for describing
radiodensity in computed tomography. It is a quantitative scale which is a linear
transformation of the linear attenuation coefficient measurement based on the linear
attenuation coefficients of water (Goldman, 2007). It has been reported that HU of
bone tissue was greater than 700 depending on the types (woven or cortical) of bone
tissues (Norton and Gamble, 2001).
In this study, HUs were used to describe the radiodensity of scanned samples. Prior
sample acquisition using 250 and 750 mg/cm3 Hydroxyapatite (HA) phantoms were
used for calibration of bone mineral density (BMD) (Figure 2.17) according to the
equation from the regression model. This allowed the BMD of the fracture callus to
be determined.
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Figure 2.17 The calibration regression curves using two different HA phantoms (250 mg/cm3 and
750 mg/cm3) and water
2.6.2 Acquisition, processing and reconstruction of images
In preparation for scanning, each rat tibia was placed in a plastic tube filled with
PBS. The bone (in the vertical axis) was then scanned in a plane perdendicular to the
x-ray beam. The image files were reconstructed using Skyscan® NRecon software.
For evaluation, the volume of interest (VOI) was selected by the following steps. The
central plane of fracture callus was selected based on the proximal and distal ends of
the osteotomy site. The regions of interest (ROI) were manually delineated around
the callus at the top plane (0.5 mm. upper from mid-plane) and the bottom plane (0.5
mm. lower from mid-plane) (Figure 2.18). The VOI was defined using automated
interpolarization in Skyscan® CTan software and the VOI was then evaluated for
accuracy. Then, the VOI was obtained over 1 mm. at the fracture site. The next step
was to segment the contents of the VOI to separate the mineralised tissues from soft
tissues. HU was used as the reference, the threshold of bone tissue was defined
according to universal HU for bone (above 750 Hounsfield units) and was applied as
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a fixed global threshold (Figure 2.19) (Goldstein, 1987); it was found that this
selected threshold gave the least change in the BV/TV from normal bone samples.
Figure 2.18 Defining volume of interest at a 1mm-gap (yellow line represents the middle of the
fracture gap, and red lines represent the delineated areas at the top and the bottom of fracture gap)
Figure 2.19 Fixed global threshold applied to separate bone and non-bone tissues
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2.6.3 Micro-CT analysis
Four main aspects of the micro-CT analysis are present in this study.
2.6.3.1 Fracture callus morphometric parameters
After acquisition of samples and segmentation of images, 3D reconstructed images
from VOI were analysed using Skyscan® CTan software to determine properties of
the fracture callus in the osteotomy gap including: Bone volume/Total volume
(BV/TV), Bone surface area/Total volume (BS/TV), Trabecular number (Tb.N)
Trabecular thickness (Tb.Th) and Trabecular separation (Tb.Sp) in order to facilitate
comparison between different treatments. Each parameter from this analysis was
described in different aspect of bone morphology.
BV/TV: The fraction of the total bone volume as defined by the threshold values to
the total volume of interested (VOI) (Parfitt et al., 1987). This parameter was
presented a percentage value as a normalised parameter in order to compare samples
of different size.
BS/TV: The bone surface density, given by the ratio of the segmented BS to the
VOI, where BS was computed using the Marching Cube algorithm (Muller and
Ruegsegger, 1995).
Tb.N: The inverse of the mean distance between the mid-axes of bone structures
from the VOI (Hildebrand et al., 1999).
Tb.Th: This represented the average of thickness of bone structures in the VOI. It
was determined using the mean diameters of fitting maximal spheres fitted into the
bone structure (Hildebrand and Ruegsegger 1997).
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Tb.Sp: This represented the average space between bone structures in the VOI. It
was determined using the mean diameters of fitting maximal spheres fitted into the
non-bone structure (Hildebrand and Ruegsegger 1997).
2.6.3.2 Bone mineral density of callus
Bone mineral density (BMD) is a parameter that determines the degree of
mineralization in fracture callus and is an important determinant of bone quality
(Miller et al., 1999). In this study, bone-equivalent phantoms were used to calibrate
and calculate the BMD of scanned object based on HU scale according to the
following equation (2.4).
= .. / Equation 2.4
(HU object: an HU value of scanned bone samples)
2.6.3.3 Describing bone continuity using minimal bone area fraction
across the fracture site
This technique was previously reported (Schmidhammer et al., 2006) to evaluate and
quantify the connectivity of the bridging cortices of the callus. The original cortical
area was delineated circumferentially at proximal and distal parts across the fracture
site over 10 mm as the references and ROI each section across the fracture were
defined using automated interpolarization in the Skyscan® CTan software. The bone
fractions (the bone area/ the total area) from each plane were assessed using 2D
analysis and these values were plotted across 10 mm-section over the fracture site.
The minimal value of bone area fraction of each sample was determined.
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2.6.3.4 Presentation of 3D images
3D images of bone samples or callus at the fracture that were presented in this study
were created and modified using Skyscan® CTvol software.
2.7 Biomechanical study
Biomechanical testing is used to determine the effects of force on biological
materials. In this study, bone samples with callus were assessed for their mechanical
properties. Bone healing was compared using biomechanical parameters in response
to given interventions.
The loading mode of testing is dependent on the direction of the force applied to the
samples. Loading modes include axial loading (compressive or tensile) bending,
torsional loading and multi-axial loading. Loading due to bending was selected to use
for evaluation of the bone samples. It has been reported that the bending test is
appropriate for determining the mechanical properties of a small animal bones such
as from rodents. This is because compression, tension and torsion tests require that
the object being tested is uniform in shape: this is not applicable for whole bone
samples particularly with long bone specimens (Turner and Burr, 1993). Bending
results in a build-up of tensile and compressive stress in the sample. Tensile bone
strength is weaker than compressive bone strength, thus the fracture propagates from
the tensile side of the sample which is the opposite side of the load cell to the
compressive side (Reilly and Burstein, 1975).
Bending can be applied using 3 or 4 point-bending. 4 point-bending is considered to
be more appropriate to test bone with callus samples. The loading point will not
touch the callus. There is no shear force in load section so it is only loaded by “pure
bending”. The bending moment is constant over the load section (Wilson and
Carlsson 1991). In this study, four-point bending test was performed to measure the
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maximum load, ultimate stress, stiffness, and toughness of fracture callus at the mid-
diaphysis of the tibia.
2.7.1 Sample preparation techniques
Tibias were harvested from experimental animals. In this study, all samples were
tested without debriding overlying muscle, unless otherwise stated. It was found,
from examining micro-CT images during a preliminary study that removal of
overlying muscle may disrupt callus. Moreover, the muscle was found to hold the
sample in the stable position during testing. This preparation technique was validated
and compared with the standard technique in chapter 5.
2.7.2 Machine and setting
Samples were tested using a Zwick/Roell Z005 material testing machine (series
4500, Instron Corp. Canton, Mass, USA) using the four-point bending. The bone was
placed on four point loading jig shown in Figure 2.20. This jig was designed and
provided by the University of Edinburgh Engineering Workshop (King Building,
Edinburgh). The upper loading had a span of 8 mm. and was manufactured to
incorporate a pivot to allow both load application points to contact the specimen
during testing. The lower loading had two supporting bars with a span of 20 mm. The
upper and lower loading bar were rounded to eliminate notching when testing. All
samples were tested in the same direction from the medial aspect of tibiae. It was
found that the samples with muscle were stable during loading. The two loading
points contacted the sample at the same time, thus, these should produce an accurate
result. The loading rate was 5mm/min. Samples were preloaded with 5 N forces. The
biomechanical testing was performed at room temperature.
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Figure 2.20 The four point bending apparatus set up with the tibia (with overlying muscles in situ)
prior to testing.
2.7.3 Analysis of the biomechanical data
The testing machine was interfaced with the laboratory data acquisition program,
“TestXpertTM”, providing simultaneous measurements of deflection and load. The
program displayed the data sets as load (N) to displacement (mm). It also showed the
load-displacement graph enabling real-time monitoring during the test. Ultimate load
was taken from load-deformation curve. Ultimate load is the maximal load that a
sample can sustain before failure (N). The recorded load-deformation curves were
normalized by cross-sectional area and this curve could be converted to stress–strain
curves. Ultimate stress, young’s modulus and toughness were determined from this
curve. The cross sectional area of normal bone appeared to be a hollow triangular
shape. The observation was done in cadaver.
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Figure 2.21 Cross sectional area; (a) normal bone (bI and bE = horizontal measurement of the internal
and external width of bone, respectively, hI and hE = vertical measurement of the internal and external
height of bone, respectively) (b) callus (b = horizontal measurement of callus and h = vertical
measurement of callus
The cross section moment of inertial of the tibia was calculated based on a triangular
shape with a base width of b and height h with respect to an axis through the
centroid, which was one third of the height from the base of triangle. The cross
section moment of inertia of the internal triangle was deducted from the cross section
moment of inertia of external triangle (Figure 2.21a). Cross sectional motion of
inertia of bone was calculated from the following equation (2.5):
= [ − Equation 2.5
The fracture callus was considered to be a solid ellipse (Figure 2.21b), thus cross
sectional motion of inertia of callus was calculated from the following equation (2.6):
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= Equation 2.6
Figure 2.22 Diagram of four point bending; F = force, a = distance from outer to inner contact and L
= span of outer contact
Then, the cross sectional moment of inertia and diagram of four point bending
(Figure 2.22) were used to calculate bending stress using the following equation
(2.7):
= ( × × ) Equation 2.7
(where c = distance from the centre of the mass)
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Strain from this study was calculated from the following equation (2.8):
= ( × × )( ) Equation 2.8
Young‘s modulus (E) was calculated from a ratio between Stress (σb) and strain (ε).
It was defined by the slope of the linear portion of the stress-strain curve (N/mm).
= ( ) × ( ) × ( − ) Equation 2.9
The area under the stress–strain curve is the toughness, which represents the energy
absorbed when the sample was loaded. The toughness was the energy required per
unit volume of sample to produce fracture. It was computed using GraphPad
programme using the calculation area under curve option.
2.8 Histological evaluation
According to the fracture assessment protocol (Figure 2.15), samples were processed
for histological evaluation following micro-CT and biomechanical testing. To
prepare samples for histological evaluation of fracture healing, 4% PFA was used for
fixation over a period of 48 hours. It has been reported that this period provides
optimal fixation (Helander, 1994). Samples were then decalcified in
Ethlyenediaminetetraacetic acid, disodium (EDTA), a gentle decalcifying agent
which perseveres most of the protein during decalcification at PH 7 for 3 weeks. This
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solution was changed every 3-4 days (McKee et al., 1991). Decalcified samples were
embedded in paraffin. 6 µm sections were cut using microtome (Shandon, Thermo
Fisher Scientific TM, Waltham, MA) and mounted onto “Superfrost plus” slides
(BDH biosciences TM, Poole, UK). These processes and the preparation of
histological sections from samples were performed at the Queen's Medical Research
Institute Shared University Research Facilities (SuRF @ QMRI) with the assistance
from staff in the unit.
2.8.1 Histological assessment of fracture healing
Prepared sections of harvested samples obtained from animal studies were stained
with Haematoxylin and Eosin (H&E). The H&E sections were observed using a light
microscope (Eclipse E800, Nikon). General morphology and bone bridging were
evaluated. The presentation of either intramedullary or cortical bone bridges
confirmed a bone union. To quantify the different tissue types present within the
fracture gap, images of the inter-fragmentary gaps were captured at x10
magnification using the microscope camera (Digital Sight DS-Fi2, Nikon). The
images were processed in NIS-Elements Br Microscope Imaging Software (Nikon)
and analysed using image J software. 10x10 grids were created and placed over the
images. The area of the grid taken up by the area of interest was divided by the total
area to calculate the percentage. (Figure 2.23)  Three sections at the middle of each
sample were examined systematically from triplicate samples.
97
Figure 2.23 Tissue quantification method; 100 grids on the histological sections determining the
percentage of tissue types (x100)
The tissue at the fracture gap was defined as bone, cartilage, fibrous tissue and bone
marrow/empty space and tissue types were expressed as a percentage. The
histological appearance of each tissue was determined from H&E staining. Bone
tissue was defined from mineralised osteoid tissue (Figure 2.24a). Masson’s
Trichrome staining was used to demonstrate and observe the area of new bone
formation (Figure2.24b). Chondrocytes were observed in defined cartilage tissue
and they can be seen to be clustered in groups (Figure2.25a). Safranin-O/Fast green
staining was used to stain the area of cartilage tissue (Figure 2.25b). Fibrous tissue
was observed (Figure 2.26a) and bone marrow or empty space was demonstrated in
Figure 2.26b.
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Figure 2.24 Bone area from histological section; (a) H&E staining, (b) Masson’s trichrome staining





Figure 2.26 Histological area demonstrating (a) Fibrous tissue and (b) bone marrow /empty space
2.8.2 Validation of tissue quantitation methods
The counting grid method to assess the tissue components was classified as a semi-
quantitative technique. The results represent the estimated percentage determined
from the dominant tissue from each grid. Thus, a percentage of bone area using a
counting grid method (estimate) and a percentage of actual bone area, calculated
from delineated bone using ImageJ software were assessed for their correlation.
Bone area was used for validation as it was a key parameter for fracture healing
evaluation. There was a strong agreement between the semi-quantitative technique
and direct selection of delineated bone area (Figure 2.27).
a) b)
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Figure 2.27 Correlation of percentages of bone area using a counting grid method (estimated) and the
actual bone area (delineated bone manually technique); Pearson r = 0.86, P-value = 0.0013, n = 10
2.9 Immunocytochemistry and
immunohistochemistry
Both immunocytochemistry (ICC) and immunohistochemistry (IHC) were applied to
label specified antigens such as proteins, synthetic polypeptides, nucleic acids, lipids,
carbohydrates and small chemical groups using an antibody from cell culture or
histological sections. These methods rely on the specificity, affinity and sensitivity of
antibody-antigen interactions. The localisation of the antibody can be visualised
microscopically using either enzyme mediated reactions visualised in brightfield or
fluorescent labelling. In this study, ICC has been used for characterising human MSC
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and human PSC with specific cell membrane markers. In addition, IHC has been
used to demonstrate the injected human cells at the fracture site from the histological
section using a human specific nuclei antibody.
2.9.1 Antibodies
Antibodies, which are also known as immunoglobulin (Ig) have a specific interaction
with targeted antigens, which forms the basis of immunochemical methods. This
principle can be applied to discriminate between related compounds. The region of
the antigen that blinds with an antibody is defined as the epitope. This forms
molecule of epitope of one molecule can be found similar to the others, this is known
as cross-reaction. The number of antibodies that are required depends on the methods
of immunocytochemistry. There are two common techniques: direct and indirect.
With the direct method, a labelled primary antibody is used to detect the targeted
antigen, where the interaction of antibody-antigen can be visualised directly. This
method is simple and requires only a single antibody, but it provides limited signal
visualisation. In this study, the direct technique was mainly applied for ICC in cell
cultures. With the indirect methods, an unlabelled primary antibody is used and a
labelled secondary antibody is added to provide signal amplification (Manning et al.,
2012). The secondary antibody interacts with the immunoglobulin of the animal in
which the primary antibody was raised. This method is more sensitive than the direct
method because the secondary antibody can react with different antigenic sites on the
primary antibody. In this study, this method was applied to paraffin sections in order
to stain antigens specific to human nuclei. This following table lists the various
antibodies used in this study.
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Table 2.4 Antibodies used in this study






































Anti-Rat CD68 Mouse ED1 Abcam™ 1:800 for IHP
Anti-Human Nuclei
Antibody










Before antibody staining, a fixative step, antigen retrieval, permeabilization of cells
membrane and blocking non-specific background labelling were required. Samples
from either cultured cell or histological sections were fixed to preserved morphology.
A mixture of Methanol and Acetone (50:50) was used for the cell culture sample or
the frozen tissue section and 4% paraformaldehyde was used with the paraffin
embedded samples. This step protected the samples from the rigours of subsequent
processing and staining. However, use of fixative can damage antibodies, so they
have to be removed or neutralized with PBS before immunolabelling. The process of
fixation or paraffin embedding may lead to the formation of cross-linkages or protein
denaturation which causes epitope masking. This may result in false negative
staining.
Paraffin sections require unmasking of the antigen in a process called “antigen
retrieval”. There are several techniques that can retrieve the antigens and maximise
the presence of antigens for interaction with a specific antibodies. In this study, heat-
induced epitope retrieval through microwave irradiation was selected.
It is important to permeablilize cell membranes to allow an antibody to penetrate into
intracellular components.  To stain the human specific nuclei, histological sections or
human cell cultures were treated with 0.1% triton X-100 in PBS.
False-positive staining may occur with “background staining” and “non-specific
labelling”, in which the antibodies interact with sites not specific to the target
epitope. Blocking agents, such as serum which contains a high concentration of
proteins, can be used to saturate these non-specific binding sites to minimise this
phenomenon. The host from which the blocking serum is derived is usually
equivalent to the host of the secondary antibody. For example if the secondary
antibody is goat anti mouse, the most appropriate blocking serum would be goat
serum. However, because of the availability of commercial serum-free protein block,
protein Block Serum-Free (DAKO, UK) was used in this study as it can be used with
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any primary or secondary antibody and eliminates cross reactivities. Blocking
solution was applied to the tissue before the primary antibody.
2.9.3 Antibody detection
There are three common detection methods; 1) colorimetric or enzyme mediated, 2)
fluorescence and 3) colloid gold. The fluorescent detection method was used in this
study. This method was used to label intact cells in culture, which was required for
cell characterisation. The enzymatic method is limited by diffusibility of the enzyme
product and unable to label intact cells in culture. A fluorescent detection method
technique requires basic fluorescent microscopy, whereas the immunogold method
requires more complex electron microscopy. In this study, fluorescent detection was
found to be a suitable method in our laboratory setting.
2.9.4 Required Controls
Controls are essential for the accurate interpretation of immunochemical results and
the avoidance either false positive or false negative results. Positive controls used in
this study confirmed the reactivity of the antigens, antibodies and substrate markers
used. In this study, human bone marrow cells were used as the positive controls for
hMSC characterisation using hMSC marker specific antibodies. Human foetal tissues
were used as positive controls for the implanted hMSC tracing study using anti
human nuclei antibody. Negative controls assess the non-specificity of the
immunolabelling technique. There are several methods by which this can be carried
out. A tissue can be used where it is known that the target antigen is absent. A
section from non-union tissue without cell injection was used as negative control for
the implanted hMSC tracing study using anti human nuclei antibody. Either omitting
primary antibodies or using an isotype control antibody as per company’s
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recommendation was applied to act as negative controls for hMSC characterisation
using hMSC marker specific antibodies.
2.10 Tracking implanted cells
In order to trace implanted cells from both animal and human source, cells were
labelled using CM-Dil (Invitrogen, USA) prior to injection. The labelling protocol
was performed as per manufacturer’s guidelines. To determine the effects of CM-Dil
at different dilution on cell viability and proliferation, a dye exclusion method
(Trypan blue) and a functional assay of colony forming-unit were used (Appendix
A). Cultured cells that were prepared for transplantation by labelling with 2.5 µg/ml
CM-Dil for about 1 hour at 37 °C followed by three PBS washes to remove the
excess dye. Thus, the labelled cells were clearly visible in in vitro condition and
therefore this method could be used to trace the implanted cells delivered to the
fracture area using fluorescence microscopy. CM-Dil labelling has been used for
tracking the distribution of MSCs in vivo and differentiation following
transplantation over long term periods (Weir et al., 2008).
Besides the CM-labelling method, a IHC technique using anti-human Nuclei
Antibody (Chemicon, UK) was also applied to identify the human cells. The sample
preparation and staining protocol was performed according to the company’s
recommendation, using a dilution of 1:50. Goat Anti-Mouse IgG (H+L) – Alexa
Fluor® 488 (Life technology, UK) was used as a secondary antibody at 1:500
dilution. Sections of paraffin embedded human foetal upper limb tissue (kindly
provided by Miss Angela Briski, Péault Bruno’s group) were used as positive
controls. The details of the IHC technique are described in section 2.9. This antibody
is specific to the human-specific nuclei, so it can be used to visualise and localise the
donor material in the host environment to identify human cells in xenograft models
under fluorescence microscope.
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2.11 Immunological reaction study
2.11.1 Evaluation of inflammatory cytokines
2.11.1.1 Assay kit for evaluation of inflammatory cytokines
A panel of inflammatory cytokines from rat serum were assessed using the
commercial kit; Rat Inflammatory Cytokines Multi-Analyte ELISArray Kit: MER-
004A (SABiosciencesTM, USA) (Figure 2.28).  This kit was used to determine 12
pro-inflammatory cytokines simultaneously (IL1A, IL1B, IL2, IL4, IL6, IL10, IL12,
IL13, IFNγ, TNFα, GM-CSF, and RANTES). A conventional ELISA (Enzyme-
Linked ImmunoSorbent Assay) protocol all at once under uniform conditions has
been designed accurate and easy use. The protocol for this assay is provided in
appendix B. An optical density (OD) from each well was interpreted within ranges
recommended by the company.
Figure 2.28 Evaluation of rat inflammatory cytokines using multi-analyte ELISA array.  Shown here
are (a) the reagents used and (b) the ELISA array machine immediately prior to sample evaluation
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2.11.1.2 Serum collection
Blood samples were obtained from animals at the time of cell injection, 2, 4, 6, and 8
weeks post injection. Approximately 1.0 ml of blood was taken from the tail vein
(Parasuraman et al., 2010). The harvested blood was collected in a sterile tube
(without EDTA) and incubated at room temperature allowing samples to clot for 30
minutes before centrifugation for 15 minutes at 1,200 rpm. Then, serum (the top part
of column) was collected and stored at -20°C. The samples were always aliquoted to
avoid repeated freeze / thaw cycles. Rat serum samples required a 2-fold dilution
with sample dilution buffer before proceeding with the assay (following kit’s
recommendation).
2.11.1.3 Rationale for using Multi-Analyte ELISArray
Cytokines or antigens present in rat serum were detected using the principle of
ELISA. Firstly, the antibodies targeting a specific antigen attach to the well of plate
in which it can bind specifically to the antigen and then another antibody linked to
enzyme for detection and amplification. Originally, this method was used to measure
only one cytokine or antigen at a time in a given sample. However, this may be a
problem if the amount of sample is limited and there are several target antigens
required in the study. In this study, the volume of serum that was harvested at each
time point was limited because the excess blood loss can affect the animals’ health.
Therefore the multiplex array was selected allowing the determination of several
inflammatory cytokines in the same sample simultaneously. The optimisation of
ELISA for multiple analytes kit requires two processes during assay development.
Firstly, screening for capture and detection antibody pairs with the best performance,
the criteria included are the high sensitivity and good linearity (Figure 2.29).
Secondly, in order to optimise for the ELISA experimental conditions to allow
simultaneous development of the read out, multiple cytokines have been evaluated
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simultaneously at the same time and condition, so their concentrations have to be
optimised under the same experimental ELISA conditions to achieve the same
development or incubation time.
Figure 2.29 Standard curve demonstrating high sensitivity and good linearity within the ELISA
2.11.4 Data interpretation
As per the manufacturing company’s recommendations, the corrected Optical
Density (OD) value was subtracted from the negative controls for each cytokine. The
data were present as the fold change using the corrected OD from the serum that was
collected at the 0 time point as the reference.
2.11.2 Popliteal lymph node evaluation
Lymph node reactions are part of the host defensive responses associated with
inflammatory stimuli (Elmore, 2006). Popliteal lymph nodes receive the lymphatic
drainage from the lower limb. They are sited around tibial blood vessels (Sainte-
Marie et al., 1982), so any inflammation or stimuli at the tibia may result in
morphological changes in this regional lymph node. They have been the object of
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histological evaluation for immune response in previous reports (Willard-Mack,
2006, Bondarenko et al., 2011).
2.11.2.1 Sample preparation
One popliteal lymph node was harvested from each animal receiving different
treatments, fixed in 4%PFA, and embedded in paraffin. Lymph nodes from the
contralateral side (non-operated site) were used as controls.  Histological sections
from the middle portion of the lymph node were cut at 6 µm thickness using a
microtome (Shandon, Thermo Fisher Scientific TM, Waltham, MA). Sections were
stained with H&E and three selected sections, consisting of the cortex area, the
medullary are and the hilum were used for the morphological assessment (Figure
2.30).
2.11.2.2 Lymph node response
All Sections were visualised under a light microscope (Eclipse E800, Nikon). The
images were captured using a microscopic camera (Digital Sight DS-Fi2, Nikon) and
they were processed in NIS-Elements Br Microscope Imaging Software (Nikon) and
analysed using image J software. The morphological changes in the popliteal lymph
node, which may reflect the condition of local immune response after exogenous cell
transplantation, were assessed using (1) the size of lymph node, (2) the number of
secondary follicles, (3) the number of infiltrated cells in the sub-capsular sinus area,
and (4) the number of macrophages in the medullary cord area.
The size of lymph node
Lymph node enlargement or lymphadenopathy is associated with immune responses
against foreign antigens (Kumar et al 2004). The size of lymph nodes reflects the
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degree of the inflammatory response. To compare the size of lymph nodes in the
different groups and the normal control, sections of prepared popliteal lymph node
were captured under x4 magnification and the area of lymph node was selected
(Figure 2.30b) and measured using Image J. The area was expressed in mm2.
The number of secondary follicles
The lymphoid follicles are located in the cortex area of lymph nodes. In the absence
of immune stimulation, there are only primary follicles which consist of small B cells
(memory B cells). In the presence of immune reaction, the primary follicles are
activated and display secondary follicles or germinal centres which consist of antigen
recognizing B cells. The increase in the number of secondary follicles or presence of
follicular hyperplasia is an indication of an ongoing immunological reaction. In this
study, the number of secondary follicles (the enlarged follicle with a light germinal
centre) were counted manually at 10x magnifications (Figure 2.30c).
The number of infiltrating cells in the subcapsular sinus area
The subcapsular sinus which surrounds the lymph node is a gateway for afferent
lymphatic drainage. The antigens and immune complexes from the inflammatory site
will initially be drained into this area (Kamperdijk et al., 1987). In this study, the
number of infiltrating cells (lymphocytes and macrophages) in the subcapsular sinus
area were counted under 20x magnification (Figure 2.30d).
The number of macrophages in the medullary sinus area.
The medullary sinus is located at the medulla area of lymph nodes (deep to the cortex
area). It is irregularly shaped and has fluid-containing spaces which predominantly
contain macrophages. Macrophages play a role in the innate immune response as
phagocytic cells that internalize and degrade foreign antigens and release mediators
to activate an adaptive immune system (Gordon, 2007).An increase in the numbers
of macrophages in the medullary sinus area is associated with the inflammatory
response (Steer and Foot, 1987, Gray and Cyster, 2012).  In this study, macrophages
which were observed as large and round cells with rich cytoplasm were counted at
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40x magnifications (figure 2.30e) on H&E sections. The presence of macrophages
was demonstrated using IHC for CD68 (Figure 2.31).
Figure 2.30 Histomorphology of lymph node; (a) Lymph node histology (x40), (b) Size of lymph
node (selected area in blue) (x40), (c)  Secondary follicles (arrow) (x100), (d) an infiltrating cell at the
subcapsular area (arrow) (x200) and (e) a macrophage at the medullary sinus area (arrow) (x400)
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Figure 2.31 Immunohistofluorescence of CD 68 of lymph node (x100): (a) DAPI staining (blue)
demonstrating cortex and medullary area of lymph node, (b) CD 68 staining (green) of macrophages
and c) Merged image of DAPI/CD 68 (blue/green) demonstrating the presence of macrophages at the
medullary area
2.12 Statistical analysis
Data that were obtained from experiments in this thesis were recorded in Microsoft
Excel (2007). Each data set was then imported into statistical analysis programmes.
Graphpad Prism for windows (GraphPad Software, LA Jolla California, USA). and
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) were used for statistical analysis
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and graph plotting. The normal distribution of each data set was initially tested using
the Kolmogorov-Smirnov test in order to select an appropriate statistical test
(parametric or non-parametric test). When data sets were too small to determine
normality, parametric tests were chosen to evaluate statistical significance as this was
recommended by (Bland and Altman, 2009).
Sample size calculation was based on a previously published study (Geris et al.,
2010). It is recommended by UK Home Office governing the experimental use of
animals that a minimum number of animals consistent with a statistically significant
result should be used. The following equation was used to calculate the sample size
required to compare proportions in two equally sized groups (Whitley and Ball,
2002).
Figure 2.32 The formulae for calculation of sample sizes and commonly used values for cp,power
According to a previous study (Geris et al., 2010) the ratio of bone union in the MSC
injection group was 0.75 (p1), while in control was 0 (p2). A probability limit of P-
value < 0.05 (α = 0.05) and a power goal of 0.9 were stipulated, gives the sample size
in each group of 3.5 (at least 4 samples in each group).
Types of data and specific tests used for statistical analysis are described individually
in each chapter.
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Chapter 3: Feasibility of producing
mesenchymal stem cells from different sources
Aim: To demonstrate the growth characteristics and differentiation abilities of
rMSCs from bone marrow, periosteal and adipose tissues and to determine the
characteristics of hMSCs from bone marrow from the femoral head
3.1 Introduction
Because of their bone regeneration potential, MSCs have been investigated for a
therapeutic potential in fracture repair. It has been reported in both pre-clinical
studies and clinical studies that MSCs can improve the bone regeneration process
(Bielby et al., 2007, Granero-Molto et al., 2008). To investigate the therapeutic
potential of MSCs, it is important to know that the sources of MSCs will produce
MSCs in sufficient number of good quality. It has been reported that MSCs can be
isolated from a variety of adult tissues (Barry and Murphy, 2004). Three sources that
are relevant for orthopaedic applications are bone marrow, periosteum and adipose
tissue.
In this thesis, rat MSCs (rMSCs) and human MSCs (hMSCs) from primary cells
cultures were utilised in transplantation experiments (Chapter 7 and Chapter 8). It
was considered important to define the optimal sources for MSC preparation. For the
preparations of rMSC, the selected source of the rMSCs was based on the growth
kinetics and colony forming ability of cultured MSCs from rat tissue from 3 different
sources. For hMSC preparation, cells were isolated from femoral heads, according to
a protocol routinely used in our group (Tremoleda et al., 2012).This technique of
MSC isolation was modified from a previous protocol (Haynesworth et al., 1996). In
the present study, Immunophenotypes of hMSC were demonstrated using
Immunocytofluorescence.
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Thus, the objectives of this chapter were (1) to compare and determine the in vitro
growth kinetics using growth curve, population doubling time (PDT) and clonogenic
ability of rMSCs from 3 different sources: namely bone marrow, periosteum and
adipose tissue. The secondary aim was (2) to demonstrate the immunophenotypes of
the hMSCs derived from the human femoral heads and to assess their in vitro
potential for osteogenesis.
3.2 Materials and methods
The full lists of materials that were used in this study are detailed in Chapter 2. The
techniques for MSC isolation and culture are provided in Chapter 2. This section
briefly summarises the techniques specifically used in this chapter.
3.2.1 MSC preparation
Bone marrow from the femur, periosteum from the femoral diaphysis and adipose
tissue from the inguinal area of Wistar rats were harvested for rMSC isolation.
Femoral head samples that were obtained from THR patients with osteoarthritis
undergoing primary total hip replacement were used for hMSC isolation
3.2.2 MSC evaluation
rMSCs and hMSCs of primary culture were evaluated for their growth curves, PDT
and colony forming ability. To induce cell differentiation, the cells were cultured
under osteogenic, chondrongenic and adipogenic conditions. These conditions have
been described in Chapter 2. Rat fibroblasts which had been isolated from rat tails
were used for negative controls. To isolate fibroblasts from the tips of the rat tails,
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the tails were digested with 0.1% trypsin and plated on plastic dishes. Attached
fibroblasts were cultured for 7 days and then the osteogenic, chondrongenic and
adipogenic supplement, similar to the conditions that had been used, for rMSCs
cultures was added.
Immunophenotyping of surface markers in hMSCs was determined using
immunocytofluorescence staining. 50% confluent MSC cultures were fixed with 4%
PFA, blocked for 1 hour with universal blocking solution (DakoTM, UK) and
incubated with an antibody against human CD90, CD44, CD31, CD34, CD19, NG2,
CD146 (further details in chapter 2). The levels of staining were observed and
classified as strong, weak and negative depending on the magnification used for
visualization. The staining with could be clearly observed at 20x magnification was
classified as strong and if the staining was visible at 40x magnification, it was
classified as weak. If it could not be seen at any magnification, it was classified as
negative.
3.2.3 Statistical analysis
The growth curves rMSCs from three sources and hMSCs were compared using
repeated measures ANOVA and mean values of population doubling time study and
clonogenic study were reported as mean + SEM. These data were analysed using
parametric tests. The data from the three sources were compared using one-way
ANOVA followed by the bonferroni’s multiple comparison tests. A P-value < 0.05
was considered to be statistically significant.
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3.3 Results
3.3.1 The characteristics of rMSC
3.3.1.1 The morphology of rMSC from 3 sources
The cells derived from these three sources showed no obvious differences in their
morphology (Figure 3.1). They attached to plastic flasks and showed similar
heterogeneous morphology at initial plating and then became a homogenous
monolayer of fibroblast-like cells with passaging. Cells from each source could be
passaged at least 12 times; however, they exhibited slightly large and flatted shape in
later passages.
Figure 3.1 MSCs from 3 sources; bone marrow, adipose tissue and periosteum (x400)
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3.3.1.2 Differentiation ability
Due to the lack of a single specific marker of rMSCs, the isolated cells from the three
were validated using physical, phenotypic and functional properties. The tri-linage
differentiation potential including (a) osteogenesis, (b) chondrogenesis and (c)
adipogenesis was demonstrated. Cells from the three sources were able to
differentiate into the direction of bone, cartilage and adipose tissue (Figure 3.2-3.4).
The cells under the osteogenic condition showed the presence of ALP activity, the
cells within the micromass culture under the chondrogeneic condition demonstrated
positive staining with Alcian blue and the cells under the adipogenic condition
formed intracellular lipid droplets which were revealed using Oil Red O staining.
Fibroblasts cells which were used as controls were not able to differentiate under
osteogenic, chondrogeneic or adipogenic conditions (Figure 3.5).
Figure 3.2 Osteogenic (ALP staining), chondrogenic (Alcian blue staining), and adipogenic (Oil Red
O staining) differentiation of MSCs from bone marrow (x400)
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Figure 3.3 Osteogenic (ALP staining), chondrogenic (Alcian blue staining), and adipogenic (Oil Red
O staining) differentiation of MSCs from periosteum (x400)
Figure 3.4 Osteogenic (ALP staining), chondrogenic (Alcian blue staining), and adipogenic (Oil Red
O staining) differentiation of MSCs from adipose tissue (x400)
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Figure 3.5 Fibroblast culture under the osteogenic (ALP staining), chodrongenic (Alcian blue
staining), and adiposgenic (Oil red O staining) condition for control (x400)
3.3.1.3 Growth kinetics of MSCs from three sources
3.3.1.3.1 Growth curves
The growth curves from rMSCs from the three sources (bone marrow, periosteal and
adipose tissues) revealed the same ‘exponential’ growth pattern which had three
phases. Initially there was a lag phase of 0-2 days' duration following which there
was a log phase of rapid cell proliferation from day 4 to day 6. Finally, there was a
plateau phase after the 8th day. The growth curves from the different sources
demonstrated significant differences during the 12 -day period in cultures (P value <
0.001 for cell source and time, and P value < 0.001 for interaction effects, two-way
repeated ANOVA) (Figure 3.6). The growth of MSCs from bone marrow and
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periosteum were comparable and both of them were significantly faster than MSCs
from adipose tissue.
Figure 3.6 The growth curves of MSCs from bone marrow, periosteum and adipose tissues under the
12-day period of culture; the growth of MSCs from bone marrow and periosteum were comparable
and both of them were significantly faster than MSCs from adipose tissue (Bonferroni’s test
subsequent to ANOVA: * = P-value < 0.05, ** = P-value < 0.01 and *** = P-value < 0.001, data
shown as mean and SEM, n = 4 per group and time)
3.3.1.3.2 Population doubling time
The growth kinetics of cells from the 3 sources were compared using the population
doubling time (Figure 3.7).The mean PDT of MSCs from bone marrow from was
4.00 days (SEM = 0.49, n = 6), from periosteum was 3.6 days (SEM = 0.49, n= 6)
and from adipose tissue was 4.6 days (SEM = 0.62, n= 6).The bone marrow derived
cells and the periosteum derived cells had faster growth kinetics than the adipose
derived cells, but this difference did not reach statistical significance (P-value = 0.37,
one-way ANOVA)
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Figure 3.7 The population doubling time (PDT) of MSCs from bone marrow, adipose tissue and
periosteum; the PDT of bone marrow derived cells and the periosteum derived cells were more than
the adipose derived cells
3.3.1.3.3 Percentages of colony forming units and area
The percentages of colony forming units from bone marrow, periosteum and adipose
tissue derived cells were 8.58 (SEM = 0.55, n = 6), 9.92 (SEM = 0.84, n = 6) and
5.91 (SEM = 0.32, n = 6), respectively. There were statistical differences in the
percentages of colony forming units from different three sources (P-value = 0.001,
one-way ANOVA) (Figure 3.8). The percentages of the area covered with colonies
from bone marrow, periosteum and adipose tissue derived cells were 25.12 (SEM =
2.98, n = 6), 32.45 (SEM = 4.39, n = 6) and 15.80 (SEM = 3.69, n = 6), respectively.
There were statistical differences in the percentages of the area covered with colonies
from different three sources (P-value = 0.02, 1-way ANOVA) (Figure 3.9). These
results indicated that the clonogenic abilty of MSCs from bone marrow and
periosteum were significantly higher than for adipose derived cells.
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Figure 3.8 The percentage of colony forming units of MSCs from bone marrow, periosteum and
adipose tissue; mean percentage of colony forming of bone marrow derived and periosteum derived
MSCs were more than adipose derived MSCs (Bonferroni’s test subsequent to ANOV A: * = P-value
< 0.05 and *** = P-value < 0.001, data shown as mean and SEM, n = 6 per group)
Figure 3.9 The percentage of colony forming area of MSCs from bone marrow, periosteum and
adipose tissue; mean area of colony forming of bone marrow derived and periosteum derived MSCs
were larger than adipose derived MSCs (Bonferroni’s test subsequent to ANOVA: * = P-value < 0.05,
data shown as mean and SEM, n = 6 per group)
124
3.3.2 Human mesenchymal stem cells derived from femoral
head
3.3.2.1 The physical morphology and osteogenesic capacity of human
mesenchymal stem cells obtained from the femoral head
Cultured hMSCs from bone marrow tissue at femoral heads had a typical shape for
MSCs, i.e. they were spindle shape and had a fibroblast-like morphology (Figure
3.10 a).  They could be cultured to at least the 12th passage and were able to form the
colonies under low density seeding (Figure 3.10 b). These cells were able to
differentiate into bone forming cells in osteogenic medium (Figure 3.10 c and 3.10
d).
Figure 3.10 hMSCs from bone marrow at femoral heads  (a) general morphology of hMSCs, (b)
Colony forming of hMSCs under low density culture, (c) Alizaline red staining of hMSCs under





3.3.2.2 Immunophenotypes of human MSCs
Isolated hMSCs were examined for some markers of MSC using Immunolabelling.
The results showed that cultured hMSCs exhibited the markers CD90 and CD44 and
did not exhibit the haematopoetic cell markers (CD19), CD34 and CD31. Cultured
hMSC also weakly expressed CD146 and NG2 markers.
A) Strong positive staining makers
CD90 and CD44 markers were observed clearly under low magnification (x100)
indicating strong staining.
Figure 3.11 Immunolabelling of hMSCs at passage 3rd with FITC a) CD90 b) CD44 (x100)
B) Weak positive staining makers




Figure 3.12 Immunolabelling of hMSCs at passage 3rd with FITC a) CD146 b) NG2 (x200)
C) Negative staining markers
CD31, CD34 and CD19 markers were all negative.





3.3.2.3 Summary of immunophenotypes of hMSC from femoral heads
The table 3.1 shows hMSC characteristics using immunolabelling from culture
hMSCs from bone marrow at femoral head samples.
Table 3.1 Summary of human mesenchymal stem cell markers








*++ strong positive staining, + weak positive staining and – negative staining
3.3.2.4 Comparison of growth kinetic between rMSC and hMSC
This section demonstrated the comparison of the growth curves, population doubling
times and the percentages of colony forming between rMSCs derived from bone
marrow tissue and hMSCs derived from bone marrow tissue. There was no
significant difference in the growth curve over the 12 day-period in cultures between
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rMSCs and hMSCs (P-value = 0.82 for group, two-way repeated ANOVA) (Figure
3.14). The mean PDT of rMSCs was 4.00 days (SEM = 0.49, n = 6) and hMSC was
4.7 days (SEM = 0.24, n = 9). There was no difference in PDT between rMSCs and
hMSCs (P- value = 0.37, unpaired t-test). The percentages of colony forming units of
rMSCs and hMSCs were 8.6 (SEM = 0.54, n = 6), 7.2 (SEM = 1.17, n = 9),
respectively. There was no difference in the percentages of colony forming units
between rMSCs and hMSCs (P-value = 0.37, unpaired t-test). The growth kinetic
characteristics of rMSCs were similar to hMSCs.
Figure 3.14 The growth curves of rMSCs and hMSCs from derived bone marrow under the 12-day
period culture
Figure 3.15 Comparison of (a) the population doubling time (PDT) and (b) the percentage of colony
forming units between rMSCs and hMSCs derived from bone marrow
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3.4 Summary and discussion
Mesenchymal stem cell research is an extremely active field both in regenerative
medicine and in orthopaedics. MSCs are able to differentiate into bone, cartilage and
fat tissue in in vitro conditions and retain the ability for self-renewal capacity or
“stemness” (Pittenger et al., 1999). Therefore, MSCs have the potential to be
expanded and to regenerate bone and cartilage for use in bone defects, fracture non-
unions, or cartilage injuries. MSCs have been identified in a variety of adult human
tissues including bone trabeculae, teeth, skin, muscle, synovium, and umbilical cord
blood (Barry and Murphy, 2004). However, three potential sources which are
relevant to orthopaedic surgeons are bone marrow, periosteum and adipose tissue.
In this study, it has been confirmed that MSCs can be isolated from bone marrow,
periosteum and adipose tissue. Cells attached to plastic flasks and demonstrated
heterogeneous morphology on the initial plating and then became a homogenous
monolayer of fibroblast-like cells with passaging. Cells from each source could be
passaged at least 12 times and they formed colonies under low-cell density. The
isolated cells from these three sources were capable of osteogenesis, chondrogenesis
and adipogenesis. Thus, these results demonstrated that isolated cells in this study
have the characteristics of MSCs.
The yield of MSCs has been reported to be an important factor in determining a
successful outcome (Hernigou et al., 2005). It has been suggested that MSCs should
be efficiently expanded in culture to obtain sufficient cells. Thus, it is important to
consider the growth kinetics of the cells from different sources. The results of this
study have shown that the bone marrow derived cells and the periosteum derived
cells had faster growth kinetics than the adipose derived cells. The percentage of
colony forming units and the colony forming area from the bone marrow derived
cells and the periosteum derived cells were significantly greater than for adipose
derived cells. The in vitro growth kinetics and the clonogenic ability of MSCs may
also reflect their power of tissue regeneration in vivo. This conjecture is supported by
Niemeyer et al (2010a) who reported the osteogenic potential of bone marrow
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derived MSCs and adipose-tissue derived stem cells (ASCs) in a sheep using a bone
defect model. They found that the bone regeneration potential of bone marrow
derived MSCs was superior to ASCs. MCSs from periosteum have also been shown
both in vitro and in vivo to have superior osteogenic differentiation potential in
comparison with adipose tissue (Hayashi et al., 2008). However, the periosteum is a
limited source and is more difficult to harvest. Furthermore, its removal will interfere
with the blood supply of the bone. Thus, in clinical practice, the bone marrow should
be still considered as an appropriate source. In this study, MSCs derived from animal
tissues have been shown to demonstrate the rMSC characteristics using several
physical, phenotypic and functional properties (Dominici et al., 2006). Classical
assays have been used to identify MSCs; i.e. the ability of adherent spindle-shaped
cells to proliferate to form colonies that can be induced to differentiate into
adipocytes, osteocytes, and chondrocytes.
Regarding the isolation of hMSC, human femoral heads were used as they were
readily available source and could be used in in vivo experiment for bone
regeneration potential. Because of the heterogeneity of hMSCs, in 2006, the
mesenchymal and tissue stem cell committee of the International Society for Cellular
Therapy (ISCT) has proposed the criteria necessary to define human MSCs. Firstly,
MSCs must be plastic-adherent when maintained in standard culture conditions.
Secondly, MSCs must express CD105, CD73 and CD90, and lack expression of
CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules.
Thirdly, MSCs must differentiate into osteoblasts, adipocytes and chondroblasts in
vitro. In this study, isolated hMSCs were characterised using their
immunophenotype, plastic adherence ability, and ability to differentiate into bone.
In conclusion, the results reported in this chapter have shown the growth kinetics of
rMSCs from three potential sources namely bone marrow, periosteum and adipose
tissue. rMSCs and hMSCs derived from bone marrow were used in chapter 7 and 8
to develop strategies for promoting fracture healing in an atrophic non-union model.
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Chapter 4: Validation of the Radiographic Union
Scale in Tibia (RUST) and Lane & Sandhu
scoring system in small animal study fracture
model
Aim: To validate the inter- and intra-observer agreement of the RUST score and
Lane & Sandhu in the assessment of animal fracture healing
4.1 Introduction
Fracture models are used to investigate the mechanism of bone repair and the
therapeutic potential of a wide range of novel interventions such as ultrasound
(Bashardoust Tajali et al., 2011), growth factors (Friedlaender et al., 2001) and cell
therapy (Bajada et al., 2007). Valid and reliable outcome measurements are essential
for assessing fracture healing. X-ray assessment of fracture healing is a simple and
inexpensive technique, which is commonly used in orthopaedic practice (Corrales et
al., 2008). Clinical scoring systems have been developed to standardise the
interpretation of the radiographs. The Radiographic Union scale in Tibia (RUST) is a
recent fracture assessment tool that assesses the presence of (a) bridging callus (b)
the fracture line on each cortex on the antero-posterior and lateral radiographs. It has
been reported that this scoring system has an excellent inter-rater reliability in
clinical practice for tibial fractures treated with intramedullary nails (Kooistra et al.,
2010, Whelan et al., 2010). However to date, the RUST score has not been evaluated
in a preclinical model. The Lane & Sandhu score has been used in animal studies
(Yang and Park, 2001, Bigham et al., 2008, Kurklu et al., 2011, Kerimoglu et al.,
2013) but has not been validated fully for fracture healing research.
132
Therefore, the objectives of this study were (1) to determine the intra- and inter-
observer reliability of the RUST and Lane & Sandhu scoring systems, when used by
orthopaedic surgeons and researchers in the orthopaedic field and (2) to demonstrate
the limits of agreement of both scoring systems using the Bland-Altman Plot.
4.2 Materials and methods
4.2.1 Radiographs
Thirty sets of antero-posterior and oblique radiographs of tibial shaft fractures treated
with external fixation in pre-clinical model were selected so that the full spectrum of
the various stages of normal fracture healing, delayed union and non-union were
represented.
4.2.2 General impression of the fracture healing and fracture
scoring systems
The general impression of fracture healing was determined according to the AO-
ASIF manual (Muller et al. 1991). The details of the RUST and the Lane & Sandhu
scoring systems are provided in the general method section (Chapter 2).
4.2.3 Raters
The criteria of scoring RUST and Lane and Sandhu were explained to six raters,
including three orthopaedic surgeons and three orthopaedic researchers (one
laboratory researcher, one bioengineer and one physiotherapist. They evaluated the
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radiographs of the fractures using the RUST and Lane and Sandhu scoring system
independently. The examiners were blinded to time since fracture/osteotomy and to
additional treatment the fracture might have had. Inter-observer reliability was
determined from the scores of six observers at the initial viewing of the radiographs.
To determine intra-observer consistency, each reviewer was asked to score the same
set radiographs but in a different order 2-3 weeks after the initial assessment.
4.2.4 Statistical analysis
The agreement of general impression of bone union was determined using Fleiss's
Kappa which is similar to Cohen's unweighted Kappa. This method can be used to
evaluate concordance or agreements of categorical variable between multiple raters.
The agreement of the summary of RUST score and Lane & sandhu score were
evaluated using the intra-class correlation coefficient (ICC). The scores were
considered as continuous variables. Komogorov-Smirnov test was used to determine
the normal distribution of the scores obtained from data sets from either RUST or
Lane & Sandhu. Kappa agreement can be interpreted as following; kappa of 0 to 0.2
represents “slight agreement,” 0.21 to 0.40 “fair agreement,” 0.41 to 0.60 “moderate
agreement,” and 0.61 to 0.80 “substantial agreement.” A value above 0.80 to 0.99 is
considered almost “perfect agreement.” (Viera and Garrett, 2005).The value of the
ICC ranges from +1, in which case there is “perfect agreement,” to -1, which
corresponds to “absolute disagreement.” (Shrout and Fleiss, 1979) The online
statistic programme was used for Fleiss's Kappa (Geertzen 2012). The statistical
package SPSS, version 19.0 (SPSS Inc., Chicago, IL, USA) was used for ICC
calculation. The Bland-altman plot graph was generated from GraphPad Prism for
windows (GraphPad Software, LA Jolla, California, USA).
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4.3 Results
All raters found both scoring systems were practical and they were able to score all
the radiographs given to them.  However, they found it difficult to decide on the
definitive diagnosis of bone union (uncertain category) about 6-16 %. Non-surgeons
used the category of “uncertain” for general impression more than surgeons.
4.3.1 Validation of general impression
The inter-observer agreement for general impression is summarised in Table 4.1. It
had moderate agreement. The inter-observer for surgeons was slightly better than for
non-surgeons. The intra-observer agreement for general impression is summarised in
Table 4.2. Similarly, the intra-observer agreement for surgeons was better than for
non-surgeons. Two raters in the surgeon group had almost perfect agreement,
whereas all of the raters in non-surgeon group had moderate agreement.
Table 4.1 Inter-observer agreements of general impression
Reviewers Kappa 95%CI
Orthopaedic surgeons 0.6400 0.4334 - 0.8466
Researchers 0.5508 0.3895 - 0.7122
Overall 0.5754 0.4956 - 0.6553
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Table 4.2 Intra-observer agreements of general impression from individual rater
Reviewers Kappa 95%CI
Non-surgeon 1 0.5706 0.2920 - 0.8491
Non-surgeon 2 0.4854 0.2250 - 0.7458
Non-surgeon 3 0.5969 0.3355 - 0.8584
Surgeon 1 0.5833 0.3131 - 0.8536
Surgeon 2 0.9268 0.7858 - 1.0678
Surgeon 3 0.8093 0.6046 - 1.0140
4.3.2 Validation of RUST score
The normal distribution of average RUST scores from raters scoring the data (Figure
4.1) was determined by Komogorov-Smirnov Test; they were distributed normally
(P-value = 0.31).
The inter-observer agreements of the RUST score are shown in Table 5.3. The
overall inter-observer agreement of the RUST scores was almost perfect. There were
strong agreement with non-surgeon raters and almost perfect with surgeon raters.
The intra-observer agreements of the RUST scores are shown in Table 5.4. Five out
of six raters had almost perfect intra-observer agreements.
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Figure 4.1 Showing the normal distribution of average RUST scores from 6 raters
Table 4.3 Inter-observer agreements of the RUST score
Reviewers ICC 95%CI
Orthopaedic surgeons 0.896 0.820 - 0.945
Researchers 0.768 0.623 - 0.872
Overall 0.814 0.718 - 0.893
137
Table 4.4 Intra-observer agreements of the RUST score from individual rater
Reviewers ICC 95%CI
Non-surgeon 1 0.613 0.330 - 0.795
Non-surgeon 2 0.873 0.751 - 0.938
Non-surgeon 3 0.876 0.756 - 0.939
Surgeon 1 0.906 0.812 - 0.954
Surgeon 2 0.944 0.886 - 0.973
Surgeon 3 0.971 0.940 - 0.986
4.3.3 Validation of the Lane & Sandhu score
The normal distribution of average Lane and Sandhu scores from raters scoring the
data (Figure 4.2) were determined by Komogorov-Smirnov Test; they were
distributed normally (P-value = 0.21).
The overall inter-observer agreement of the lane & Sandhu score was almost perfect
(Table 4.5). There were almost perfect agreements in both non-surgeon and surgeon
raters. The intra-observer agreements of the lane & Sandhu score are demonstrated in
Table 4.6. All of the raters had almost perfect agreement using the lane & Sandhu
score.
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Figure 4.2 Showing the normal distribution of average Lane & Sandhu scores from 6 raters
Table 4.5 Inter-observer agreements of the Lane & Sandhu score
Reviewers ICC 95%CI
Orthopaedists 0.883 0.798 - 0.938
Researchers 0.898 0.823 - 0.946
Overall 0.880 0.811 - 0.933
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Table 4.6 Intra-observer agreements of the Lane & Sandhu score from individual rater
Reviewers ICC 95%CI
Non-surgeon 1 0.944 0.877 - 0.973
Non-surgeon 2 0.879 0.762 - 0.941
Non-surgeon 3 0.915 0.829 - 0.958
Surgeon 1 0.852 0.712 - 0.927
Surgeon 2 0.874 0.753 - 0.938
Surgeon 3 0.947 0.891 - 0.974
4.3.4 The Bland-altman plot showing the limits of agreement
between two scoring systems
The difference between the two scoring systems was assessed using a bland-Altman
plot (Figure 5.3). The difference between the two scoring systems (Y axis) was
plotted against the average of the score from both scoring systems (X axis). The two
scoring systems had very similar results on average, and the difference between the
means was 4.01. The 95% limits of agreement were between 2.84 and 5.18. The
minimal score of the RUST system was 4, whereas the Lane & Sandhu, it was 0.
Thus, the RUST scores would be expected to be 4 points higher than the Land &
Sandu scores, as the baseline is 4 points higher. The dot plot of the difference and
average scores between two scoring systems was close to 4, thus, both scoring
systems had a very good agreement.
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Figure 4.3 The limits of agreement between RUST and Lane and Sandhu scoring system
4.4 Summary and discussion
This study validated the inter- and intra- observer variability of fracture healing using
(a) general impression and (b) two fracture scoring systems namely the RUST score
and the Lane and Sandhu score in a pre-clinical fracture model. The results showed
that the fracture scoring systems allowed researchers to evaluate fracture healing
with better inter- and intra- observer agreement. In contrast, the general impression
of bone union or non-union was found to be more difficult to use, particularly for
non-surgeons.
For the general impression rating the inter-observer agreement was considered as
substantial for the orthopaedic surgeon group, but only moderate for the non-surgeon
group. Interestingly, the intra-observer agreements for the orthopaedic surgeons were
graded as perfect. These results suggested that the “general impression” rating for
whether a bone was healed or not should be graded by an orthopaedic surgeon. In a
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clinical study, it has been reported that the inter-observer agreement using “general
impression” in the assessment of the healing of tibial fractures after intramedullary
fixation between orthopaedic surgeons was substantial (kappa = 0.60; 95%
confidence interval (95%CI) 0.52 to 0.68) (Whelan et al., 2002). However, the
limitation of “general impression” is that it is assessor dependent. It is also difficult
to give a diagnosis of bone union in the early stage of the fracture healing process.
As a result, it cannot be used for evaluation and comparison of the fracture
progression in different time points which is normally required in preclinical studies.
Thus, appropriate scoring systems should be of great use for assessing multiple
aspects of the fracture healing process.
The radiographic Union Scale of Tibia Fracture (RUST) was developed to assess
tibial fracture healing. This scoring system is based on the presence or absence of
callus and a visible fracture line at each of the 4 cortices from the antero-posterior
and lateral radiographs. It is scored from 4 points (minimum) to 12 points
(maximum). The results presented here showed that the inter-observer agreement
increased was 0.81 (perfect agreement). Both inter-and intra-observer rating for non-
surgeons were better than using general impression. The findings concerning inter-
observer agreement were similar to the previous report using the RUST score in
clinical study. The findings showed a strong inter-observer reliability of using RUST
score to determine 549 sets of tibial shaft fracture (ICC = 0.84) (Bhandari et al 2011)
The results presented here showed that the RUST score was a reliable outcome
assessment tool for preclinical studies of fracture healing.
The Lane & Sandhu scoring system has been used in pre-clinical studies. The scores
are based on the extent of bone healing, the state of the bone cortex and remodelling.
The inter-and intra-observers agreements for non-surgeons were about 0.8-0.9. This
compared favourably with the reliability found for the RUST score. The bland-
altman plot showed the agreement of the two scoring systems. Most of the results
were scattered within +/-1.96 SD. The results demonstrated that the RUST score as
well as the Lane and Sandhu score were reliable and repeatable in the pre-clinical
setting.
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Both the RUST and the Lane & Sandhu score were demonstrated to be superior to
“general impression” in the pre-clinical setting. These scores were especially useful
if non-surgeons were assessing the healing process on x-ray. Both scores were
comparable with excellent reliability. However, although the RUST score was not
better than the Lane & Sandhu score in term of reliability, it was easier to assess and
more objective than the Lane & Sandhu score. As the scoring systems examined
different aspects of healing, it was decided that they both would be applied in the
further chapters (Chapter 6, 7, 8) for assessing the fracture healing process.
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Chapter 5: Comparison of the biomechanical
testing using 4-point bending of the rat Tibia
between specimens with and without the
muscle attached
Aim: To compare the biomechanical parameters due to different sample preparation
techniques using sample with and without muscle from 4-point bending mechanical
testing
5.1 Introduction
The biomechanical properties of bone are important when evaluating the functional
outcomes of the fracture healing process. Bending tests are common methods used to
evaluate the mechanical behaviour of small animal bones such as mice or rats
(Turner and Burr, 1993). Proper preparation of the specimen is necessary for
accurate biomechanical testing. When testing whole bones, it is recommended that
the soft tissue should be removed before testing (Aspden, 2003). In practice, it was
noticed that it was difficult and time-consuming to clean the bone specimen,
particularly when there was a callus on the harvested sample, as this is a relatively
soft structure which can be easily damaged. The use of a scalpel to remove the soft
tissue and clean the specimens can disturb the callus structure and create stress
raisers (Figure 5.1) which may interfere with the mechanical properties of the callus.
It could be more appropriate to test bone samples without the muscle removal. Thus,
this study aimed to compare the mechanical properties of the rat tibia specimens with
and without muscle removal.
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Figure 5.1 Bone samples after muscle cleaning; (a) and (b) The micro-CT images from two
specimens; arrows show small defects after cleaning, (c) gross morphology of sample
5.2 Materials and Methods
Twelve Wistar rat cadavers (mean weight = 355.33, SEM=19.34) were used for this
study. One rat tibia from each of 12 pairs was harvested for biomechanical testing.
All soft tissues including skin and muscle were dissected from the right tibias,
whereas muscles on the left tibias were left intact. The mechanical properties of
specimen with and without muscles were tested using 4-point bending conducted on
a custom designed test rig mounted on a Zwick/Roell 2005 mechanical test machine
(Zwick, Ulm, Germany). (Figure 5.2) Ultimate load, ultimate stress, Young‘s
modulus and toughness from each group were compared. The details of the
mechanical testing protocols and the parameters for calculation are described in the
general methods (chapter 2). A paired t-test was used to determine the statistical
significance of the biomechanical parameters with normally distributed data and the











was used to determine the significant difference of data variation between two
techniques of specimen preparation.
Figure 5.2 Comparison between the mechanical testing of samples with and without muscle; (a)
sample without muscle (b) sample with muscle
5.3 Results
5.3.1 The characteristic of stress-strain curve
Examples of the stress-strain curves from samples with and without and muscle are
shown in Figure 5.3. This curve was derived from the recorded results from the
biomechanical testing. The toe region of the stress-strain curve from the specimen
with muscle was larger than in the specimen without muscle (the arrow in Figure
5.3). This indicated that there was an initial increase in displacement for a small
increase in load. This was because the load was transmitted through soft tissue and
muscle before reaching the bone sample. As the stiffness of bone is considerably
higher than muscle (hard vs soft tissue), it allowed simple differentiation between the
low load deformation of the muscle in compression and the onset of load carried by








portion of the curve, representing the Young’s modulus and green lines which
indicate the maximum stress required (ultimate stress). The area under the curve is
defined as the toughness. The toe regions of specimens with muscle were not
included when calculating the area under the curve, as this area represented the
energy absorption from muscle associated with the deformation of muscle prior to
loading the bone.
Figure 5.3 The stress-strain curve from the mechanical testing; (a) from sample with muscle and (b)
from sample without muscle
5.3.2 The comparison of biomechanical parameters between
samples with and without muscle
The table 5.1 shows the summary of biomechanical parameters from sample with
and without muscle. The average of the ultimate load, ultimate stress, Young’s
modulus and modulus of toughness from the specimen with muscle and without
muscle are shown. Each parameter between specimen with muscle and without
muscle is shown in the Figure 5.4. No statically significant differences were found
for any parameters using either the paired t-test (for normally distributed data) or the
Wilcoxon signed-rank test (for non-normally distributed data).
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Ultimate load N 105.18 26.34 0.25
Ultimate stress MPa 281.47 121.18 0.43
Young’s modulus GPa 9.89 5.00 0.50
Modulus of
toughness
MPa 4.72 1.83 0.35
Tibia with muscle
sample (n=12)
Ultimate load N 101.62 25.38 0.25
Ultimate stress MPa 288.45 72.16 0.25
Young’s modulus GPa 10.45 2.38 0.24
Modulus of
toughness
MPa 4.33 1.50 0.39
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Figure 5.4 The comparisons of biomechanical parameters between bones with and without muscle
detached
5.3.3 The comparison of coefficient of variation
The Coefficient of Variation (CV) is defined as the ratio of the standard deviation to
the mean. It expresses the variation of the data in this case obtained from sample
with and without muscle. The CV of stress and young’s modulus from the sample
with muscle was less than the sample without muscle, whereas the CV of the load
and toughness was comparable (Figure 5.5). Although there were no statistically
significant differences in the biomechanical parameters from between sample
preparation techniques, testing samples without cleaning muscle was shown to be a
technique which produced less variation.
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Figure 5.5 The coefficient of variation of biomechanical results obtained from bone with and without
muscle (* p-value <0.029)
5.4 Summary and discussion
It has been suggested that soft tissue including muscle and subcutaneous tissue
around bone samples should be removed prior to testing. However, during this
experiment, despite careful dissection, notching caused by the scalpel in the callus
region of bone sample was revealed by the three-dimensional images produced by
micro-CT. This notching might affect the biomechanical properties and increase
variation. Additionally, removal of the soft tissue and muscle around the bone
specimen increased the sample preparation time. Thus, testing a sample without
removal of the soft tissue minimised the risk of disrupting the fracture callus and
decreased the sample preparation time. However, it was important to determine
whether the mechanical properties of sample with and without muscle were different
or not before using this preparation technique to assess the biomechanical properties
of whole specimens.
The results from this study demonstrated that soft tissues and muscle did not have
any effects on the mean of the mechanical properties; ultimate load, ultimate stress,
Young’s modulus and toughness. These parameters were comparable between the
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groups, i.e. bone with and without muscle. In addition, that the coefficients of
variation which were calculated from the ratio of the standard deviations to the mean
of each parameter were found to be less for the biomechanical parameters from
samples with muscle compared to those without muscle.
One area of evaluation that required special consideration was the toughness, as this
property was derived from the area under the stress/strain curve. In this study, the toe
region of the specimens with muscle was subtracted in order to derive the toughness
that reflected the energy absorption from just the bone. When the areas under the
curve representing the deformation of the bone were analysed, the results showed
that the toughness of bone from the two sample preparation techniques investigated
was comparable.
In conclusion, the advantages of testing the bone without prior removal of soft tissue
and muscle were (a) a reduction in specimen preparation time, b) a reduced risk of
creating a stress raiser at the callus and, c) a reduction in variability. This modified
sample preparation technique for mechanical testing was used for sample preparation
for biomechanical testing in chapter 8 and 9 in this thesis.
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Part 3: The results
152
Chapter 6: The characteristics of the atrophic
non-union Model: in vitro and in vivo
experiments
Aim: The aim of this chapter was to characterise an established atrophic non-union
model both biomechanically and biologically.
6.1 Introduction
This model is analogous to the clinical scenario of a patient with a stiff atrophic non-
union. An osteotomy was created with a small gap (1 mm) which was a “non-critical
size defect”. The periosteal stripping and intramedullary curettage were performed in
order to induce an atrophic non-union. There were three objectives of this study; (1)
to demonstrate the mechanical stability of the external fixator; the fixation should
maintain the osteotomy site under the physiological weight-bearing of the rat (2) to
determine the reproducibility of this technique in creating an atrophic non-union in
vivo (3) to evaluate the number of MSCs in the atrophic non-union model from both
the local site and from a remote site using a colony forming assay.
6.2 Materials and methods
The surgical technique and fracture evaluation have been described in full in chapter
2. This section provides only specific details that related to this chapter.
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6.2.1 Experiment design
Twenty one male Wistar rats (4-5 months of age) were used for this study.  Five rat
cadavers were used to determine the stability of the fixator devices.  Twelve rats
were used to validate the atrophic non-union model for the in vivo study. Another
four rats were used as normal controls for comparing the number of MSCs. The
operated rats and controls were kept in the same conditions.
6.2.2 Biomechanical testing in cadaveric model
An osteotomy was created in the mid shaft of the tibia and an external fixator was
placed to stabilise the bone in 5 rat cadavers (as described in chapter 2). Then, the
lower leg was disarticulated from the knee. Proximally, for approximately 5 mm. the
soft tissue was removed from the proximal Tibia to expose the bone. The foot was
then removed by disarticulation at the ankle. Distally, for approximately 5 mm. the
surrounding soft tissue was removed to expose the distal tibia. The sample was then
custom mounted using poly methyl methacrylate (PMMA) and put between load
cells. Biomechanical testing was performed using a standard mechanical test
machine (Zwick/Roell) and its software (as described in chapter 2). However, in this
study the axial compression mode was employed. The load required to close the 1
mm gap was noted and used to calculate the expected displacement from
physiological forces. For the hind leg, the magnitudes of physiological forces have
been estimated to be approximately 50% of body weight (Clarke, 1995). The axial
stiffness of the external fixator was determined from the slope of the load-
displacement graph.
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6.2.3 The fracture assessment of atrophic non-union in vivo
study
To determine the reproducibility of the model, twelve rats were used to create
atrophic non-union. Atrophic non-union was diagnosed in all animals using serial
radiographs with digital imaging every two weeks (as described in chapter 2). The
diagnoses were judged by two independent orthopaedic surgeons. At eight weeks, the
external fixator was carefully removed, and the animals were examined by manual
clinical assessment, which confirmed the presence of motion at the fracture site at
eight weeks. The fracture site was also scanned with a micro-CT (Skyscan®) (n = 7)
in order to assess of the bone bridge at the fracture site in detail (see details in
chapter 2). Four randomly selected samples were processed for histological
examination. Haematoxylin and Eosin staining was used for general histology,
Modified Masson’s Trichrome for new bone formation and Safranin O/Fast Green
for new cartilage formation. Stained sections at the fracture gap were observed using
light microscopy under 10x and 20x magnification.
6.2.4 Progenitor isolation and colony forming assay
6.2.4.1 Colony forming fibroblast assay from bone marrow at
contralateral femur
Bone marrow derived MSCs from the contralateral femurs of nine atrophic non-
union rats and four age-matched normal rats (control) were isolated using a
previously reported technique (Lennon and Caplan, 2006). In brief, using sterile
technique, the soft tissues were cleaned from the femurs and then the bones were
flushed using a 21-gauge needle and the cell suspension produced was filtrated with
100 and then 70 µL. filters. The filtrated cell suspension was added to 10 mL. of low
glucose (LG) DMEM containing   10% FBS and 1% penicillin/streptomycin (P/S)
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and centrifuged at 1,200 rpm for 5 minutes. The mononuclear cells were counted and
processed for colony forming assessment. The mononuclear cells obtained from bone
marrow isolation were seeded in 6-well plates at varying densities (1x105, 0.5x106
and 1x106 per cm2) in duplicate in the LG DMEM containing 10% FBS and 1% P/S
for two weeks without change of the medium.
6.2.4.2 Colony forming fibroblast assay from tissues at the fracture site
To isolate the mononuclear cells from the non-union gap (n=3), the tissues from the
atrophic non-union gap were collected and digested using 1% collagenase type 1
solution (Sigma) at 37oC for 45 minutes. Periosteal tissues from the mid shaft of
femur from the same animal were also isolated by the same method as the tissues
from the non-union gap. The suspension obtained from this digestion was
centrifuged at 1,200 rpm for five minutes. The pellet was suspended in 10 ml. of
10% FBS DMEM with 1% penicillin/streptomycin and filtrated with 100 and then 70
µL filters. The mononuclear cells were counted and processed for colony forming
assessment. An equal number of mononuclear cells from the non-union gap and from
the periosteum were seeded directly at a concentration of 0.5x106 per cm2 in 6 well-
plates in duplicate in the LG DMEM containing 10% FBS and 1% P/S for three
weeks without the medium be changed. The cultures were left for a longer period
than the bone marrow cell culture to ensure plastic adhered cells with colony forming
ability were able to develop.
6.2.4.3 Giemsa staining for colony counting
Following culture of the cells for two weeks (bone marrow) or three weeks (tissues
from fracture gap) without the medium being changed, the cultures were fixed in
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100% methanol for 5 min and stained with Giemsa. The number of colonies which
contained more than 50 cells was counted using light microscopy.
6.2.5 Statistical analysis
GraphPad Prism for windows (GraphPad Software, LA Jolla, California, USA) was
used for statistical analysis of data. Paired and unpaired t-test were used to compare
the mean minimal bone fraction obtained with micro-CT and the mean number of
colony forming units from mononuclear cells of bone marrow, respectively. A p-
value of <0.05 was considered statistically significant.
6.3 Results
6.3.1 The stiffness of the external fixator
The axial stiffness of the external fixator was derived from the gradient of the load-
displacement graph shown in Figure 6.1. The mean axial stiffness was 6.90 x 103
N/m (+ 0.20 SEM, n=5). The load (N) required to close the 1 mm-gap and predicted
displacement (mm) of the fracture gap with 50% of animal weight were shown in
Table 6.1. The mean weight required to close 1 mm.-gap was 0.70 kg (+ 0.02 SEM,
n=5), whereas the mean predicted physiological weight bearing of animals was 0.23
kg (+ 0.003 SEM, n=5). The weight required to close 1 mm-gap was significantly
more than the physiological weight bearing (p < 0.01), so this result demonstrated
that the gap would be maintained by the external fixator.
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Table 6.1 Sumary of load used to close 1mm gap and predicted displacement of 5 animals











1 6.75 0.67 0.45 0.34
2 6.25 0.63 0.46 0.37
3 7.5 0.76 0.47 0.31
4 7 0.71 0.49 0.35
5 7 0.71 0.47 0.35
Figure 6.1 Graph showing load-displacement of one of cadaveric test
6.3.2 The clinical behaviour and health status of the animals
Twelve rats were fully recovery after the procedure. There were wound
complications three days following surgery in two rats during development of the
procedure, necessitating euthanasia before completion of the experiment. All of the
remaining animals (10 rats) were able to eat and drink normally and had no
significant weight loss. The animals had no abnormal posture (piloerection) and no
abnormal behaviour. The animals were able to weight-bear fully immediately
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following surgery. Their surgical wounds healed by one week and no pin tract
infections were noted for the duration of the experiment (Figure 6.2).
Figure 6.2 Health status of the animal following surgical procedure: (a) The ability to weight bearing
immediately after surgery, (b) The appearance of skin at the pin tract b) and (c) Mean weight change
of animal after operation
6.3.3 Diagnosis of atrophic non –union fracture
6.3.3.1 Clinical diagnosis
At eight weeks after the operation, all animals (n=10) had developed atrophic non-
unions. The fracture gaps were grossly palpable at the osteomy site. After removal of
the external fixators, the tibias showed gross motion on clinical examination. Figure
6.3 shows the gross morphology of atrophic non-union.
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Figure 6.3 Gross morphology at fracture site:  (a) The fracture gap is clearly visible and (b) the tibia
shows gross motion; when grasped at one end and held horizontally, movement occurs at the non-
union site so it cannot even support its own weight.
6.3.3.2 Serial radiographs
In all of the animals (n=10), serial radiographs revealed a persistent gap. There was
an absence of callus formation from both the proximal and the distal fragments
(Figure 6.4). The immediate post-operative radiographic images showed the good
bone alignment and the required position of the pins and the external fixator needed
to maintain the 1 mm-gap without significant movement of the bone fragments. Two
weeks after the operation, radiographic images showed no significant difference from
immediate post-operative images. The 1 mm-gap was maintained and there was still
no callus formation and no change in the size of the fracture gap. Four weeks after
the operation, there continued to be no change in the radiographic appearance in all
animals. Six weeks after operation, radiographic images showed an increase in gap
size in some animals. Both the proximal and the distal bone ends developed blunt
edges. Eight weeks after operation, the bone ends remained rounded and the gap
appeared to increase. These results demonstrated the pattern of development of an
atrophic non-union.
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Figure 6.4 The radiographic assessment: serial radiographs; AP (above) and Oblique views (below)
every 2 weeks from immediately post-operative to 8 week post-surgery.
6.3.3.3 Histological appearance of fracture gap
Four of the ten tibiae were randomly selected for histological assessment. In all of
the selected samples, the fracture site had formed a clear atrophic non-union with
rounded bone ends and fibrous tissue present in the inter-fragmentary gap. There was
no woven bone or cartilaginous callus at the fracture gap. (Figure 6.5 (a)) There
were active osteoclasts creating rounded bone ends (Figure 6.5 (b)) producing the
typical appearance of an atrophic non-union. Neither intramembranous nor
endochondral ossification could be detected (Masson’s Trichrome stain and Safranin-
O/Fast Green, respectively). (Figure 6.5 (c-f))
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Figure 6.5 Histology assessments of atrophic non-union model: a) H&E stain (x100):  At the end of
the experiment, the gap was filled with fibrous tissue, loosed areolar tissue and also infiltration of
muscle fibres and adipose tissue into the gap b) H&E stain (x400): There were osteoclasts resorbing
bone at the end of fracture site. c) Masson’s Trichrome stain (x100) There were no bone formation at
the fracture at 8 weeks; d) Masson’s Trichrome stain (x100) The periosteum area around the pin tract,
there were new bone formation.  e) Safranin-O/Fast Green stain (x100) There was no cartilage
formation or endochondral ossification at the fracture gap at 8 weeks f) Safranin-O/Fast Green stain
(x100) The new cartilage formation was show at the proximal tibia epiphysis.
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6.3.3.4 Three-dimension micro-computed tomography
Three dimensional images from Micro-CT showed the fracture gap clearly. Neither
external callus formation nor bone bridges could be detected. The fracture ends
became round, reflecting atrophic non-union (Figure 6.6). The shape of the non-
union was also demonstrated by the bone area fracture, that is, the fraction of area
formed by the external borders of the diaphysis and the continuation of these borders
across the fracture site that was filled with bone (see details in chapter 2). This was
plotted across the fracture site from proximally to distally along the region of
interest. Proximal and distal to the atrophic non-union was approximately 0.9. The
bone area fraction dropped to a minimum at the middle of fracture gap. The bone
area fraction then rose back to nearly 0.9 in the distal fragment (Figure 6.7). The
bone area from the region of interest in the atrophic non-union was significantly less
than from the equivalent position of the unoperated side (0.84 vs 0.12, p < 0.01)
Figure 6.6 Three dimensional images of atrophic non-union: Three different views of three
dimensional images from MCT show clearly rounded ends both proximal and distal.
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Figure 6.7 The plotted bone fraction area from proximal to distal part of the volume selection
between normal bone and atrophic non-union
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6.3.3.5 Colony forming units of mesenchymal stem cells in atrophic
non-union
6.3.3.5.1 Assessment of the increase in the number of the colony forming
units from bone marrow from a remote site in the atrophic non-union
model
The number of mononuclear cells from atrophic non-union rats and control rats was
55.9 ± 4.8 x 106 (mean ± SEM, n=9) and 47.1 ± 4.1 x 106 (mean ± SEM, n=4) cells,
respectively. There was no statistically significant difference in the mean cell count
between atrophic non-union and control (P-value=0.19). The densities of colonies of
the well plates seeded at 5x105 cells (0.5x105 cells per cm2) were found to be
appropriate for counting. The colony forming units from both atrophic non-union and
normal controls had a similar morphology and the fibroblast-like cells in the colonies
were also similar. The number of colony forming unit counts from atrophic non-
union was significantly higher compared with control. The mean number of colony
forming from atrophic non-union group was 10.4 ± 1.1 (mean ± SEM, n=9), whereas
from control group was 5.8 ± 0.7 (mean ± SEM, n=4); (P-value=0.0041). (Figure
6.8)
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Figure 6.8 The colony forming assay for remote bone marrow from the atrophic non-union model:
(a) The mean number of colony forming unit from the bone marrow from the contralateral femur of
the atrophic non-unions and also from normal control animals. The appearance of the colony formed
from the femoral bone marrow of (b) a normal rat and with (c) atrophic non-union
6.3.3.5.2 Assessment of atrophic non-union tissue for colony forming units of
mononuclear cells
Tissues from the non-union gap (n=3) were digested with collagenase type one
solution in order to isolate stromal cells. Periosteal tissues from the mid shaft of
femur from the same rats were used as the control. Following digestion of the tissues
with collagenase, 5x105 mononuclear cells from each source were seeded onto six
well plates (0.5x105 cells per cm2) and the media was left unchanged for three weeks.
No colony forming units were obtained from the atrophic non-union tissue from any
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of the three samples, whereas colony forming units of mononuclear cells were
obtained from the periosteal tissues. The morphology of the cells in the colonies
formed from the periosteum was similar to MSCs derived from bone marrow
(Figure 6.9).
Figure 6.9 The cultured cells obtained from non-union tissues:  a)-b)The culture of mononuclear cells
from atrophic non-union tissues after culture for 2 weeks, x100 (a) and x200 (b), c)-d) The culture of
mononuclear cells of from periosteal tissues after culture for 2 weeks, x100 (c) and x200 (d)
6.4 Summary and discussion
In order to investigate the therapeutic effect of new interventions for fracture healing,
clinically relevant atrophic non-union models are essential. This study was conducted
to characterise an atrophic non-union animal model for studying the therapeutic
potential of adult stem cells. The model involved stripping of the periosteum for one
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bone diameter either side of and osteotomy and removal of the local bone marrow
over the same distance. A small (1 mm.) non-critical size defect was created and the
tibia was stabilised with an external fixator. The atrophic non-union model presented
in this study was originally reported by Reed et al (2003). However, the components
of the external fixator have been modified in that aluminium rings were used instead
of plastic because the plastic rings were chewed by rats (Mills and Simpson, 2012).
The stability of the fixation was tested using the axial compression in a cadaveric
study and found to be sufficiently strong and stiff.
In this study, the procedures used for creating atrophic non-unions were found to be
simple and reproducible. A 23G needle was used to remove the bone marrow and
endosteal components. Periosteal tissues were destroyed both proximal and distal to
the osteotomy site using a periosteal elevator. It has been reported that the periosteal
elevator can remove both the cambial and fibrous layers of the periosteum
(Brownlow et al., 2000).
In this study the atrophic non-union was confirmed by (1) by direct inspecting, (2)
serial radiographs, (3) histology and (4) three-dimensional imaging using micro-CT
was used to demonstrate connectivity across the fracture site. From the CT images
the bone fraction area was derived using 2D analysis of the region of interest at the
cortical area across the fracture site. The bone cortex of proximal and distal bone was
used as the reference, providing a quantitative measurement of the shape of the
fracture repair.
Eight weeks after the non-union operation, all of the animals that had undergone this
procedure had developed a non-union. There were only 2 animals, who suffered from
wound complications and needed euthanasia before the completion of the
experiment. This complication occurred at the initial period of study; before the
operation technique had been refined.
In addition, the progenitor cells in the atrophic non-union model were characterised
both systemically and locally. Colony forming assays were used to determine the
number of MSCs in the atrophic non-union both at a remote site and at the tissue gap.
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The number of colony forming units from the remote site (contralateral femoral bone
marrow) was significantly higher in animals that had undergone the atrophic non-
union procedure compared to control animals. Conversely, the colony forming units
could not be detected from the non-union gap tissue. These results suggested that
there was a systemic response to the creation of the atrophic non-union.
The absence of colony forming units from the gap tissue supported the investigation
of the local delivery of MSCs into the atrophic non-unions to ascertain whether they
were able to rescue the fracture healing process in atrophic non-union. This
intervention is investigated in the following chapters.
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Chapter 7: Determination of bone regeneration
potential of mesenchymal stem cells implanted
either at an early or at a late stage in the
atrophic non-union model
Aim: To determine an optimal time for using injectable rat mesenchymal stem cells
(rMSCs) based approach in atrophic non-union model
7.1 Introduction
Atrophic non-union is a major complication of a fracture. It is considered to result
from biological insufficiency either locally or systematically. MSCs can produce
bone progenitor cells which are capable of osteogenesis (Pittenger et al., 1999).
Therefore, MSCs are a potential promising approach for enhancing fracture healing.
One of the advantages of using MSCs is that they can be delivered by a minimally
invasive technique. During the developing stages of an atrophic non-union, there are
differences in the biological components that presented compared to the early stages
of normal fracture repair (Reed et al 2003). Thus, as the biological environment at
the fracture sites varies, this must be taken into account when assessing the
therapeutic effects of MSCs. In this study, the hypothesis that the stage of the
fracture healing process affects the outcome of MSC treatment is tested. The aim of
this study is to determine the therapeutic effects of MSCs in the atrophic non-union
model using a minimally invasive percutaneous injection technique at both an early
(three weeks) and a late (eight weeks) time point after inducing an atrophic non-
union.
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7.2 Materials and Methods
The surgical details of the atrophic non-union model, rat MSC preparation and
fracture assessments were described in the general materials and methods (Chapter
2). In this section, only the specific details related to this chapter are described.
7.2.1 Experiment design
All the procedures were conducted following approval by the Local Research Ethics
Committee and the UK Home Office, according to the animal (Scientific Procedure)
Act 1986. Twenty adult male Wistar rats (400-500g) were randomly assigned into
four groups immediately after inducing the atrophic non-union: Group 1 for rMSC
injection at three weeks post inducing the atrophic non-union (n=6), Group 2 for PBS
injection (control) three weeks post inducing the atrophic non-union (n=4), Group 3
for rMSC injection at 8 weeks post inducing the atrophic non-union (n=5) and Group
4 for PBS injection (control) eight weeks post inducing the atrophic non-union (n=5).
The treatment groups (group 1 and 3) were injected with the 5 x 106 rMSCs in PBS
suspension (200 µL). The fracture healing process was monitored with radiographs
every two weeks until the end of the study. Further assessments of bone healing were
performed at eight weeks after injection (at 11 weeks for early intervention and 16
weeks for late intervention) by quantitative micro-CT and histology.
7.2.2 rMSCs preparation
rMSCs derived from femoral bone marrow from 4 month old male Wistar rats were
isolated by flushing them from the femoral canal. Cultured MSCs from passage 3-4
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of primary culture were used for implantation. The details of rMSC preparation and
culture expansion have been described in chapter 2 and 3.
7.2.3 Fracture assessments
Digital radiographs were taken of all the animals every two weeks after injection.
They were blindly evaluated and assessed by two orthopaedic surgeons; any
disagreements of diagnosis were decided by a senior trauma orthopaedic surgeon.
The progression of the fracture healing in all experimental animals was evaluated
using (1) the radiopacity, (2) both the proximal and the distal callus index, (3) the
callus area and fracture scoring systems. At the end of the study specimens were
harvested and scanned with the micro-CT (n= 6 in group 1, n= 3 in group 2, n=4 in
group 3 and n= 5 in group 5). The amount of each tissue component in the fracture
site was evaluated using H&E sections (n= 4s in group 1, n= 3 in group 2, n=3 in
group and n=3 in group 4). The new bone formation and cartilage formation were
demonstrated with Modified Masson’s Trichrome and Safranin-O/Fast Green
staining, respectively.
7.2.4 Statistical Analysis
GraphPad Prism for windows (GraphPad Software, LA Jolla California USA) was
used to calculate the means and SEMs for each group. The normality of the data was
tested using the Kolmogorov-Smirnov normality test. The differences in the ratios of
the number united out of the total number in both the rMSC injection and controls
were tested using Fischers’exacts test at both early and late time points. The mean
difference of fracture progression parameters i.e. radiopacity, callus index,
percentage increase of callus area and total on the fracture scoring system over the
post injection period was tested using two-way repeated measure ANOVA followed
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by the bonferroni’s multiple comparison tests. The measurements from histology and
micro-CT were tested using unpaired t-test. A P-value < 0.05 was considered to be
statistically significant.
7.3 Results
7.3.1 Animal health status after the atrophic non-union
procedure and cell implantation
All rats successfully underwent the operation to induce an atrophic non-union and
then returned to their normal activities within two to three days. No sign of any
adverse reactions was noticed following the injection of either cells or PBS. There
was neither superficial nor deep wound infection at the surgical site or pin tract
infection during the post-operative period in any rats, except one rat in group 2 that
accidentally died due to an anaesthetic problem during the post-operative x-ray two
weeks after the transplantation procedure. It was excluded from this study. Thus, 19
animals remained until at the end of the study and could be used for analysis.
7.3.2 The fracture healing assessment after injection at the
early time point (3 weeks)
7.3.2.1 Assessment of bone union in groups 1 and 2
Bone union in all rats was evaluated by gross morphology immediately after
euthanasia. Samples which had developed non-union of the fracture revealed motion
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upon gravity (Figure 7.1). However, the primary diagnosis of bone union/non-union
was made from the radiographic series by the two orthopaedic surgeons.
Figure 7.1 Gross appearance and radiographic at 8 weeks following the early intervention (3 weeks):
from (a) PBS treatment group and (b) rat MSCs injection group
In the early injection groups (group 1 and 2), five out of six of the animals that had
received rMSC (group 1) had bone union, but in the control group (group 2) none
achieved bone union at 8 week post-injection. Table 7.1 shows the number of unions
and non-unions for rats injected either with rMSC or PBS. The rMSC group showed
a significantly higher bone union rate (Odds ratio = 25.67, P-value = 0.048)
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Table 7.1 The number of the animals used in the early time point and results of bone union between
group 1 and group 2
Treatment group Outcome* Total
Bone union Non-union
rMSC (group 1) 5 1 6
PBS (group 2) 0 3 3
Total 5 4 9
* Statically significant (P-value =0.048) by Fisher’s exact test
In one of animals in the treatment group, the bone did not heal; the fracture line was
still present at eight weeks after injection, however, some callus formation could be
seen (Figure 7.2).  This animal was diagnosed as a non-union because the bone was
not in continuity. However it was an hypertrophic rather than an atrophic non-union.
Figure 7.2 Radiographs at 8 weeks post injected of the animals treated with rMSC that was graded as
a non-union
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7.3.2.2 The progression of the fracture healing process of animals in
group 1 and 2
The progression of fracture healing was initially evaluated every week (Figure 7.3)
as the pilot stage. However, as the x-ray appearance did not differ much within a
one-week period, the animals were evaluated with radiographs every two weeks.
Figure 7.3 Serial radiographic assessment: The serial radiographs of the fractures in the rat MSCs
treatment group showed progression of healing (above), whereas the radiographs from the PBS
treatment group showed no sign of fracture healing (below)
7.3.2.2.1 Relative Radiopacity in group 1 and 2
An aluminium step wedge was used to calibrate the x-rays and used to provide a
normalised value of the radiopacity at the fracture gap of the rMSC treated group and
the control group (Figure 7. 4). There was a marked increase in opacity in the rMSC
treatment group from 2 weeks to 4 weeks. After 4 weeks, the radiopacity remained
stable until the end of the experiment, whereas in the control group, the mean opacity
at the different times did not change significantly. The mean radiopacity in the rMSC
treatment group was significant higher than the control during the eight-week period
(P-value < 0.0019 for treatment, P-value <0.0001 for time, and P-value < 0.0018 for
interaction effects, two-way repeated ANOVA)
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Figure 7.4 The comparison of opacity between treatment (rMSC) and control (PBS) over the 8 week
period post injection (Bonferroni’s test subsequent to ANOVA: ** = P-value < 0.01, and *** = P-
value < 0.001, data shown as mean and SEM, n= 3-6 per group and time)
7.3.2.2.2 Callus index in groups 1 and 2
Using the modified callus index, a proximal callus index and a distal callus index
were calculated. There were significant increases in the callus size of rMSC injected
animals following injection compared to the control (Figure 7.5) (Proximal callus
index, P-value=0.0284 for treatment, P-value=0.58 for time, and P-value<0.0001 for
interaction effects: Distal callus index, P-value=0.0021 for treatment, P-value=0.49
for time and P-value=0.0029 for interaction effects, two-way repeated ANOVA)   .
The callus index of proximal and distal parts changed in the same way.
*** ** **
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Figure 7.5 The comparison of callus index; (a) proximal and (b) Distal between treatment (rMSC) and
control (PBS) over the 8 week period post injection (Bonferroni’s test subsequent to ANOVA: ** = P-
value < 0.01, and *** = P-value < 0.001, data shown as mean and SEM, n= 3-6 per group and time)
7.3.2.2.3 Percentage of callus area increase in groups 1 and 2
The graph in Figure 7.6 shows the percentage increases of the callus area over the
eight week period after injection for both the rMSC group and the control group. In
the rMSC injection group, the percentage change of callus gradually increased from
the 2nd week to the 6th week and then slightly decreased at the 8th week. In contrast,
the percentage change of callus in the control group where PBS solution alone was
injected at the non-union site resulted in a decrease of callus area. This could be
indicated the presence of atrophic non-union in PBS treatment animals. There was a
statistically significant difference in the amount of callus between the two groups (P-
value=0.0025 for treatment, P-value =0.0006 for time, and P-value=0.0039 for
interaction effects, two-way repeated ANOVA).
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Figure 7.6 The comparison of the percentage callus increase between treatment (rMSC) and control
(PBS) over the 8 weeks period post injection (Bonferroni’s test subsequent to ANOVA:  * P-value
<0.05, ** = P-value < 0.01, and *** = P-value < 0.001, data shown as me an and SEM, n= 3-6 per
group and time)
7.3.2.2.4 The progression of the fracture healing process in groups 1 and 2
assessed using fracture scoring systems
The results of the RUST score (which was determined from the number of cortices
that showed bone bridging) and the Lane & Sandhu score (which was derived from
three subcategories: (i) percentage bone in the fracture gap, (ii) presence of the
fracture line and (iii) evidence of bone remodelling) showed the progress of the
fracture healing process (Figure 7.7). The RUST score in the rMSC treatment group
was significantly different from the control group after 6 weeks and the Lane &
Sandhu score demonstrated a significant difference after 4 weeks.
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Figure 7.7 The fracture scoring systems: (a) The RUST score evaluation and (b) Lane and Sandhu
score evaluation (Bonferroni’s test subsequent to ANOVA:  * P-value <0.05, and ** = P-value < 0.01,
data shown as mean and SEM, n= 3-6 per group and time)
7.3.2.3 Histological evaluation for groups 1 and 2
The histological observations from H&E stained sections supported the radiological
results. In rat MSC injection group, the interfragmentary gap consisted of bone and
cartilage. (Figure 7.8) Callus was formed at the fracture gap. Both intramembranous
bone formation and endochondral bone formation contributed to the healing process
in the rat MSC treatment group. Cortical remodelling could be seen in one animal.
(Figure 7.8 (a, b)) Safranin-O/Fast Green showed the area of cartilage formation and
Masson’s trichrome staining showed the area of bone formation (Figure 7.9). In the
PBS injected group, the tissue within the interfragmentary gap consisted
predominantly of fibrous tissue and was similar to the histology of the uninjected
atrophic non-union at eight weeks depicted the chapter 6 (Figure 7.10).
180
Figure 7.8 H&E staining of the fracture site of a MSC injected rat: a)-d) Cortical remodelling can be
found at the fracture gap (x100, a), (x200, b) and both bone formation (x200, c) and cartilage
formation (x200, d) were found at the fracture gap
Figure 7.9 Safranin-O/Fast Green and Masson’s trichrome staining at the fracture site of a rat MSc
injected rat: Safranin-O/Fast Green staining shows the area of cartilage formation (x100, a) and
Masson’s Trichrome staining shows the bone trabeculae at the fracture (x100, b)
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Figure 7.10 H&E staining at fracture site of PBS injected rat: (a) The fracture end (arrow) has
become rounded and (b) fibrous tissue is present at fracture gap (x100)
To measure the tissue constituents in the fracture gap, a 10x10 square grid was
applied to the histology images, the tissue components in the gap were classified as
bone, cartilage, fibrous and marrow/empty space. The relative amounts of the tissue
components were compared between the treated group and the control group (Figure
7.11). In the treatment group, bone predominated whereas in the control group,
fibrous tissue was the dominant component in the fracture gap. The bone component
was significantly higher in the treatment group (P-value<0.01, unpaired t-test).
Figure 7.11 Quantitative evaluation of the tissue component in the fracture gap (* =P-value <0.01,
unpaired t-test)
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7.3.2.4 Micro-CT analysis in groups 1 and 2
Three dimensional images from micro CT demonstrated bony bridging in all animals
which were treated with rat MSCs (Figure 7.12 (a, b)). There was also the cortical
remodelling in one of animals in the treatment group. The bone gap was still evident
in the controls, although there were, occasional islands of bone in the fracture gap.
To provide a quantitative measurement, the percentage of bone tissue volume per
total tissue volume at the centre of the fracture site was measured for all samples. All
parameters are shown in table 7.3. In the treatment group (group1), the percentage
bone volume (P-value <0.001, unpaired t-test), trabecular thickness (P-value <0.001,
unpaired t-test), and bone mineral density (P-value <0.001, unpaired t-test) were
significantly higher than in the control group (group2).
Figure 7.12 The results from Micro computed tomography of the early treatment groups: Three
dimension image of (a) control group and (b) rat MSCs injected group
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BV/TV 52.67 (4.83) 18.52 (9.19) P < 0.01*
Bone surface density
(1/mm)
4.97 (0.43) 3.29 (1.22) P = 0.14
Tb.N 1.17 (0.12) 0.77 (0.27) P = 0.14
Tb.Th 0.44 (0.03) 0.23 (0.04) P < 0.01*
Tb.Sp 0.47 (0.06) 0.50 (0.12) P = 0.81
Bone mineral density
(g HA/mm3)
0.66 (0.03) 0.29 (0.14) P < 0.01*
*Statistically significant difference
7.3.3 The fracture healing assessment after injection at late
time point (8 weeks)
7.3.3.1 Assessment of bone union in groups 3 and 4
Unlike the early injection group (group 1), the late rMSC injection group (group 3)
had only two animals out of the five animals that demonstrated bone union. In the
late control group (group 4), one fracture/osteotomy achieved bone union at eight
weeks after injection. Table 7.3 depicts the number of unions and non-unions of the
rats injected at the late time point either with rMSCs or with PBS. The animals that
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were injected with rMSCs at the later time point showed no greater union rate than
the PBS controls (p = 1.00, Fisher’s exact test).
Table 7.3 The number of the animals used at the late time point and numbers that achieved bone
union rates
Treatment group Outcome Total
Bone union Non-union
rMSC (group 3) 2 3 5
PBS (group 4) 1 4 5
Total 3 7 10
The group who had rMSC injected at the later time point showed inconsistent results
with only 2 of them proceeding to union (Figure 7.13). Although there was no
connectivity in 3 animals in group 3 (i.e. they were non-unions), they did not develop
the full characteristics of an atrophic non-union (Figure 7.14). In contrast, in the
control group, the animals demonstrated the full characteristics of an atrophic non-
union (Figure7.15).
Figure 7.13 Radiographs of one of the animals in the rMSC injection at late time point that healed
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Figure 7.14 Radiographs of one of the animals in the rMSC injection at the late time point that
progressed to non-union
Figure 7.15 Radiographs of one of the control animals in the PBS injection at late time point
demonstrated an established atrophic non-union
However, one of the animals in the control group had a healed bone gap, this
appeared to be due to a double fracture of the fibula enabling it to contribute to
fracture repair of the tibia (Figure 7.16)
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Figure 7.16 Radiographs of the single animal in the PBS injection at late time point that processed to
union; (a) after 2 week post injection and (b) after 8 weeks post injection
7.3.3.2 The progression of the fracture healing process in groups 3 and
4 (late injection groups)
The rates of bone union in the treatment and control group injected at the late time
point showed inconsistent results which were not significantly different. Thus, the
progression of the fracture healing process in the late injection group treatment was
evaluated using serial radiography to determine if there was any more subtle
advantage of using rMSC at the late stage i.e. in an established atrophic non-union.




The mean relative radiopacity at the fracture gap of rMSC treated animals (group 3)
and of the PBS control animals (group 4) is demonstrated in Figure 7.17. It was seen
that there was no significant difference between the mean radiopacity of group 3 and
4 at any of the time point (P>0.05 for treatment, time and interaction effects, two-
way repeated ANOVA)
Figure 7.17 The comparison of radiopacity between treatment (rMSC) and control (PBS) over the 8
week period post injection at the 8 week time point
7.3.3.2.2 Callus index in groups 3 and 4
The modified callus index produced a proximal callus index and a distal callus index.
The callus size of group 3 and 4 were not significantly different at any stages over
the 8 week period after injection (For both proximal and distal callus index; P>0.05
for treatment, time and interaction effects, two-way repeated ANOVA) (Figure 7.18)
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Figure 7.18 The comparison of callus index; (a) proximal and (b) Distal between treatment (rMSC)
and control (PBS) over the 8 week period post injection
7.3.3.2.3 Percentage of callus increase area of the callus in groups 3 and 4
In the rMSC injection at eight week group (group 3), the percentage change of callus
gradually increased from the 2nd week to 4th week and then it remained stable until
the end of the study. There was no significant change in the percentage change of
callus in the control group and the fracture site remained constant as a fully
developed atrophic non-union at 16 weeks after the procedure to induce the atrophic
non-union (Figure 7.19). Although, there was a slight increase in the percentage
change of fracture callus in the rMSC treatment group, there was no statistically
significant difference in the amount of callus at any time point between the two
groups (P>0.05 for treatment, time and interaction effects, two-way repeated
ANOVA).
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Figure 7.19 The comparison of the percentage callus increase between treatment (rMSC) and control
(PBS) over 8 weeks period post injection in the ‘late’ treatment group
7.3.3.2.4 The progression of the fracture healing process assessed using
fracture scoring systems
The results from RUST score and Lane & Sandhu score from group 3 and 4 (Figure
7.20) did not have any significant differences in their scores. There were slight
improvements in both groups, especially, in the Lane & Sandhu score; however,
these differences were not statistically significant (For both scoring systems; P>0.05
for treatment, time and interaction effects, two-way repeated ANOVA). The results
demonstrated that if the percutaneous injection itself was affecting the fracture site,
this effect was very minor.
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Figure 7.20 Fracture healing assessed by Fracture scoring system (a) the RUST score evaluation and
(b) the Lane and Sandhu score evaluation
7.3.3.3 Histology evaluation in groups 3 and 4
In groups 3 and 4, the tissue within the fracture gap consisted predominantly of
fibrous tissue. It was similar to the histology of the atrophic non-union model at eight
weeks. There was no difference in the tissue components on direct inspection
between the treatment and control groups at the fracture gap (Figure 7.21). However,
in the treatment group, in one of the two animals that had united; there was an area of
cartilage formation in the middle of the fracture gap (Figure 7.22).
Figure 7.21 H&E staining from the fracture site in (a) the rat MSC injected group, and (b) the control
PBS injected group; Fibrous component was dominant in the fracture gap (x100)
a) b)
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Figure 7.22 H&E staining from the fracture site of one of the animals in MSC injected group; a
cartilage component could be found in the middle of the fracture gap (x100)
The tissue components were compared between the rMSC treatment group and the
control group (Figure 7.23). There were no differences in the amounts of bone,
cartilage, fibrous and marrow/empty space (P-value > 0.05, unpaired t-tested).
However, the bone tissue component in group 3 was less than group 4.
Figure 7.23 Quantitative evaluation of the tissue components in the fracture gap
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7.3.3.4 Micro-CT analysis in groups 3 and 4
There was no significant bony bridging on 3D images in either the rMSC or the PBS
injection groups at the late time point (Figure 7.24 (a, b)). The bone gap was still
evident in both the treatment group and the control group in most of the animals.
Although there were inconsistent bone unions in some animals in the rMSC
treatment group, there were no significant differences in any parameters of bone
structure of the rMSC injection group compared to the PBS control group. All of the
parameters obtained from micro-CT analysis are shown in table 7.4.
Figure 7.24 The results from Micro computed tomography of the late treatment groups: Three
dimension image of (a) control group and (b) rat MSCs injected group
193









BV/TV 32.84 (17.81) 26.35 (17.74) P = 0.81
Bone surface density
(1/mm)
3.48 (1.43) 2.38 (0.91) P = 0.54
Tb.N 0.58 (0.19) 0.41 (0.14) P = 0.50
Tb.Th 0.29 (0.03) 0.35 (0.08) P = 0.55
Tb.Sp 0.55 (0.05) 0.59 (0.04) P = 0.50
Bone mineral density
(g HA/mm3)
0.31 (0.13) 0.39 (0.16) P = 0.74
7.3.4 Comparison between early and late injection (groups
1and 3)
This section provides a summary of the results between early and late time points
using data from section 7.3.2 and 7.3.3.:  it reports that the injection of MSCs at an
early time point had a better outcome on the basis of radiographs, histology and
micro-CT evaluation.
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7.3.4.1 Radiographic parameters between early and late injections
The graphs in Figure 7.25 compare radiographic parameters such as radiopacity
(Figure 7.24 a), proximal callus index (Figure 7.24 b), distal callus index (Figure
7.24 c) and the percentage area increase of the callus (Figure 7.24 d) between early
injection and late injection of MSCs at the eight weeks after injection. There were
statistically significant differences in radiopacity (P-value = 0.0025 for treatment,
two-way repeated ANOVA), proximal callus index (P-value = 0.048 for treatment,
two-way repeated ANOVA) and distal callus index (P-value = 0.009 for treatment,
two-way repeated ANOVA) between early and late treatment of MSC injection.
Figure 7.25 The comparison of radiographic parameters between early and late time injection groups
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7.3.4.2 Histology between early and late injection
The relative amount of bone, cartilage, fibrous and undifferentiated tissue at the
fracture gap for the early and late injection groups were compared at eight weeks
after injection (Figure 7.26). The bone component in the fracture gap of animals in
the early injection group was significantly more than in the late injection group (P <
0.01, unpaired t-test).
Figure 7.26 The tissue components at the fracture gap at early and late injection time points
7.3.4.3 Micro-CT analysis for early and late injection groups
The micro-CT analysis demonstrated the bone structure at the fracture gap which
was represented by bone structural parameters and bone mineral density (Figure
7.27) between the early treatment and late treatment groups.
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Figure 7.27 The comparison of bone structural parameters and bone mineral density between early
treatment and late treatment groups (* statistically significant difference, P-value < 0.05, unpaired t-
test)
7.4 Summary and discussion
The percutaneous injection of MSCs locally into the atrophic non-union in the early
‘post-injury’ period (three weeks) significantly improved the fracture healing process
(P-value = 0.048). Five out of six MSC-injected rats demonstrated improvement in
fracture healing, whereas none of the PBS-injected rats (0 of 3) showed improvement
on serial radiographs. Atrophic non-unions with MSCs implantation in the late ‘post-
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injury’ period (eight weeks) showed no significant improvement of fracture healing
(2 of 5) (P-value > 0.05). The quantitative analysis of bone healing using
radiographic image, histology and micro-CT also showed the beneficial effect of the
treatment at an early time point over the control group and the late treatment group.
Percutaneous local implantation of MSCs rescued the fracture healing process in
cases destined to progress to atrophic non-union. However, the timing after the
fracture was a considerable factor and this should be taken into account when
designing MSCs protocols.
MSCs could play a role as bone progenitors or trophic secreting cells to promote the
fracture healing process. It has been reported that an insufficient biological
environment at the fracture gap in atrophic non-unions at three weeks leads to the
development of the atrophic non-union (Reed at el 2003). Thus, augmentation of the
biological components at the three week time point would be a reasonable strategy
for restoring the normal fracture healing process. In this study, when MSCs were
injected at an early stage, they rescued the fracture and returned it to the normal
process of fracture healing.
Surprisingly, injection of MSCs into an established atrophic non-union did not show
any significant improvement in the fracture healing process. According to the
observations described in this thesis, in the established non-union, the gap became
larger from the original 1 mm. created at surgery to around 2 mm. In addition, there
was further bone loss in the late stage of the atrophic non-unions. It is possible that
the cells alone could not contribute to bone healing as the bone may have needed
scaffold and the fracture environment is not suitable to induce osteogenesis because
the native biological components are different in each stage of the disease.
MSCs combined with scaffolds have been shown to improve the process of fracture
healing process in a bone defect in several animal models (Bruder et al., 1998,
Peterson et al., 2005, Nair et al., 2009). An atrophic non-union, however, might
occur without a bone defect. In order to prevent an atrophic non-union, becoming
established, it is advantageous to augment the fracture healing process using a
minimally invasive technique. Because of the absence of a critical size defect, a
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scaffold might not be required. Percutaneous injection can be performed under local
anaesthesia. A percutaneous injection technique has been used to treat non-unions in
a human study. Connolly (1998) reported that autologous bone marrow delivered by
percutaneous injection or by direct transplant as a composite graft was effective at
producing osteogenic stimulation in a series of 100 skeletal healing problems,
including delayed unions and nonunions of fractures, arthrodeses, and bone defects.
Hernigou et al, (2005) used percutaneous concentrated autologous bone-marrow
grafting for the treatment of an atrophic tibial diaphyseal non-union. The non-unions
went on to unite successfully in 90% of the patients (n= 53). In the union group, the
bone marrow that had been injected into the non-unions contained >1,500
progenitors/cm3 and an average total of 54,962 +/- 17,431 progenitors. Seven
patients in whom bone union was not obtained both had a significantly lower
concentration (634 +/- 187 progenitors/cm3) and a lower total number (19,324 +/-
6843) of progenitors injected into the non-union sites (p = 0.001 and p < 0.01,
respectively) than the patients who progressed to union. The results suggested that
the percutaneous technique could be used to deliver the cells into an atrophic non-
union and the yield of MSCs was an important factor in determining the success of
the technique.
This study has shown that the percutaneous injection of bone marrow derived MSC
could improve and rescue the fracture healing process in an atrophic non-union
model. However, the cells had to be introduced at three weeks (early stage) after the
operation when the fracture had not developed into an established atrophic non-
union. The data presented here suggests that percutaneous injection techniques of
MSCs can be used as a strategy for the prevention of atrophic non-union when used
in the early stage of the disease. MSC augmentation using percutaneous injection
could be translated into clinical use. The MSCs used in this study, however, were
harvested from rat bone marrow. Further experiments should investigate the
therapeutic effects of ‘non-like’ immune cells (i.e. allogeneic/xenogeneic cells) as
these could have advantages in the trauma setting as they may be more readily
available at an earlier time point and be more cost effective. Therefore, to explore
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whether xenotransplantation of human MSCs into the rat non-union model is as
effective as rat MSCs a further experimental study is needed.
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Chapter 8: Human bone marrow derived
mesenchymal stem cells implantation in
xenotransplantation model of an atrophic non-
union
Aim: To investigate the therapeutic effects of xenogeneic MSC implantation for bone
regeneration in atrophic non-union model
8.1 Introduction
The results from the previous chapter (chapter 7) showed that bone marrow derived
MSCs promoted bone regeneration in the atrophic non-union model. A minimally
invasive percutaneous injection technique was used to deliver the stem cells. The
time of injection was found to be a critical factor. To achieve the most favourable
outcomes, MSCs should be injected earlier (three weeks) rather than later.
In clinical practice, there are several advantages of using MSCs from a universal
donor:  MSC isolation and preparation are time and resource consuming. The yield
of MSCs in bone marrow is relatively small in number, so cells have to be expanded
in an appropriate culture condition to obtain an adequate number of cells prior to
implantation into the fracture site. These steps take about two weeks or more to
complete. Thus, it may not to be possible to use cultured MSCs at an appropriate
time point. Moreover, it has been reported that in old age as well as in several
conditions such as osteogenesis imperfecta, smoking and DM, the quality and
function of MSC may be diminished (reviewed in section 1.5.4). Thus, the
autologous transplantation of MSCs from patients who have one of these conditions
may not result in bone regeneration. In these patients, MSCs from a different donor
such as a healthy universal donor may be a better option. One of the characteristics
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of MSCs is their immune privileged status, which suggests that it may be possible to
transplant exogenous MSCs without eliciting a host inflammatory immune response.
In this chapter, a xenogeneic model has been used to determine (1) the bone
regenerative potential of exogenous MSCs in an atrophic non-union and (2) the
response of the immune system to exogenous MSCs (i.e. human). Xenogeneic cells
can be considered to represent the extreme immune stimulus and previously a
xenogeneic model has been used to evaluate the feasibility of using MSCs from a
universal donor cells in the cardiovascular field (Atoui et al., 2008). Thus, if there are
any positive effects when human MSCs are injected to promote fracture healing in an
immunocompetent animal model, the results should also be relevant to the situation
where universal donor cells are used in the clinical setting. The objectives of this
study were to (1) to compare the bone regeneration potential of xenotransplantation
and allogeneic implantation of MSCs into an atrophic non-union (2) to demonstrate
the immune response after MSC implantation in the in vivo condition and (3) to trace
the distribution and fate of injected MSCs either hMSC or rMSC at the fracture gap
after cell implantation.
8.2 Materials and Methods
The details of the surgical procedure of the atrophic non-union model, the
percutaneous injection technique, the method of human and rat MSC preparation, the
fracture assessments have been described in the general materials and methods




Twenty six adult male Wistar rats (400-500g) were used in this study, however two
animals were excluded due to wound complication and anaesthetic problems. So that,
twenty four animals were randomly assigned into three groups after inducing an
atrophic non-union: Group 1 for rMSC injection (n=8), Group 2 for hMSC injection
(n=8) and Group 3 for PBS injection as controls (n=8). All animals received either
cells or PBS intervention at three weeks after inducing atrophic non-union procedure.
Animals in the treatment groups (group 1 and 2) were injected with the 5 x 106 cells
either rMSCs or hMSC in PBS suspension (200 µl), whereas animals in the control
group were injected with PBS (200 µl). The fracture healing process was monitored
with radiographs every two weeks until the end of the study. The assessments of
bone healing were performed at four weeks (n=12) or eight weeks (n= 12) after
injection by quantitative micro-CT and histology. Micro-CT assessments were
carried out on all samples. Histology evaluation was performed on three specimens
randomly selected by blinded assessors; the sections were assessed in triplicate in a
blinded fashion. Biomechanical evaluation was carried out on three specimens from
each group at four and eight weeks post injection. The study flow diagram is shown
in the Figure 8.1.
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Figure 8.1 Flow diagram of experimental plan in this study
8.2.2 Biomechanical evaluation
Rat tibia bones (n=9, at four weeks-assessment and n= 12, at eight week-assessment)
were randomly selected for biomechanical testing. The samples were tested using a
four-point bending test (Zwick/Roell) as described in Chapter 2. The biomechanical
properties of callus of animals from each group were compared using ultimate load,
ultimate stress, young’s modulus and toughness.
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8.2.3 Cells tracking after injection
CM-Dil was used to label cells before implantation as per the company’s protocol.
The full details of the optimisation of the technique used are described in the section
2.10 (Chapter 2). Anti-human nuclei antibody was also used to detect implanted
human cells. Analysis of these cells was done immediately after transplantation
(using animals in the optimisation of injection technique as the control for injection),
at four weeks and at eight weeks to determine the distribution and fate of implanted
cells.
8.2.4 Evaluation of inflammatory cytokines from the serum
Serum samples from animals in the each group were collected at 0, 2, 4, 6 and 8
weeks. The Multi-Analyte ELISArray (SABiosciencesTM, USA) was used to evaluate
12 inflammatory cytokines from pool samples as per the company’s protocol
(Chapter 2).
8.2.5 Histology of lymph node
Popliteal Lymph nodes from both hind limbs; the injected side (right) and the
contralateral side (left) were collected after euthanasia at the end of the experiment.
They were fixed in 4%PFA for routine histological procedures by H&E staining.
Three sections at the middle of lymph nodes (6 μm) from animals in each group
(rMSC injection, hMSC injection and PBS injection) at four weeks and eight weeks
were evaluated under light microscopy. The following parameters from each group
were compared; (1) the size of lymph node, (2) the number of secondary follicles, (3)
the number of infiltrating cells in the sub-capsular sinus area, and (4) the number of
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macrophages in the medullary cord area. (Further details are given in section 2.11.2,
Chapter 2)
8.2.6 Statistical analysis
The Kaplan-Meier curves were used to present the number of animals that reached
union each time point after treatment and the Log-rank test was used to compare
between curves. The mean difference of fracture progression parameters, which were
radiopacity, callus index, percentage increase of callus area and the fracture scoring
systems over the post injection period were compared with repeated measures
ANOVA followed by bonferroni’s multiple comparison tests. The qualitative
measurement of histology from fracture sites, morphological changes of popliteal
lymph nodes, the micro-CT parameters and biomechanical parameters were
determined using the one-way ANOVA. The post-hoc analysis was conducted
appropriately using bonferroni’s multiple comparison tests. A P-value of less than
0.05 was considered significant.
8.3 Results
8.3.1 Health status of the animals after received MSC injection
The animals were able to weight- bear fully immediately following MSC injection.
There was no abnormal bleeding, swelling or skin irritation at the injection site. All
animals returned to their normal activity after recovering from anaesthesia. After
randomisation, all of the animals remained alive with neither signs of wound
infection nor pin tract infection until the end of the experiment (at four weeks and
eight weeks after cell injection).
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8.3.2 Diagnosis of bone union in rat MSC, human MSC and
PBS (controls)
In the cell injection groups (rMSC and hMSC), seven out of eight of the animals
from each group that had received cells progressed to union, but only one of animals
in the control group achieved bone union. Table 8.1 shows the number of unions and
non-unions for rats injected either with rMSC, hMSC or PBS. The survival time to
healing was estimated using Kaplan-Meier survival analysis. Figure 8.2 shows the
Kaplan-Meier curves demonstrating the number of radiographic bone unions at each
time point over the 8 week-period from animals in the rMSC treated group, the
hMSC treated group and the control group. The mean healing time of animals in the
rMSC injection group was 4.3 (S.D. = 2.14) and in the hMSC injection group was
5.4 (S.D. = 1.90). There was a statistically significant difference in the survival
curves of the different groups (P = 0.02). The survival curves of the rMSC injection
group and the hMSC injection group were significantly different from the control (P
= 0.003 and P = 0.008, respectively). However, there was no significant difference
between the rMSC injection group and the hMSC injection group (P = 0.36)
Table 8.1 Outcome of fracture union (inclusive of four and eight week results) according to group.
The number of the animals used and results of bone union between three groups
Treatment group Outcome TotalUnion Non-union
rMSC 7 1 8
hMSC 7 1 8
PBS (control) 1 7 8
Total 15 9 24
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Figure 8.2 The Kaplan-Meier curves showing the number of animals that had achieved radiographic
bone union over the 8 week-period (P-value = 0.02, Log-rank test)
8.3.3 Detailed radiographic assessment of the progression of
fracture
The progression of fracture healing was evaluated every two weeks (Figure 8.3).
There was no noticeable difference of the x-ray appearance between the rMSC and
the hMSC injection group. Both groups showed a progression of fracture healing
over the eight week period after cell injection. In contrast, in the control group, the x-
rays showed the fracture site proceeding to the full characteristics of an atrophic non-
union.
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Figure 8.3 Radiographic progressions after injection over the 8 week period after injection
8.3.3.1 Relative Radiopacity
The radiopacity of the fracture gap was calibrated using an aluminium step wedge.
The opacity of the fracture gap from each group was significant differences during
the eight week period after injection (P-value < 0.0001 for treatment groups and
times, and P-value < 0.01 for interaction effects, two-way repeated ANOVA). There
was a significant increase in opacity in the MSC treatment groups after injection,
whereas in the control group, the mean opacity at the different times did not change
significantly. The progression of fracture healing in animals in the rMSC injected
group was slightly faster than in the hMSC injected group, but it was not statistically
significantly different (Figure 8.4).
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Figure 8.4 The comparison of radiopacity between treatment groups over the 8 week period after
injection; the radiopecity at the fracture site in the rMSC and hMSC group were comparable and both
of them were significantly higher than in the PBS treatment (Bonferroni’s test subsequent to ANOVA:
* = P-value < 0.05, ** = P-value < 0.01 and *** = P-value < 0.001, data shown as mean and SEM, n =
4 or 8 per group and time)
8.3.3.2 Callus index
Similar to the radiopacity results, there were significant increases in the callus index
from the animals in the rMSCs and hMSCs treatment groups both proximal (P-value
< 0.0001 for treatment groups, P-value = 0.0006 for times, and P-value = 0.22 for
interaction effects, two-way repeated ANOVA) and distal (P-value < 0.0001 for
treatment groups, P-value = 0.002 for times, and P-value = 0.47 for interaction
effects, two-way repeated ANOVA) to the fracture site compared to the control
(Figure 8.5). At the 8 week time point, the callus became smaller as potentially, it
had entered the remodelling phase of the fracture healing process.
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Figure 8.5 The comparison of callus index; (a) proximal and (b) distal between the treatment groups
(rMSC and hMSC) and control (PBS) over the 8 week period post injection which were significantly
differences compared to the control group (Bonferroni’s test subsequent to ANOVA: * = P-value <
0.05, ** = P-value < 0.01 and *** = P-value < 0.001, data shown as mean and SEM, n = 4 or 8 per
group and time)
8.3.3.3 Percentage increase in the area of radiopaque bone tissue
Line graphs in Figure 8.6 show the percentage increases between in the MSC groups
(rMSC and hMSC) and control over the 8 week period after injection. In both MSC
injection groups, the callus gradually increased in area from the 2nd week to the 4th
week and then remained stable after the 6th week. In contrast, there was a decrease in
the area of radiopaque bone tissue in the control group where PBS solution alone was




statistically significant difference in the amount of callus between the MSC treatment
groups and the PBS control group (P-value < 0.0001 for treatment groups, P-value =
0.007 for times, and P-value = 0.13 for interaction effects, 2-way repeated ANOVA).
Figure 8.6 The comparison of the percentage callus increase between treatment groups (rMSC and
hMSC) and control (PBS) over the 8 weeks period post injection; there were significant increases in
the area of radiopaque bone tissue in the MSC treatment groups compared to the control group.
(Bonferroni’s test subsequent to ANOVA: * = P-value < 0.05, and *** = P-value < 0.001, data shown
as mean and SEM, n = 4 or 8 per group and time)
8.3.3.4 The progression of the fracture healing process assessed using
fracture scoring systems
The values for the RUST score and the Lane & Sandhu score showed the progression
of the fracture healing process (Figure 8.7). There were significant differences in the
RUST score (P-value < 0.0001 for treatment groups and times, and P-value = 0.004
for interaction effects, two-way repeated ANOVA) and the Lane & Sandhu scores
(P-value < 0.0001 for treatment groups and times, and P-value = 0.0004 for
interaction effects, two-way repeated ANOVA) over the eight week period after
injection between the MSC treatment groups and the PBS treatment group. There
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was no significant difference between the value of the RUST and the Lane & Sandhu
scores in the rMSC and hMSC treatment groups. However, the scores in both
treatment groups were significantly different from the control group after 2-4 weeks
for the RUST score and for the Lane & Sandhu score.
Figure 8.7 The evaluation of fracture healing using the fracture scoring systems; (a) the RUST score
evaluation, and the (b) Lane and Sandhu score evaluation (Bonferroni’s test subsequent to ANOVA: *
= P-value < 0.05, ** = P-value < 0.01 and *** = P-value < 0.001, data shown as mean and SEM, n = 4
or 8 per group and time)
8.3.4 Micro-CT evaluation
Figure 8.8 shows a three dimensional reconstruction of the bony callus of a
representative specimen from each group. At eight weeks after MSC injection, there
was a solid bony callus in the rMSC and hMSC treatment groups and the appearance
of bone bridges in both groups was similar. In contrast, the fracture gap was clearly
observed in the control group. Quantitative micro-CT analysis showed that the
percentage bone volume (BV/TV) and bone surface density in both MSC injected
groups were significantly greater at four and eight weeks after injection compared to
the control group. Similarly, bone microarchitecture parameters (Tb.N, Tb.Th and
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Tb.Sp) and BMD in the cell treatment groups either rMSC or hMSC were higher
than in the control group. There were no statistically significant differences in micro-
CT parameters between the rMSC treatment group and the hMSC groups either at
four weeks or at eight weeks after injection. The summary of the micro CT
parameters from the different treatment groups at four weeks and eight weeks is
shown in Table 8.2
Figure 8.8 Three dimensional images from Micro computed tomography; (a) animal with rMSC


















































Table 8.2 The summary of micro CT analysis from the animals from different groups at 4 weeks and














(n = 3) (n = 3) (n = 3)
BV/TV 43.29 (7.26) 68.09 (4.49) 16.01(5.44) 0.0004
Bone surface
density (1/mm)
4.46 (0.55) 5.28 (0.36) 2.24 (0.62) 0.0019
Tb.N 1.02 (0.13) 1.38 (0.20) 0.51 (0.10) 0.0098
Tb.Th 0.46 (0.02) 0.51 (0.05) 0.29 (0.08) 0.0535
Tb.Sp 0.41 (0.06) 0.32 (0.04) 0.62 (0.05) 0.0058
Bone mineral
density (g HA/mm3)
0.49 (0.01) 0.52 (0.01) 0.13 (0.13) 0.02
8 weeks after
injection
(n = 4) (n = 4) (n = 4)
BV/TV 68.10 (7.73) 64.10 (6.49) 29.92 (12.91) 0.036
Bone surface
density (1/mm)
4.24 (0.26) 4.94 (0.36) 3.10 (0.62) 0.046
Tb.N 1.12 (0.06) 1.37 (0.12) 0.72 (0.15) 0.0096
Tb.Th 0.61 (0.06) 0.47 (0.01) 0.37 (0.11) 0.11
Tb.Sp 0.34 (0.06) 0.34 (0.07) 0.56 (0.08) 0.0878
Bone mineral
density (g HA/mm3)
0.66 (0.03) 0.61 (0.03) 0.28 (0.16) 0.05
8.3.5 Biomechanical test for xenotransplantation
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Biomechanical testing with four-point bending was used to evaluate the mechanical
properties of the bone samples. Representative load-displacement curves for each of
the three different treatment groups are shown in Figure 8.9. Readings from the
load-displacement graphs were obtained and used to determine the various
biomechanical parameters of fracture repair (i.e. ultimate load, ultimate stress,
young’s modulus and toughness). The samples in the PBS treatment group were also
evaluated with the four point bending test. However, minimal resistance against the
bending load was detected during testing. The load-displacement curve in the PBS
treatment group (Figure. 8.9c) indicated that the control samples could not withstand
the force applied during the test. The limbs from the PBS injection group were found
to be macroscopically unstable and they were not suitable for determining the
biomechanical parameters. Thus, the results presented for the biomechanical
parameters were compared between the rMSC and hMSC treatment groups at four
weeks and eight weeks after injection, respectively. The biomechanical parameters
from samples in the rMSC and hMSC treatment group are summarised in Table 8.3.
Although the mechanical properties of bone samples in the rMSC treatment group
were better than in the hMSC injection group, there was no statistical difference
between the two groups at four weeks and eight weeks after injection.
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Figure 8.9 Representative load-displacement curves from (a) the rMSC injection group, (b) the hMSC
injection group and (c) the PBS injection group
Table 8.3 The summary of biomechanical properties of healing bone in the animals with rMSC
injections and the animals with hMSC injections
Mechanical
property








Ultimate load N 47.7 (7.2) 72.5 (29.3) 0.46
Ultimate stress MPa 53.7 (16.7) 63.5 (19.3) 0.72
Young’s modulus GPa 1.1 (0.4) 1.3 (0.6) 0.75




Ultimate load N 116.2 (34.7) 62.8 (6.7) 0.18
Ultimate stress MPa 150.0 (18.3) 89.89 (18.6) 0.06
Young’s modulus GPa 2.7 (1.0) 2.0 (0.6) 0.58
Toughness MPa 3.2 (0.5) 2.1 (0.9) 0.39
217
8.3.6 Histological evaluation
Histological assessment was performed on specimens at 4 and 8 weeks following cell
implantation in the rMSCs, hMSC and PBS treatment groups.  The sections were
stained with H & E, Masson's Trichrome stain and Safranin-O/Fast Green were
assessed using light microscopy under appropriate magnification. These sections
revealed the progression of fracture healing and demonstrated the area of bone and
cartilage formation that can be distinguished from fibrous tissue. Bony bridges were
observed in some specimens and confirmed the radiographic finding of bone union.
8.3.6.1 Observation of general morphology at 4 weeks
At four weeks after implantation, the inter-fragmentary gap in the rMSC and hMSC
treatment groups had a large area of new bone formation and there was an area of
endochondral ossification (Figure 8.10, Figure 8.11). The osteotomy site was still
visible and there was no remodelling of the callus. The area of the fracture gap was
occupied with the bone and cartilage tissue. Overall, the fracture gap of the hMSC
and rMSC treatment group had a similar appearance. In contrast, in the control
group, the inter-fragmentary gap was filled predominantly with cellular fibrous tissue
(Figure 8.12).
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Figure 8.10 At week 4 post rMSC injection histological sections.  (a) H&E stain demonstrating an
area of bone formation, arrow and the osteotomy site, asterisk (x100), (b) Masson’s trichrome stain
(x100), (c) Safranin-O/Fast Green demonstrating an area of cartilage template, box (x100) and (d)





Figure 8.11 At week 4 post hMSC injection histological sections.: (a) H&E stain demonstrating an
area of bone formation, arrow and the osteotomy site, asterisk (x100), (b) Masson’s trichrome stain
(x100), (c) Safranin-O/Fast Green demonstrating an area of cartilage template, box (x100) and (d)





Figure 8.12 At week 4 post PBS injection (control) histological sections: (a) H&E stain
demonstrating the presence of a fracture gap containing fibrous tissue, arrow and the osteotomy site,
asterisk (x100), (b) fracture gap at higher magnification (x200), (c) Masson’s Trichrome stain (x100),
(d) Safranin-O/Fast Green (x100)
8.3.6.2 Observation of general morphology at 8 weeks
The histological sections at eight weeks also demonstrated a difference in appearance
between the cell implantation groups and control group. Bone bridges were observed
in both the rMSC and hMSC implantation groups, but not in the PBS group (control).
Masson‘s Trichrome staining also demonstrated areas of new bone formation. In the
rMSCs implantation group, there was full bridging callus connecting the bone ends
(Figure 8.13), the callus size was slightly larger than in the hMSCs implantation





distinguish. In the human cell implantation group, the area of bone at the fracture
was less than in the rat cell implantation group, but there was good bone continuity
between the proximal and distal bone fragments and the bone cortex had remodelled
(Figure 8.14). In the PBS injected group (control), the fracture site went on to form
an atrophic non-union in which the bone ends became more rounded and the inter-
fragmentary gap increased. Fibrous tissue remained at the fracture gap (Figure 8.15).
Figure 8.13 At week 8 post rMSC injection histological sections: (a) H&E stain demonstrating bone
bridges, arrows (x40), (b) Masson’s Trichrome stain demonstrating an area of new bone formation,
asterisk (x40)
Figure 8.14 At week 8 post rMSC injection histological sections: (a) H&E stain demonstrating bone
bridges, arrows (x40), (b) Masson’s Trichrome stain demonstrating an area of new bone formation,
asterisk (x40)
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Figure 8.15 At week 8 post PBS injection (control) histological sections.  (a) H&E stain
demonstrating full characteristics of atrophic non-union (x40), (b) Masson’s Trichrome stain (x40)
8.3.6.3 Quantitative comparison of the tissue at the fracture gap from
the three different treatments
Figure 8.16 shows the percentage of each tissue component; bone, cartilage, fibrous
tissue and bone marrow/empty space at the fracture. There was a significant
difference in tissue constituents between the cell treatment groups (either rat or
human MSCs) and the PBS group both at four weeks and at eight weeks. The amount
of bone at the interfragmentary gap in the MSC implantation groups was
significantly more than the control at both four weeks and eight weeks. The amount
of bone at the inter-fragmentary gap in the rMSC was 31.6% (P < 0.05, 95%CI of
diff. -1.3 to 64.4) and 57.6% (P < 0.001, 95%CI of diff. 24.8 to 90.4) more than in
the control group at four weeks and eight weeks, respectively, while the amount of
bone at the  inter-fragmentary gap in the hMSC group was 19.9% (P > 0.05, 95%CI
of diff. -12.9 to 52.7) and 58.1% (P < 0.001, 95%CI of diff. 24.8 to 90.4) more than
the control group at four weeks and eight weeks, respectively. The amount of bone
formation in the rMSC injection group was slightly more than the hMSC injection
group in at both time points, but there was no statistical significant (P > 0.05,
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bonferroni test). At 4 weeks, the cartilage component in the MSC injection group
was significantly more than in the control (13.6 %, P < 0.01, 95%CI of diff. 3.5 to
23.7 in the rMSC injection group and 14.7 %, P < 0.01, 95%CI of diff. 4.5 to 24.8 in
the hMSC injection group).
Figure 8.16 Quantitative evaluation of the tissue component in the fracture gap of the rMSC, hMSC
and PBS (control) treatment groups; (a) Bone tissue component, (b) Cartilage tissue component, (c)
Fibrous tissue component and (d) Bone marrow component
8.3.7 Tracking of injected cells
8.3.7.1 In vitro: CM-Dil labelling of cells
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MSCs derived from either rat or human bone marrow were labelled with CM-Dil
before injection. This dye stained the membrane of cells in vitro and was
demonstrated using a fluorescence microscope (Figure 8.17 and Figure 8.18). The
images showed fluorescent signal in the red channel for both rMSCs and hMSCs.
Figure 8.17 rMSCs labelling with CM-Dil in an in vitro culture: (a) rMSC under phase contrast
microscope (x200) and (b) rMSC under fluorescence microscope (x200)
Figure 8.18 hMSCs labelling with CM-Dil in an in vitro culture: (a) hMSC under phase contrast
microscope (x200) and (b) hMSC under fluorescence microscope (x200)
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8.3.7.2 In vivo: MSCs with CM-Dil labelling at the fracture site after
implantation
At 0 weeks (immediately after cell implantation), numerous labelled cells were
observed at the fracture gap in both the rMSC and hMSC implantation groups
(Figure 8.19a, b, c and Figure 8.20a, b, c). These results indicated that the
percutaneous technique reliably delivered cells directly into the fracture gap.
Four weeks after cell implantation, labelled rMSCs were still detected at the fracture
gap but the number of cells appeared to have decreased (Figure 8.19d, e, f).  Eight
weeks after cell implantation, cells were not found at the fracture (Figure 8.19g, h,
i). In the hMSC injection group, hMSC were not detected at four weeks (Figure
8.20d, e, f) nor eight weeks (Figure 8.20d, e, f) after implantation.
Despite the improvement in the fracture healing process in both the rMSC
implantation and hMSC groups, no hMSCs and only a few rMSCs engrafted at the
fracture callus suggesting that the effect of MSCs on bone healing did not rely on
their differentiation potential from progenitor cells.
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Figure 8.19 CM-Dil staining rMSC (Red) at the fracture gap at 0 weeks, 4 weeks and 8 weeks after
cell injection with corresponding nuclear (DAPI, Blue) counter stain (x400)
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Figure 8.20 CM-Dil staining hMSC (Red) at the fracture gap at 0 weeks, 4 weeks and 8 weeks after
cell injection with corresponding nuclear (DAPI, Blue) counter stain (x400)
8.3.7.3 In vitro hMSC staining with Anti-human nuclei antibody
hMSCs were stained in vitro using anti human specific nuclei antibody. Figure 8.21
shows the fluorescence signal in the nucleus of cultured cells. For human cells, the
signal in green can be seen in the nuclei.
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Figure 8.21 Anti-nucleic positive staining for hMSC in the in vitro culture (Green) with
corresponding nuclear (DAPI, Blue) counter-stain (x400)
8.3.7.4 Anti-human nuclei antibody staining for identifying hMSC cells
after implantation in atrophic non-union fracture
In the human tissue sections, there was a fluorescence signal from staining (Figure
8.22a, b, c). The human nuclei were stained using the anti-human nucleus antibody.
This specimen was used as the positive control for this experiment.  The tissue from
the fracture gap of the hMSC implantation group demonstrated that there were no
positive staining cells after 4 weeks (Figure 8.22d, e, f) or after 8 weeks (Figure
8.22g, h, i) after hMSC implantation. These results corresponded well with the CM-
Dil labelling study in which there was no hMSC engraftment after implantation at the
fracture callus.
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Figure 8.22 Anti-nucleic positive staining for hMSC (Green) at the fracture gap at 4 weeks and 8
weeks after cell injection with corresponding nuclear (DAPI, Blue) counter stain (x400) and (a,b,c)
foetal human tissue from upper limb was used as the positive control
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8.3.8 Evaluation of immune response after cells implantation
8.3.8.1 Systemic response to the different treatments
Seven inflammatory cytokines were detectable with the multiple ELISA assay
including IL-1a, IL-1b, IL-2, IL-12, IL-13, TNF-α and GM-CSF. Serum samples
from animals at the 0 time point (before injection) were used for comparison of the
fold difference change every two weeks over a period of eight weeks after cell
injection. Figure 8.23 shows the mean fold difference of detectable cytokines over
the post-injection period of rMSC, hMSC and control (PBS).
In the PBS injection group (control group), there was no significant change in any of
the inflammatory cytokines. In contrast, in the cell injection groups, at two week post
injection, there were an increase in the level of IL-1b and IL-2 in both the rMSC and
the hMSC injection groups. The levels of IL-1b and IL-2 decreased by the 4th week
and remained at this level until the end of the experiment. Il-1a, IL-12, IL-13 and
TNF-α did not change over the time period in the MSC treatment groups. However,
in the human cell injection group, there was a remarkable increase in the GM-CSF
compared to other cytokines at four weeks and eight weeks compared to the rat cells
injection group and the control group. This result indicated the inflammatory
reactions in the hMSC injection group.
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Figure 8.23 Inflammatory cytokines from multiple ELISA assay from (a) the rMSC injection group
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8.3.8.2 The popliteal lymph node response
The popliteal lymph nodes are the closest regional lymph nodes to the fracture site.
These lymph nodes were evaluated in order to assess the immune response following
cell injection to the fracture site.  There were four parameters that were determined in
the regional lymph nodes; (1) the size of lymph node, (2) the number of secondary
follicles, (3) the number of infiltrating cells at the subcapsular sinus and (4) the
number of macrophages at the medullary sinus. The results from quantitative
evaluation of the ipsilateral right popliteal lymph node from the three treatments
(rMSC, hMSC and PBS) and from the contralateral left popliteal lymph node for
comparison (unoperated side) are shown in Figure 8.24.
Four weeks after injection, there were no significant differences between the
treatment groups in the size of lymph node, the number of secondary follicles or the
number of macrophages from treatment groups. However, the number of infiltrating
cells at the subcapsular area in the hMSC injection group was significantly higher
than in the rMSC and PBS injection groups. The left popliteal lymph node
(unoperated side) was smaller than the lymph node from the hMSC treatment group.
The number of secondary follicles and the number of infiltrating cells at the sub-
capsular area in the left lymph node was less than from the operated side of the
hMSC treatment groups. There was no significant difference in the number of
macrophages at the medullary sinus area between the operated and unoperated side.
Eight weeks after injection, the size of lymph node, the number of secondary follicles
and the number of infiltrating cells increased in the rMSC and hMSC group, but
there was no significant change in any of these parameters in the PBS injection group
or in the lymph node from the unoperated (control) side. The size of lymph nodes
from the hMSC injection group was significantly larger than the PBS injection group
and there was a significant increase in the number of secondary follicles compare to
the PBS injection group.  There were no differences in the number of macrophages at
the medullary sinus from any of the treatments or from the control lymph node.
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In summary, there was a significant increase in the lymph node reaction at the injury
site demonstrated by the size of lymph node and the number of secondary follicles.
Although there was an increase in the size of the lymph node, the number of
secondary follicles and infiltrating cells in the lymph node from the rMSC injection
group, the differences were not statistically significant compared to the PBS injection
group. In the hMSC injection group, the size of lymph node and the number of
secondary follicles significantly increase when compared to the PBS injection group.
However, the difference between the hMSC and rMSC groups was not significant.
The number of macrophages at the medullary sinus was not different in the rMSC,
hMSC or PBS injection groups.
Figure 8.24 Histomorphology of popliteal lymph nodes from both operated and unoperated (control)
side 4 and 8 weeks after injection with rMSC, hMSC and PBS control; (a) Size of Lymph nodes , (b)
Number of secondary follicles, (c) Number of infiltrating cells at capsular sinus, and (d) Number of
macrophages at the medullary sinus
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8.4 Summary and discussion
In this chapter, the therapeutic effect of hMSC in promoting fracture healing of an
atrophic non-union model was found to be comparable to the therapeutic effect of
rMSC in promoting healing in the same model. Both treatments led to an
improvement in fracture healing, especially when injected into the atrophic non-
union model at an early stage. There were no clinical adverse effects detected with
xenogeneic transplantation. Although there was an increase in GM-CSF level at the
later time point after hMSC injection, there were no significant differences in the size
of the lymph node, the number of secondary follicles, the number of infiltrating cells
at capsular sinus and the number of macrophages at medullary sinus between rMSC
injection and hMSC injection groups. The cell tracing results showed that the hMSCs
did not persist at the fracture site; either four weeks or at eight weeks the implanted
cells were not evident. In comparison, there were a few rMSCs observed at the
fracture gap at four weeks after injection but not at eight weeks. Both allogeneic and
xenogeneic MSCs implantation contributed to the fracture healing process however,
rMSCs and hMSCs had disappeared by the time the fractures had united. These
results suggest that exogenous MSCs improve fracture healing via their paracrine
effect and not necessarily as progenitor cells. Although immune responses were
raised by implantation of hMSC, the therapeutic effect of hMSCs in bone repair was
not significantly inhibited.
There are advantages in a cell therapy being allogeneic rather than autologous. To
determine whether exogenous stem cells are effective, the most extreme case to
investigate would be xenogeneic cells (Samstein and Platt, 2001). This model has
been reported in myocardial regeneration studies using xenogeneic implantation to
evaluate the concept of universal cells donor (Atoui et al., 2008). This thesis has
examined the concept for bone regeneration. If there are any benefits of using
xenogeneic stem cells (e.g. hMSCs) to promote fracture healing in an
immunocompetent animal model, the results should reflect the outcomes of using
allogeneic stem cells as universal donor cells in a clinical setting.  However, in the
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recent literature on bone regeneration, xenogeneic implantation is still controversial:
a range of studies have reported inconsistent effects of hMSC in xenogeneic models
(Fatkhudinov et al., 2005, Niemeyer et al., 2010b, Niemeyer et al., 2010c). These
experiments were conducted using bone defect models, which are different to an
atrophic non-union model. In a bone defect model, healing may be more dependent
on engraftment of the cells, whereas in a non-union model the cells may act by
stimulation of endogenous cells and therefore be less dependent on engraftment.
Thus, if the therapeutic potential of MSCs in a bone defect model is more dependent
on engraftment and differentiation of the cells, then the immune response may have a
greater role and inhibit the ability of MSCs to bring about healing of a bone defect.
Chloromethyl-benzamidodialkylcarbocyanine (CM-Dil) is a fluorescent membrane
marker and was used to label the injected cells. It has been reported that CM-Dil
labelled hMSCs could be detected from the graft area up to 10 weeks after
implantation in a rat calvarial model (Zong et al., 2010). However, in the present
study, no injected hMSCs could be found either at four weeks or eight weeks after
injection. These results were confirmed using immunostaining with an antibody that
was specific to human nuclei. The findings from this study are in contrast to a
previous report conducted in a critical size defect model (Zong et al., 2010). As the
therapeutic effects of injecting MSCs in this study could not be explained by cell
engraftment or differentiation; it is postulated that exogenous hMSCs may contribute
to the fracture healing process in the fracture at risk of atrophic non-union by
providing the paracrine or trophic factors that are required to stimulate fracture
healing and that tissues at the fracture site are stimulated to form fracture callus via
trophic effects from the exogenous MSCs. In support of this, it has been reported that
MSCs release many cytokines and mediators into the medium including interleukin-
1, -6, -7, -8, -11, -14 and-15, leukaemia inhibitory factor (LIF), stromal cell-derived
factor (SDF-1), stem cell factor (SCF-1),Flt-3 ligand, macrophage, granulocyte and
granulocyte macrophage colony stimulating factors (M-, G-, and GM-CSF) and
Vascular endothelial growth factor (VEGF) (Haynesworth et al., 1996, Majumdar et
al., 1998, Hung et al., 2007). These mediators act as regulators during fracture repair.
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Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of the key
regulators in the pro-inflammatory cascade which is able to stimulate the innate
immune response and thus increase the number of granulocytes including
neutrophils, eosinophils, and basophils as well as supporting the differentiation of
monocytes into macrophages (Hamilton, 2002). The innate immune response has
been reported to play an important role in xenograft rejection (Wang and Yang,
2012, Yang and Sykes, 2007). In this study, there was an increase in GM-CSF level
in hMSC group, and there was a significant lymph node reaction compared to the
control. However, there was no significant difference in lymph node response
between the rMSC and hMSC injection group. These immune responses observed
after cell injection are not specific to xenogeneic cells; both infections and foreign
bodies can also increase the GM-CSF levels (Szeliga et al., 2008) and cause lymph
node reactions (Bondarenko et al., 2011). In the current study, there was no evidence
of infection suggesting the reaction was due to the injected cells, however the
reaction of the external fixator still could not be excluded. The increase in immune
response in the hMSC treatment group did not negate the beneficial effects of the
injected cells on fracture healing and the injected cells did not cause any adverse
effects in this study. However, further studies on the detail of the immune response
and the interactions of MSCs in an allogeneic or xenogeneic environment are
required before MSCs from a universal donor could be used to improve fracture
healing in the clinical setting.
Alternatively, a better autologous source of bone progenitors could be used as a
clinical strategy. For instance, adipose tissue has been investigated as an alternative
source of autologous cells. It has been reported that perivascular stem cells (PSCs)
(also known as pericytes), which are found in the perivascular area in several tissues
such as adipose tissue may serve as a source of bone progenitors. Thus, the
therapeutic effects of PSCs for bone regeneration will be evaluated in the next
chapter.
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Chapter 9: Bone regeneration potential of
adipose tissue derived perivascular stem cells
or pericytes
Aim: To evaluate the therapeutic potential using perivascular stem cells to promote
bone healing in an atrophic non-union model
9.1 Introduction
Atrophic non-union is a fracture complication caused by biological failure of the
healing process. The last two chapters (Chapter 7 and 8) have determined the
appropriate time for using percutaneous MSC implantation and evaluated the
therapeutic effects using hMSCs from bone marrow in an atrophic non-union model.
To develop a possible clinical strategy using cells from different sources, adipose
tissue derived cells were investigated in this chapter. It has been reported that
perivascular stem cells (PSCs) (also known as pericytes) which are found in the
perivascular area may serve as a source of bone progenitors (James et al., 2012a).
PSCs can be isolated from fat tissue with CD146 markers. They are reported to share
the characteristics and differentiation potential of MSCs (Crisan et al., 2009) in
particular pericytes are capable of osteogenesis. PSCs also provide trophic factors
required in the fracture healing process (Chen et al., 2009). The healing potential of
these cells may prevent a fracture destined to progress to non-union from doing so.
Thus, the aim of this study was to evaluate the bone regeneration potential of PSCs
in an atrophic non-union model.
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9.2 Materials and Methods
The atrophic non-union model, the percutaneous injection technique and the fracture
assessments have been described in the general materials and methods (Chapter 2).
In this section, the specific experimental design and statistical analysis are provided.
9.2.1 Experiment design
The atrophic non-union operation was carried out on five male Wistar rats (400-
500g). Five million hPSC in 200 µL PBS were injected at three weeks post
operation. Control animals who had undergone the identical procedure except for
having PBS injected instead of cells from previous chapters (n=7) were used for
statistical analysis. Bone healing was evaluated using radiographic parameters
including micro-CT, histological parameters, and biomechanical properties.
9.2.2 Statistical analysis
The difference in numbers of bone unions between the hPSC injection group and the
control group was determined using Fishers’exact test. The mean differences in
fracture progression parameters including radiopacity, proximal and distal callus
index, the percentage increase of callus area as well as changes in the fracture scores
(RUST and Lane & Sandhu) were tested using repeated ANOVA and the post-hoc
analysis was performed using Bonferroni multiple comparisons test. The
measurements from histology and micro-CT were also tested using unpaired t-tests.
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9.3 Results
9.3.1 Animal health status after PSCs implantation
All rats (n=5) successfully underwent the operation to induce an atrophic non-union
procedure and then they were then injected with hPSCs three weeks after operation.
There was no sign of any adverse reactions following the injection of hPSCs. All of
the animals remained alive without any complications until the end of the study.
9.3.2 Diagnosis of bone union in PSC group and control
In the PSC injection group, three out of the five animals received that had received
PSCs progressed to fracture union, whereas in the control group, only one achieved
bone union eight weeks after injection of PBS. The table 9.1 shows the number of
fracture unions and non-union in rats injected either with PSCs or PBS. More
animals achieved bone union in the PSC injection group compared to the control
group. However, the difference was not statistically significant (P-value=0.22,
Fishers’exact test)
Table 9.1 The number of the animals used in the early time point and results of bone union between
the PSC injection group and the PBS (control) injection group
Treatment group Outcome Total
Bone union Non-union
PSCs 3 2 5
PBS (control) 1 6 7
Total 4 8 12
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Although, one of the animals in the treatment group was diagnosed as a non-union,
there was callus present at the fracture gap. Serial radiographic images showed an
improvement of bone healing over the eight week period after injection of PSCs
(Figure 9.1).  This fracture may have progressed to union at a later stage (more than
eight weeks).
Figure 9.1 Radiographic at 8 weeks of injected PSCs animal who developed atrophic non-union
(Arrows show bone callus at the fracture gap)
9.3.3 The progression of the fracture healing process
The progression of fracture healing was evaluated with radiography every two weeks
to assess and monitor the radiographic parameters of bone healing. The serial
radiographs of the fracture showed progression of healing in most animals in the PSC
treatment group (4/5), while the fracture sites of most animals in PBS treatment
group (6/7) proceeded to fully developed atrophic non-unions.
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9.3.3.1 Relative Radiopacity of PSC treatment group compared to
control group
The Mean relative radiopacity which was normalised with an aluminium step wedge,
at the fracture gap of the hPSC and control groups are shown in Figure 9.2. The
mean radiopacity in the hPSC treatment group was significantly higher as early as 4
weeks after injection of the cells compared to the control group (P < 0.001,
ANOVA).
Figure 9.2 The comparison of radiopacity between treatment (hPSC) and control (PBS) over 8 weeks
period post injection (*P-value < 0.05, Post-tests using bonferroni)
9.3.3.2 Callus index in hPSC treatment group compared to control
group
The proximal and distal callus indices increased significantly in the hPSC injected
animals over the 8 week period after cell injection (Proximal callus index; P-value =
0.01, ANOVA and Distal callus index; P-value = 0.02, ANOVA) (Figure 9.3). The
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callus index of the controls slightly decreased over the 8 week period after PBS
injection. This may represent atrophic change at the fracture site.
Figure 9.3 The comparison of callus index; a) proximal and b) Distal between treatment (hPSCs) and
control (PBS) over the 8 week period post injection
9.3.3.3 Percentage increase of callus area in the hPSC treatment group
compared to control group
The graph in Figure 9.4 shows the percentage increases of callus between the hPSC
group and control groups over the 8 week period after injection. Similar to the callus
index, the percentage change of callus area significantly increased from the 2nd week
to the 8th week. In contrast, the percentage change of callus in the control group
which had been injected with PBS at the non-union site resulted in a decrease in
callus area. There was a statistically significant difference in the percentage area
increase between the hPSC group and the control group (p-value < 0.001, ANOVA).
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Figure 9.4 The comparison of the percentage callus area increase between treatment (hPSC) and
control (PBS) over 8 weeks period post injection (*p<0.05, Post-tests using bonferroni)
9.3.3.4 The progression of the fracture healing process using fracture
scoring system in the hPSC treatment group compared to the
control group
The RUST score and Lane & Sandhu score both showed a trend towards
improvement in the fracture healing process over the 8 period after cell injection
(Figure 9.5). However, this was not statistically different between the treatment and
the control (RUST score; P-value = 0.28, ANOVA and Lane & Sandhu score; P-
value = 0.39).
Figure 9.5 Fracture scoring systems: (a) The RUST score evaluation and (b) Lane and Sandhu score
evaluation
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9.3.4 Histology evaluation in hPSC treatment group compared
to control group
The histological observations from H&E stained sections supported the radiological
results. In the hPSC injection group, the inter-fragmentary gap consisted
predominantly of bone (Figure 9.6a) and a bony bridge was present connecting the
bone ends. Conversely, in the PBS injected group, the tissue within the inter-
fragmentary gap consisted predominantly of fibrous tissue (Figure 9.6b). Masson’s
Trichrome staining confirmed the area of new bone formation (Figure 9.7) at the
fracture site in the hPSC injection group.




Figure 9.7 Histological sections: (a) H&E staining, x100 and (b) Masson’s Trichrome, x100 at
fracture site of hPSC injected animals demonstrating the area of new bone formation (Arrow)
In the animals in the hPSC injection group, which was not categorised as a ‘union’ at
8 weeks after hPSC injection, the fracture had not developed into an established
atrophic non-union and the serial radiographic of fracture showed some bone callus.
The histology show bone trabeculae and cartilage tissue at the fracture gap but no
connectivity of bone (Figure 9.8).
A B
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Figure 9.8 Non-union gap of one of the animals in the hPSC injection at 8 weeks after cell injection
demonstrating soft (Black arrow) and hard callus (White arrow); there was no bony bridge present.
(a) H&E, x100 , (b) Masson’s Trichrome, x10 and (c) Safronin O/Fast Green, x100
The 10x10 grids were applied to images from histology for evaluating the tissues
component semi-quantitatively. The tissue components (bone, cartilage, fibrous and
bone marrow space) were compared between the cell treated group and the control
group (Figure 9.9). The bone content was the largest component in the treatment
group and it was significantly higher than the control group (P-value < 0.05,
Unpaired t-test). Fibrous tissue and marrow space were the dominant components in




Figure 9.9 Quantitative evaluation of the tissue components in the fracture gap (a) bone tissue
component, (b) cartilage tissue component, (c) fibrous tissue component and (d) bone marrow/empty
space component (*P-value < 0.05, unpaired t-test)
9.3.5 Micro-CT analysis in the PSC and control groups
Three-dimensioned images from micro-CT depicted the bone component at fracture
sites in the animals treated with hPSCs. There were full bone bridges present at the
fracture gap in three animals that developed bone union. In the two animals that were
diagnosed with non-union, there was some bone formation present at the fracture gap
in one of them (Figure 9.10).  For quantitative measurement, the percentage of
endosteal calcified tissue volume per tissue volume, at the centre of the fracture site
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was measured for all samples. All parameters are shown in Table 9.2. In the PSC
treatment group, the bone mineral density, which identified the quality of bone
content and degree of mineralisation was statistically significantly higher than in the
control group (P-value = 0.04, unpaired t-test).
Figure 9.10 The results from 3D Micro computed tomography of five animals in the PSC injected
group












34.14 (5.57) 25.03 (8.10) P = 0.43
Bone surface density
(mm2/mm3)
4.29 (0.72) 3.18 (0.57) P = 0.25
Tb.N (1/mm) 0.98 (0.18) 0.74 (0.13) P = 0.29
Tb.Th (mm) 0.29 (0.03) 0.35 (0.08) P = 0.55
Tb.Sp (mm) 0.34 (0.03) 0.31 (0.07) P = 0.65
Bone mineral density
(g HA/mm3)
0.57 (0.01) 0.29 (0.12) P = 0.04*
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9.3.6 Biomechanical testing
The functional outcome of bone healing after hPSC injection was demonstrated by
biomechanical testing. The summary of biomechanical parameters between the
fractured leg (right) and normal leg (left) is presented in Table 9.3. The mean of
biomechanical parameters of the treated bone gained up to 23.9% (SEM =11.11,
n=5) for ultimate force, 15.2% (SEM = 4.44, n=5) for ultimate stress, 9.9% (SEM =
3.11, n=5) for young’s modulus, and 67.8% (SEM = 16.19, n=5) for toughness.
Mechanical testing in the PBS injection group was not performed due to gross
motion against gravity (i.e. the bone deflected at the fracture site under its own
weight when held horizontal).
Table 9.3 Biomechanical properties of bone for bone samples from limbs injected with hPSC and
from normal bone from the contralateral unoperated side




Ultimate load N 51.0 (22.21) 228.2 (11.87)
Ultimate stress MPa 43.4 (13.40) 299.5 (19.68)
Young’s modulus GPa 0.8 (0.29) 9.0 (1.26)
Toughness MPa 1.9 (0.53) 2.7 (0.18)
9.4 Summary and discussion
In this chapter, therapeutic effects of hPSCs using percutaneous injection as a
minimally invasive technique were assessed in an atrophic non-union model. In the
hPSC injection group of five animals, three animals had united at eight weeks after
injection and one of them showed sign of progression of healing, while in the control
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group, only one of seven animals had bone union at eight weeks. Although there was
no statistical difference in union rate between the hPSC treatment and control groups,
the bone radiopacity indicated that the degree of bone mineralisation and percentage
increase of callus area were significantly improved over the period after hPSC
injection. Semi-quantitative analysis of the histomorphology of the fracture gap
showed that there was significantly more bone tissue in the hPSC injection group
compared to the control group. Similarly the parameters from micro-CT analysis
showed significant increases: the BMD was significantly higher in the hPSC
treatment group. There were improvements in mechanical properties demonstrated
by biomechanical testing. These results suggested that the percutaneous injection of
hPSC at the fracture gap at 3 weeks after fracture improved the fracture healing in an
atrophic non-union model.
Although it has been reported that hPSCs have demonstrated in vivo ectopic bone
formation with intramuscular implantation (James et al., 2012b) and bone
regeneration effects in a critical size calvarial defect model (James et al., 2012a), the
current study is the first to demonstrate the bone regeneration benefit of hPSC in an
atrophic non-union model which is relevant to the clinical scenario. These findings
support the use of hPSC for bone regeneration. It has been proposed that pericytes or
perivascular stem cells are perivascular ancestors of human MSCs (Corselli et al.,
2010). The in vivo localisation of these cells has been demonstrated (Corselli et al.,
2012). In in vitro culture, they show the characteristics of MSCs including theirs
abilities of proliferation and multi-lineage differentiation (Crisan et al., 2008). It has
been reported that PSCs can be isolated from several tissues and can be purified
using cell surface markers including positive markers of CD146, NG-2, PDFG-b and
negative markers of CD45, CD56, CD31 and CD34 (Crisan et al., 2009, Montemurro
et al., 2011, Park et al., 2011). In this study the adipose tissue source was used
because it was readily available and easy to harvest and can be used as an alternative
source of MSCs. Notably, sufficient PSCs can be obtained without culture expansion
but purely by cell selection. A previous published protocol was used in this study.
(James et al., 2012a).
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As the results reported in chapter 7 found that timing was a critical factor for using
MSCs to promote bone healing in an atrophic non-union, the optimal method of
preparing sufficient cells in a timely manner should be considered. The results from
chapter 8 showed that MSCs from different hosts i.e. allogeneic and even in
xenogeneic sources improved the fracture healing in an atrophic non-union without a
significant immune response. The findings support the assertion that MSC have an
immunoprivileged characteristic. However, the results were in contradiction with
previous studies which reported that there was significant increase in immune
responses against allogeneic MSCs (Schu et al., 2012, Eliopoulos et al., 2005, Huang
et al., 2010). Thus, safety of using stem cells from different donor in cell therapies
should be further investigated in appropriate animal models to determine adverse
events and to understand further the specific immune reactions of MSCs before
clinical application in humans.
Defined perivascular stem cells from adipose tissue or pericytes have the advantage
that they could be used autologously as they can be harvested and isolated from
enriched source. PSCs can be immediately used as required. It is possible to use
hPSCs for cell based therapies within an intraoperative approach to augment fracture
repair because the cells can be sorted with sufficient numbers from adipose tissue
without culture expansion and implanted back to the fracture site in one setting.
Although the stromal vascular fraction of human adipose tissue (SVF) from
lipoaspirate can be used intraoperatively to generate autologous cell based therapies
for bone repair (Muller et al., 2010), it has been shown that the potential for
regeneration was inferior to sorted hPSC from SVF from matched patients (James et
al., 2012b). In addition, as hPSCs are a defined and homogeneous cell population,
they should have more consistent in vivo outcomes in bone repair compared to SVF
which contains a nonhomogeneous mixture of, haematopoietic stem cells, progenitor
cells and endothelial cells.
Although there was no statistically significant difference in union rate between the
hPSC treatment group and the PBS control group, other parameters demonstrated
significant improvements in the fracture healing process over the eight week period
after cell injection. The underlying mechanisms of PSC for bone regeneration have
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not been evaluated in this study. However, there are at least two possible
mechanisms; (1) as precursor cells or (2) by paracrine effects (Chen et al., 2009).
PSCs can undergo multi-lineage differentiation similar to MSCs and may improve
bone regeneration via direct differentiation into osteoblast cell lineages (Crisan et al.,
2008). PSCs can secrete several growth factors such as heparin binding epidermal
growth factor (HB-EGF), basic fibroblast growth factor (bFGF), platelet derived
growth factor-B chain (PDGF-BB), vascular endothelial growth factor (VEGF),
keratinocyte growth factor (KGF), angiopoietin 2 (ANG2) and thrombopoietin
(TPO) (Chen et al., 2009) and may improve the fracture healing process via
vasculogenesis (Askarinam et al., 2013).
Thus, the administration of PSC using percutaneous injection technique may improve
the fracture healing process in atrophic non-union. PSCs from adipose tissue have
advantages over conventional bone marrow derived MSCs as they are a defined and
homogenous population, which can be isolated from the fat tissue abundantly
without culture expansion. PSCs may be considered as a potential choice for cell
therapies to promote fracture healing in fractures at risk of progressing to atrophic
non-union.
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Part 4: General discussion, future direction and
conclusion
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Chapter 10: General discussion
The aim of this thesis was to develop an injectable MSC- based approach to promote
fracture healing in atrophic non-union. In this chapter, the main findings and the
implications for clinical translation are discussed. The assessments of fracture
healing in preclinical studies and the limitation in this study are addressed. Then
further investigations are proposed.
10.1 Discussion of the main findings and their
clinical implications
A clinical relevant model of atrophic non-union
A number of studies have evaluated bone regeneration potential in segmental defect
models (Arinzeh et al., 2003, Tsuchida et al., 2003, Choi et al., 2011), however, these
models do not simulate the biological or mechanical conditions of a clinical non-
union. For this reason the non-critical defect atrophic model described in chapter 6
was used.
Resection of periosteal tissue and removal of bone marrow at the fracture impaired
the healing process. Periosteum and endosteum are biological components required
for fracture healing. The role of periosteum and endosteum was demonstrated using
mice that express the LacZ reporter gene (Colnot, 2009). This technique can be used
for identification of an active enzyme for β-galactosidase using X-gal (5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside) staining. Bone graft with intact periosteum
and endosteum was taken from LacZ reporting mice and transplanted at the fracture
of wild type mice. Chondrocytes, osteoblasts and osteocytes were recruited from the
periosteum and endosteum of the graft, contributing to the fracture healing process.
As these structures represent key sources of bone progenitors, their damage can lead
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to atrophic non-union. The results from chapter 6 further demonstrated the
contribution of local progenitors in an established atrophic non-union.
The insufficient nature of bone Progenitors in local site of atrophic non-union
tissue
The regeneration potential of the native progenitors from remote bone marrow (the
contralateral femur) of animals with an atrophic non-union model of the tibia was
investigated. This study has shown that the non-union appeared to stimulate a
systemic response. A clinical study of Marchelli et al, has demonstrated that the
serum OPG, which is a bone formation marker, was significantly higher in patients
with an atrophic non-union of a shaft fracture indicating that there was a systemic
response to the non-union (Marchelli et al., 2009). However, it has been reported that
the number of colony forming units from bone marrow in an established atrophic
non-union patient was significantly less than in the normal control patient (Seebach
et al., 2007). It is possible that the systemic response to fracture or non-union may
depend on the stage of the healing process (Bastian et al., 2011) and the results from
one time point cannot be extrapolated to other time points.
Local cells in the non-union tissue were investigated. Colony forming units could not
be detected from cells isolated from tissue at the atrophic non-union gap. It was
postulated that the systemic response in atrophic non-union patients might be higher,
whereas local tissue progenitors were unable to contribute sufficiently to the healing
process. It has been reported that cells isolated from human non-union tissues have
increased senescence and reduced capacity to form osteoblasts, which was associated
with significantly elevated secretion of Dickkopf-1 (Dkk-1) (Bajada et al., 2009). In
addition, significantly down-regulated factors in non-union osteoblasts included
canonical Wnt-, IGF-, TGF-beta-, and FGF-signalling pathways. These factors have
been reported to be involved in the proliferation and differentiation of bone
progenitors (Hofmann et al., 2008). The results presented here suggest that tissue
from atrophic non-unions has an insufficient number of functional progenitors.
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The preparation of MSCs from the different tissues
Chapter 3 demonstrated the ease of isolation of rMSCs from three sources relevant to
orthopaedics including bone marrow, periosteum and adipose tissue. Human femoral
heads were used for isolation of hMSCs as they were readily available and could be
used in in vivo experiments. Isolated cells were capable of osteogenesis,
chondrogenesis and adipogenesis. The results of this study have shown that bone
marrow derived and periosteum derived cells had faster growth kinetics than adipose
derived cells. The percentages of colony forming units and the colony forming area
from bone marrow derived cells and periosteum derived cells were significantly
greater than for adipose derived cells.
Colony forming unit assays are based on the ability of MSCs to adhere to plastic and
to form colonies when plated at low densities (Prockop, 1997, Colter et al., 2000).
The colony forming capacity has been used to present a functional unit of bone
marrow derived MSCs (Friedenstein et al., 1974, Owen and Friedenstein, 1988).
Morphology and the number of colonies have been shown to be correlated to the cell
growth characteristics (Colter et al., 2000, Gothard et al., 2013). The number of
colonies formed from cells of different sources has been investigated (Yoshimura et
al., 2007). The colony number from passage 0 (after isolation) from the rat
synovium, periosteum, adipose, and muscle tissues was higher than those from cells
derived from rat bone marrow. Cells-derived from periosteum and adipose tissue
gave rise to more colonies than cells-derived from bone marrow. These results were
different from the finding in this thesis because of the difference of evaluated cells.
The passage of cells (passage 3-4) used in this thesis was later than those used in the
aforementioned study (passage 0). The colony forming unit ability of cells after
isolation reflected the number of stem cells residing in the stem cell source, while the
colony forming unit of the cultured cell represented the proliferative function of the
cells. As cells at culture passage 3-4 were used for transplantation in this thesis,
cultured MSCs from the different source was investigated to determine the functional
ability.
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Adipose tissue is more accessible than bone marrow and periosteum, however, the
results from this study showed that the growth of cultured cells from this source was
significantly slower than the two others sources. In addition, in previous in vitro
studies (Hayashi, Katsube et al. 2008) and in previous in vivo studies (Niemeyer et
al., 2010a) the bone regeneration potential of cells from adipose tissuehas been
reported to be inferior to cells from a bone marrow source. However, due to the
accessibility of adipose tissue, further investigation should focus on how this cell
type might be utilised effectively.
In chapter 3, hMSCs were isolated from the femoral heads of patients undergoing hip
replacement procedures. These cells were able to differentiate into bone forming
cells in osteogenic medium. They exhibited the markers CD90 and CD44 and not the
haematopoetic stem cell markers (CD19) or endothelial markers (CD34 and CD31).
Our group reported that 90% of cells isolated using this technique expressed CD105
(a recognised MSC marker) (Tremoleda et al., 2012). In order to compare bone
regeneration in the in vivo model of atrophic non-union, the number of functional
units of rMSC and hMSC should be controlled. The results in chapter 3 showed that
the growth characteristics and the functional units of cultured rMSCs and hMSCs
from the in vitro study were not significantly different. In contrast, Javazon et al
(2001) reported that rMSCs can expand more rapidly than hMSCs. This may be
because of the differences in rat strain (Barzilay et al., 2009), isolation technique
(Bourzac et al., 2010), temperature (Reissis et al., 2013), or culture condition
(Ayatollahi et al., 2012), which preclude direct comparison. So, in this study, the
source of cultured cells, isolation technique, and culture condition were maintained
for all experiments to obtain consistent results.
Timing is a critical factor for an injectable MSC based approach
In chapter 7, the stage of fracture healing was shown to influence the therapeutic
potential of MSCs and as such clinical candidates for MSC therapy will have to be
carefully selected to obtain favourable outcomes (i.e. patients would need to be with
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a few weeks of injury or the fracture repair process would need to be restarted with
the operation). The importance of intervention timing has been highlighted in
previous studies evaluating the regenerative effect of hMSCs in a rabbit mandible
distraction osteogenesis model (Kim et al., 2013). hMSCs suspended in 0.15 ml of
saline were injected transcutaneously into the osteotomy gap either before or after
distraction. The group receiving injections prior to distraction had superior bone
formation compared to those receiving injection after distraction. BMD values and
BV/TV ratios at the osteotomy site were also significantly higher in those receiving
early injections. These results highlight the importance of injection time and the
nature of the underlying disease condition.
In chapter 7, atrophic non-union with MSCs implantation in the late ‘post-injury’
period (8 weeks) showed no significant improvement of fracture healing. The
environment of the non-union site at this stage may not be appropriate to induce or
stimulate MSCs to function. Growth factors may be required, in addition to MSCs, to
improve fracture healing in an established atrophic non-union. A previous pre-
clinical study evaluated the effectiveness of treating established femoral non-union in
rat using bone marrow suspension or cultured MSCs (Ferreira et al., 2012). 3 x 106
cells in 0.5ml DMEM was injected at the fracture site of established non-union.
Treatment with heterologous bone marrow cells was more effective than the cultured
MSCs. Bone marrow suspension contains cellular elements and growth factors that
can have actions at the docking site of atrophic non-union. These findings suggest
that cultured MSC based therapy in late stage of non-union may require additional
growth factors with (or possibly without) the exogenous cultured MSCs.
In established atrophic non-unions with a fracture gap, scaffolds may be required.
Allogeneic bone graft, demineralized bone matrix, hydroxyapatite and calcium
phosphate have been used as carriers for cell delivery. Newly developed scaffolds
aim to provide an appropriate environment for cell growth and differentiation while
protecting cells from apoptosis. Scaffolds also may have to provide early structural
support that may be required, particularly in long bone with large segmental defects.
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Cell based therapies should be tailored specifically to the requirements and healing-
condition of the fracture. The delivery technique should be applicable and minimise
patient morbidity. Cultured MSCs can be used to reduce the risk of fractures
developing atrophic non-union. However, the timing for MSC delivery and the
clinical scenario of each individual must be taken into account. Additionally, it is
important to obtain an adequate number of cells prior to implantation into the
fracture site.
Possible strategies using an universal cell donor and alternative cells in fracture
healing
The feasibility of using MSCs from an universal cell donor was evaluated in a
xenogeneic model. The results from chapter 9 demonstrated that xenogeneic cells
can improve bone healing. The findings support the feasibility of using universal
donor cells for bone repair. MSCs are immunoprivileged. They can avoid or actively
suppress immunological responses because they lack MHC class Ia and MHC class
II and co-simulation molecules (Tse et al., 2003). Previous reports from in vitro
studies demonstrated that MSCs cannot stimulate an immune response in allogeneic
lymphocytic cell cultures (Le Blanc et al., 2003). In a number of pre-clinical studies,
MSCs have been implanted in allogeneic and xenogeneic models without eliciting an
immune response. It has been reported allogeneic transplantation of MSCs improved
bone regeneration in a critical-size canine segmental defect without production of
alloantibodies (Arinzeh et al., 2003). However, a study from an in vivo ovine massive
bone tumour implant model, comparing osteointegration at the implant between
spraying of autologous and allogeneic MSCs within a fibrin glue carrier,
demonstrated significant bone growth in the autologous MSC treatment group, but
not in the allogeneic MSC treatment group (Coathup et al., 2013b). The effectiveness
of allogeneic MSCs on bone formation may vary in different clinical situation as the
in vivo environment at the implantation site can influence the ability of cells to
contribute to bone regeneration (Barrere et al., 2006). The benefit of MSCs being
immune privileged has been shown in xenotransplantation for defects in femoral
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bone (Fatkhudinov et al., 2005) and calvarial bone (Zong et al., 2010). Both studies
showed that the animals did not have any local pathological reactions or
complications when xenogeneic MSCs were implanted and that the MSCs could
stimulate reparative osteogenesis significantly. In a clinical study, Horwitz et al.
(2004) reported on the allogeneic transplantation of MSC into patients with
osteogenesis imperfecta. The study showed an increase in mineral content and that
the cells were capable of engraftment and differentiation into osteoblasts
(approximate 2%). This study demonstrated the possibility of using allogeneic
transplantation in systemic bone disease and indicates the potential of universal
donor cells from healthy donors providing and MSCs that can be used as an off-the-
shelf therapy for bone repair.
Bone marrow is a conventional source for MSC isolation; however, it is a limited
source. The yield of MSCs from bone marrow is relatively small, so cells have to be
expanded in appropriate culture conditions to obtain an adequate number of cells
prior to implantation into the fracture site. Adipose tissue is more abundantly
available but it has been reported that the bone regeneration potential of ASC may be
inferior to bone marrow (Hayashi et al., 2008). However, it is possible to improve the
regeneration potential by adding growth factors (Niemeyer et al., 2010a). It has been
reported that perivascular stem cells (PSCs) or “pericytes” from adipose tissue may
serve as a promising source of bone progenitors. Pericytes are capable of
osteogenesis, chondrogenesis and adipogenesis. The results from chapter 9
demonstrated the bone regeneration potential of PSCs in an atrophic non-union
model.
PSCs have been isolated from the non-cultured total stromal vascular fraction (SVF)
of fat tissues using fluorescence-activated cell sorting (FACS). These cells can be
purified on the basis of an established repertoire of cell surface markers including the
presence of CD146 and the absence of endothelial markers (CD31 and CD34) and a
haematopoietic marker (CD45) (Crisan et al., 2008). These cells can be identified in
vivo in perivascular regions where they display MSC surface markers. In vitro these
cells also share characteristics including morphology, clonal expansion and multi-
lineage potential. It has been reported that hPSCs produce ectopic bone in vivo
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following intramuscular implantation (James, Zara et al. 2012a) and bone
regeneration effects in a critical sized calvarial model (James, Zara et al. 2012b). The
findings of chapter 9 are the first reports of PSCs regenerating bone in a clinically
relevant atrophic non-union model. These findings support the use of hPSC for bone
regeneration. These cells may represent a viable source of MSCs for future clinical
bone regeneration strategies.
Injected MSCs disappeared after injection
According to the cell tracing results from chapter 8, there were no hMSCs found in
histological sections at four weeks, whereas rMSCs were still detected at the fracture
gap at four weeks after cell implantation, but the number of cells appeared to have
decreased. Neither hMSC nor rMSC were found at the fracture gap at eight weeks
after cell injection. An explanation may be that transplanted MSCs were eliminated
by host immune responses after implantation. Although MSCs appear to be
immunoprivileged cells, it has been reported that MSCs which undergo osteogenic
differentiation in vivo subsequently express MCH class II and then lose their immune
privileged status (Liu et al., 2006). MHC class I and II play an important role in
eliciting immune responses in MHC-mismatched cell donors (Eliopoulos et al.,
2005). An in vitro study has shown that rat MSCs which underwent chondrogenic
differentiation stimulated peripheral blood in a mixed lymphocyte reaction (MLR)
culture and increased cytotoxicity as the differentiated cells expressed co-stimulatory
B7 molecule, required to activate cytotoxic T cells (Chen et al., 2007).
The function of transplanted MSCs has been demonstrated in an allogeneic model
(Eliopoulos et al., 2005). Genetically modified MSCs which secrete erythropoietin
(Epo) were transplanted into allogeneic mice (MHC mismatch) without
immunosuppression. Results showed that the Haematocrit (Hct) in MSC-implanted
mice rose transiently and declined to baseline values. The Hct increased from a basal
to a peak value at 27 days after implantation and then decreased to baseline levels by
day 52. Transplantation of MHC mismatched MSCs function transiently at an early
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stage of transplantation. Therefore, there may still be a benefit of using exogenous
MSCs for bone regeneration as long as the injected MSCs can improve or stimulate
fracture healing of the naïve tissues at the fracture site. Results from chapter 8
showed that injected MSCs can contribute to the fracture healing process; however
cells disappeared when the fracture progressed to union. This result suggests
exogenous MSCs may improve fracture healing via their paracrine effect, but not as
progenitor cells. Caplan and Dennis (2006) referred to this as a trophic effect which
is an ability of MSCs to secrete a number of cytokines and growth factors which
suppress the local immune system, inhibit fibrosis and apoptosis as well as enhance
angiogenesis, stimulate mitosis and differentiation of intrinsic tissue. Although, the
findings from this study suggested that MSCs play a role in the prevention of
atrophic non-union, the mechanisms by which this occurs require further
investigation.
10.2 Limitations of the study
Atrophic non-union model
In this study a clinically relevant model of atrophic non-union model resulting from
severe injury was used. Wild type systemically healthy rats were used. In clinical
practice, patients with non-union may have co-morbidities. In addition, in patients,
the degree of injury severity and the fracture configuration varies. In the animal
model the osteotomy site and the degree of biological injury were well controlled in
order to improve reproducibility. Rodent models are commonly used in preclinical
studies of fracture healing. The skeletal structure of bone in rodents is more primitive
than human. The representation of cortical remodelling in rodents may be different
from humans because of the lack of Haversian systems. However, in this study, the
primary aim was not to evaluate cortical structure of bone, but to assess the bone
regeneration potential of cell therapy in fracture healing, which is similar in rodents
and humans. There are several advantages of using rodents in this study. They are
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inexpensive and easy to house. The size of bone is not too small, enabling intricate
surgical procedures and facilitating mechanical testing. The stabilization of bone
using external fixation was also reliable.
The cells and delivery technique
The effect of cell number was not evaluated in this study, as this study primarily
evaluated the efficacy of an injectable MSC-based strategy. Investigating optimal the
cell number remains an important issue; however it may be more appropriate to
conduct these study in a large animal model which is more similar in size to humans.
A potential limitation of this injection technique was leakage which might have
reduced the total number of cells injected. To overcome this problem, the size of
needle should be small and the speed of injection should be slow. Importantly, cells
should be injected when the surgical wound has healed completely preventing
leakage from the surgical wound.
Cell tracking
In order to visualise injected cells at the non-union gap and to assess their role,
administered cells were labelled using CellTracker (CM-Dil). Following animal
sacrifice, the transplanted cells labelled with cellTracker could be assessed using
fluorescence microscopy. A limitation of CM-Dil is that a decrease in the signal
intensity can occur with cell proliferation (Progatzky et al., 2013). This may lead to
incorrect interpretation of results. Thus, an immunohistofluorescence technique using
anti-human nuclear antibody with appropriate controls was also applied to identify
the human cells in the xenogeneic cell treatment group. This confirmed the CM-dil
findings. As injected cells disappeared after healing, the extent of cellular
differentiation could not be assessed in this study.
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Immunological assessments
In this study, serum samples harvested from each time point were limited, so the
multiplex ELISA kit was used to screen inflammatory cytokines simultaneously.
Results from each time point were presented as a relative fold difference compared to
the zero time point using optical density (OD). Although further investigation of
individual cytokines was not performed to obtain the absolute quantities of
cytokines, the results from multiplex ELISA kit could detect a significant change in
the level of GM-CSF after xenogeneic cell injection. Moreover, the local immune
reaction at the popliteal lymph node after cell implantation of exogenous cells was
also evaluated using histomorphology (the size of lymph node, the number of
follicles, the number of infiltrating cells at the subcapsular sinus and the number of
macrophages at the medullary sinus). These results demonstrated the inflammatory
reaction after cell injection.
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Future directions
Further investigation of clinically relevant MSC based treatments in an established
atrophic non-union should be carried out. Although autologous bone graft remains
the gold standard for atrophic non-union treatment, autologous bone graft is limited
by availability, quantity and donor site morbidity. MSCs based treatment can be used
as a less invasive approach which may be beneficial in reducing patient morbidity.
However, in MSCs based treatments for established atrophic non-unions,
consideration should be made to combining growth factors with transplanted cells.
Scaffolds may also be required if there is a significant defect at the non-union site.
The bone regeneration potential of bone marrow derived MSCs and adipose derived
PSCs should be compared quantitatively. However, both cell types should be isolated
from the same patient or matched patients to minimise the variability introduced by
unmatched donors. If the bone regeneration potential of refined PSCs is comparable
or better to conventional MSCs from bone marrow, pericyte isolated from adipose
tissue may be considered as an alternative cell source. The advantage of using
adipose tissue includes its abundance and availability. In addition, PSCs can be
sorted without a requirement for in vitro culture.
The optimisation of cell carriers for cell administration and development of
injectable scaffolds should be investigated to improve the efficacy of cell based
approaches, especially in patients requiring early cell therapy. Scaffolds or cell
carriers should be considered to enhance cell engraftment, promote differentiation
and maximise initial cell survival.
The use of ultrasound to guide percutaneous injection for bone surrounded by a thick
soft tissue envelope may improve accuracy of cell delivery. Further investigations
should aim to evaluate the potential benefits of cell placement guided by ultrasound
guided. These would be most appropriately performed in large animal models or in
the clinical setting.
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Future studies in large animals should investigate in the optimal cell number required
for augmentation of healing. In addition, studies should include long term follow-up
to determine the remodelling process of fracture healing and possible adverse effects.
Although results from this thesis have demonstrated a role for MSCs in the
improvement of fracture repair in an atrophic non-union model in immunocompetent
animals, this did not rely on the differentiation of cells into osteoblasts. However, the
mechanisms by which MSCs stimulate fracture repair were not definitively
elucidated and they require further investigation. Immunohistological studies on
growth factor expression at the fracture gap for both the MSCs and PBS injection
groups may be useful to help elucidate these mechanisms. Genetically Engineered
MSCs expressing green fluorescence protein (GFP) could be used to trace implanted
cells and establish cell fate after injection.
Immunostaining of immune cells at the fracture site and in the lymph nodes could be
performed to demonstrate the presence of specific inflammatory cells (e.g. CD68 for
macrophages, CD3 for T cell lymphocytes or B220 for B cell lymphocytes)
As PSCs can be purified from SVF without culture, it is interesting to compare bone
regeneration potential in vitro (in culture conditions) and in vivo (in the atrophic non-
union model) between uncultured PSCs and PSCs which have been expanded in
culture.
It is important to investigate the role of endogenous MSCs or progenitor cells at the
site of atrophic non-union. Further studies should investigate the temporal change of
yield of MSCs from bone marrow during the development of non-union.
In clinical studies, it will be important to use MSCs at an appropriate stage of disease
to achieve favourable outcomes. Therefore, the factors characteristics of patients who
may be best served by cellular therapy need to be defined.
Ultimately, clinical trials evaluating injectable MSCs based approaches are required
to address the efficacy and safety of MSC implantation in the prevention of atrophic
non-union. The findings from this thesis suggest that patients who are at high risk of
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progressing to non-union, (such as patients with open fractures or heavy smokers)
would be good candidates to study.
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Conclusion
Stem cell technology, and specifically the use of MSCs, is emerging as a promising
treatment to promote fracture healing. Several studies have investigated the potential
of MSCs for the regeneration of musculoskeletal tissues.  However, the potential for
their application in an appropriate and clinically relevant model of fracture non-union
has not been explored. The core question for this thesis was how to use MSCs to
improve fracture healing in fracture non-unions using an injectable MSC-based
approach. A clinically relevant model of atrophic non-union in small animals was
established and validated. This model provided insights into the pathogenesis of
atrophic non-union. In particular it was found that local progenitor cells at the site of
non-union do not have sufficient potency to regenerate bone, as assessed using
colony forming ability and tri-lineage differentiation (the capacity to differentiate
into bone, cartilage and fat) assays. This inability to regenerate bone may contribute
to the progression of non-union. Exogenous stem cells (rMSCs, hMSCs and PSCs)
were shown in the animal model to rescue bones destined to proceed to no-union
from doing so. Results from this thesis also suggested the feasibility of using MSCs
as universal donor cells and using alternative adipose derived PSCs for improving
bone repair in atrophic non-union. These may allow the development of an “off-the-
shelf” cellular therapy that could be used for any patient at risk of progressing to
atrophic non-union without delay. It is important to consider the timing of cell
injection when devising MSC treatment protocols. The findings of this thesis have
improved the understanding of the regenerative processes involved in fracture
healing and how these may be augmented, using MSCs, in the setting of atrophic
non-union. These results can form the basis for establishing a valid and innovative
biological technique for the treatment of long bone non-unions.
This study has examined the hypothesis “Percutaneous injection of MSCs promotes
the process of fracture repair in a small animal model of atrophic non-union”. The




The effects of CM-Dil on MSCs
In this study, CM-Dil staining was a method of choice to track cells in vivo.
According to the company’s recommendation, it is suggested that CM-Dil is soluble
at concentrations up to 20 µg/ml. The following bar graphs demonstrate a cell
viability and CFU-F as functional assay of labelled hMSCs at different
concentrations. The labelling of 2.5 µg/ml CM-Dil protocol seems to be an optimum
choice.
Bar graphs show the number of CFU-F units (upper) and the number of cell dead (lower) at the
different units:  DMEM, culture media and DMSO (Dimethyl sulfoxide), solvent solution
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Appendix B:
Protocols used in this study
H&E Method:
- Place sections in a rack and dewax in xylene for 15 minutes
- Rehydrate through graded alcohol: 100%, 100% ,90%, 70%, respectively for
2 minutes each
- Rinse in running tap water and then in distilled water
- Place in Mayer’s haematoxylin for 7 minutes
- Rinse in running tap water and then in distilled water to remove excess stain
- Blue section in 2% hydrogen carbonate for 2 minutes
- Rinse in running tap water
- Place in Eosin for 5 minutes
- Rinse in running tap water
- Dehydrate through graded alcohols: 70%, 90%, 100% and 100%, respectively
for 2 minute each
- Place in xylene clearing and mount one at a time in DPX
- Observe under light microscope
Modified Masson’s Trichrome Method:
- Place sections in a rack and dewax in xylene for 15 minutes
- Rehydrate through graded alcohol: 100%, 100% ,90%, 70%, respectively for
2 minutes each
- Rinse in running tap water and then in distilled water
- Stain with ferric chloride for 3 minutes
- Rinse in running tap water and then in distilled water to remove excess stain
- Stain with Mayar ‘s haematoxylin (diluted in water 1:10) for 1 minute
- Rinse in running tap water
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- Stain with Ponceau-acid fuchsin for 8 minutes
- Rinse quickly with 0.5% acetic acid
- Stain with 0.5% Phosphomolybdic acid for 3 minutes
- Rinse quickly with 0.5% acetic acid
- Stain with light green for 5 minutes
- Rinse quickly with 0.5% acetic acid
- Dehydrate through graded alcohols: 70%, 90%, 100% and 100%, respectively
for 2 minute each
- Place in xylene clearing and mount one at a time in DPX
- Observe under light microscope
Safranin-O/Fast green Method:
- Place sections in a rack and dewax in xylene for 15 minutes
- Rehydrate through graded alcohol: 100%, 100%, 90%, 70%, respectively for
2 minutes each
- Rinse in running tap water and then in distilled water
- Stain with Mayar ‘s haematoxylin (diluted in water 1:10) for 1 minute
- Rinse in running tap water
- Stain with fast green (FCF) solution for 5 minutes
- Rinse quickly with 1% acetic acid solution for no more than 10 –15 seconds
- Stain in 0.1% safranin O solution for 5 minutes
- Rinse quickly with 1% acetic acid solution for no more than 10 –15 seconds
- Dehydrate through graded alcohols: 70%, 90%, 100% and 100%, respectively
for 2 minute  each
- Place in xylene clearing and mount one at a time in DPX
- Observe under light microscope
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The Brief Protocol for Rat Inflammatory Cytokines Multi-Analyte ELISArray
Kit (SABiosciencesTM, USA)
- Prepare replicate serial dilutions of the Antigen Standard and your
experimental samples
- Pipette 50 µl of Assay Buffer into each well of the 8-well ELISA strips
- Transfer 50 µl samples and/or standards to the appropriate wells of the
ELISA strips
- Gently shake or tap plate for 10 seconds. Incubate for 2 hours at room
temperature
- Decant or aspirate well contents. Add 350 µl 1 × Washing Buffer. Gently
shake or tap plate for 10 seconds. Decant or aspirate. Blot array upside down
on absorbent paper to remove any residual buffer ( step for Washing ELISA
Wells)
- Repeat wash twice more
- Pipette 100 µl of Detection Antibody solution. Incubate 1 hour at room
temperature
- Wash ELISA wells as described above
- Add 100 µl Avidin-HRP solutions to all wells. Incubate for 30 minutes at
room temperature.
- Wash ELISA wells for a total of 4 washes
- Add 100 µl of Development Solution to each well. Incubate the plate for 15
minutes at room temperature in the dark
- Add 100 µl of Stop Solution to each well. The colour changes from blue to
yellow
- Read absorbance at 450 nm within 30 minutes of stopping the reaction. If
wavelength correction is available, subtract readings at 570 nm from the
reading at 450 nm
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Appendix C
Presentations at National and International Meetings
Poster presentations
“Bone Regeneration Potential Using Adult Stem Cells in Atrophic Non-union” in
Post-graduation open day, QMRI, University of Edinburgh, UK, on the 18th
November 2011 (The best poster award, QMRI)
“Available Sources of Mesenchymal Stem Cell in Orthopaedic” in Regeneration
strategies and innovative biomaterials in orthopaedic surgery meeting, University of
Brighton, on the 3rd April 2012
“Non-Critical Size Defect Atrophic Non-union Model in Rat; Surgical technique and
its mesenchymal progenitor cells” in the 13th The European Federation of National
Associations of Orthopaedics and Traumatology (EFFORT) Congress in Berlin,
Germany, on the 23rd-25th May2012
“Validation of the radiographic union scale in tibia and Lane & Sandhu scoring
system for fracture healing in small animal model” in BRS/BORS (Bone Research
Society and the British Orthopaedic Research Society) Annual Meeting in Oxford,
UK, on the 4th-5th September 2013
“Xenogeneic Implantation of Human Mesenchymal Stem cells to Promote Fracture
Healing in Atrophic Non-Union Model” ORS (Orthopaedic Research Society)




“Comparison of biomechanical testing using 4-point bending in rat tibia between
specimen with and without muscle” in British Orthopaedic research society (BORS)
Annual Meeting (2012) in Stratford Circus, London, UK, on the 24th-25th September
2012 (Bursary awarded)
“Critical time point for MSCs implantation in atrophic non-union” in EORS
(European Orthopaedic research society) Annual Meeting in Amsterdam, 26th – 28th
September 2012
“Role of perivascular stem cells in the prevention of atrophic non-union” in
BRS/BORS (Bone Research Society and the British Orthopaedic Research Society)
Annual Meeting (2013), Oxford, UK, on the 4th-5th September 2013
“Role of perivascular stem cells in the prevention of atrophic non-union”  in School
of surgery days, The Royal College of Surgeons of Edinburgh, Edinburgh, UK, on
the 29th November 2013
Invitations
Speaker: “Roles of mesenchymal stem cells for atrophic non-union”, The 1st Thai-
UK Stem Cell Network meeting, Sheffield, UK, on the 5th-7th April 2011
Co-chairperson with Dr Ines Reichert: “Session 4” BORS (British Orthopaedic
research society) 2012, in Stratford Circus, London, UK, on the 24th-25th September
2012
Co-chairperson with Dr Martin Stoddard: “Stem Cell Session” in EORS
(European Orthopaedic research society) 2012, in Amsterdam, Netherlands, on the




Publication in Conference proceeding
“Comparison of Biomechanical Testing Using 4-Point Bending in Rat Tibia Between
Specimen with And without Muscle” Tawonsawatruk T, Spadaccino A, Wallace RJ,
Simpson H The Bone & Joint Journal (Orthopaedic Proceedings) 2013 vol. 95-B no.
sup. 13 16
Publications in peer-reviewed journals
“Natural history of mesenchymal stem cells, from vessel walls to culture vessels”
Murray IR, West CC, Hardy WR, James AW, Park TS, Nguyen A, Tawonsawatruk
T, Lazzari L, Soo C, Péault B. Cellular and Molecular Life Sciences.  2013 Oct 25.
[Epub ahead of print]
“Evaluation of Native Mesenchymal Stem Cells from Bone Marrow and Local
Tissue in an Atrophic Non-union Model” Tawonsawatruk T, Kelly MB, Simpson H.
Tissue Engineering Part C: Methods. 2013 Oct 22. [Epub ahead of print]
“Growth kinetics of rat mesenchymal stem cells from 3 potential sources: bone
marrow, periosteum and adipose tissue” Tawonsawatruk T, Spadaccino A, Murray
IR, Peault B, Simpson HA. Journal of the Medical Association of Thailand. 2012
Oct; 95 Suppl 10:S189-97.
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